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Résumé
La découverte récente des angiopoïétines (Angi et Ang2) a permis de
démontrer qu’elles peuvent, via leur liaison au récepteur Tie2, moduler la
perméabilité et la stabilité vasculaire, et ainsi contribuer à diverses étapes du
processus angiogénique. Nous avons démontré que les angiopoïétines sont capables
de moduler des processus proinflammatoires dans les cellules endothéliales (CE),
notamment la synthèse du facteur d’activation plaquettaire (PAF) et la transiocation
de la P-sélectine.
Le vascutar endothetiat growth factor (VEGF) est le seul facteur
angiogénique capable d’induire une réponse inflammatoire et cet effet inflammatoire
est médié par la synthèse endothéliale du PAF. De plus, la synthèse de PAF
endothéliale induite par le VEGF-A165 implique l’activation des voies de
signalisation des p38 et p42/44 mitogen-activated protein kinases (MAPK). Sachant
que l’inflammation joue un rôle important dans l’angiogénèse et que les
angiopoïétines agissent de concert avec le VEGF dans la modulation de la plasticité
vasculaire, nous avons donc étudié la capacité des angiopoïétines d’induire la
synthèse du PAF et les mécanismes intracellulaires par lesquels cette synthèse se
produit dans les CE. Nous avons observé qu’Angl et Ang2 induisent la
phosphorylation rapide et transitoire de Tie2, des voies p42144 et p38 MAPK ainsi
que PI3KIAkt et finalement la synthèse de PAF de façon dose- et temps-dépendante
dans les cellules d’aortes bovines (BAEC). L’effet maximal d’Angl et Ang2 sur la
synthèse de PAF est obtenu après 240 minutes de stimulation (1695% et 851%
d’augmentation respectivement). La synthèse de PAF médiée par les angiopoïétines
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nécessite l’activation des voies de signalisation intracellulaires des p38 MAPK,
p42!44 MAPK et PI3K ainsi que d’une phospholipase A2 sécrétée de type V (sPLA2-
V). De plus, nos résultats démontrent que la synthèse de PAF endothéliale induite
par les angiopoïétines est en partie médiée par une relocalisation de VEGF endogène
vers la membrane cellulaire.
Nous avons récemment démontré que le PAF est impliqué dans la
translocation de la P-sélectine et l’adhésion de neutrophiles sur les CE induite par le
VEGF-A165 et que Angi et Ang2 étaient capables de promouvoir la translocation de
la P-sélectine endothéliale et l’adhésion de neutrophiles sur des CE. Par conséquent,
nous avons voulu déterminer les mécanismes impliqués et le rôle du PAF endogène
dans la translocation de la P-sélectine endothéliale par les angiopoïétines. Nous
avons observé que Angi et Ang2 (11Y9 M) pouvaient induire une activation rapide du
récepteur Tie2 et une translocation rapide et transitoire (maximale à 7,5 minutes et
correspondant à des augmentations de 125% et 100% sur les valeurs témoins,
respectivement) de la P-sélectine. De plus, nous avons décrit pour la première fois
que la translocation de la P-sélectine endothéliale induite par les angiopoïétines
dépend du calcium en plus d’être régulée par l’activation de la phospholipase C-y
(PLC-y).
En conclusion, nos résultats démontrent que les angiopoïétines possèdent la
capacité de moduler des effets proinflammatoires tels la synthèse de PAF et la
translocation de la P-sélectine au niveau de l’endothélium.
Mots clés: Angiopoïétines, inflammation, angiogénèse, facteur d’activation
plaquettaire (PAF), P-sélectine, Tie2.
VSummary
Recently discovered, Angi and Ang2, upon binding to the Tie2 tyrosine
kinase receptor, modulate vascular permeabïlity and integrity, contributing to
angiogenesis. Herein, we demonstrated that angiopoietins are capable of modulating
proinflammatory processes in endothelial ceils (EC), namely the synthesis of platelet
activating factor (PAF) and P-selectin transiocation. In addition, we also identified
the intracellular mechanisms responsible for these biological effects.
Vascular endothelial growth factor (VEGF) is the only angiogenic growth
factor capable of inducing an inflammatory response and we have demonstrated that
this effect is mediated by the endothelial synthesis of PAF. Furthermore, VEGF-A165-
mediated endothelial PAF synthesis requires the activation of both p38 and p42144
mitogen-activated protein kinases (MAPK). Since inflammation exists in a mutually
dependent association with angiogenesis and angiopoietins act in concert with VEGF
to modulate vascular plasticity during postnatal neovascularization, we sought to
determine whether Angi andlor Ang2 were capable of inducing endothelial PAF
synthesis and if so, what mechanisms were implicated. Treatment of bovine aortic
endothelial ceils (BAEC) with Angi or Ang2 (iOE9 M) induced a rapid Tie2
phosphorylation and a rapid, progressive and sustained endothelial PAF synthesis
maximal wïthin 240 minutes (1695% and 851% increase, respectively). Angiopoietin
mediated endothelial PAF synthesis requires the activation of the p38 and p42144
MAPKs, PI3K intracellular signalling pathways, and a secreted phospholipase A2
(sPLA2-V). Furthermore, angiopoietin-mediated PAF synthesis is partly driven by a
relocalization of endogenous VEGF to the ceil surface membrane.
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We have recently reported that VEGF-A165 inflammatory effects are mediated
through the synthesis of PAF by endothelial ceils which contributes to the induction
of endothelial P-selectin transiocation and neutrophil adhesion onto activated EC.
Furthermore, our laboratory demonstrated that Angi and Ang2 are also both capable
of promoting endothelial P-selectin transiocation and neutrophil adhesion onto EC.
We therefore sought to investigate the cellular mechanisms implicated in
angiopoietin-mediated P-selectin transiocation in BAEC and assess the role of PAF
in this process. We observed that Angi and Ang2 (11Y9 M) are both capable of
mediating a rapid Tie2 phosphorylation as well as a rapid and transient endothelial P
selectin transiocation maximal within 7.5 minutes (125% and 100% increase,
respectively over control values). In addition, we demonstrate for the first time that
angiopoietin-mediated endothelial P-selectin transiocation is calcium-dependent and
regulated through phospholipase C-y (PLC-7) activation.
In conclusion, our data demonstrate that angiopoietins are capable of
modulating proinflammatory events, namely endothelial PAF synthesis and P
selectin transiocation in BAEC and shed light on the intracellular pathways through
which angiopoietins regulate these events.
Keywords: Angiopoietins, inflammation, angiogenesis, platelet-activating factor
(PAF), P-selectin, Tie2.
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1.0 Introduction
1.1 Biology of the vascutar endothelium
1.1.1 Role of the endothehum in vascular homeostasis
The vascular system has fascinated mankind for thousands of years. Egyptian
physicians recognized that ‘there were vessels in him for every part of the body’ ,
Aristotie considered that ‘bfood vessels are like watercourses in gardens: they start
from one spring and branch off into numerous channels so as to supply every part of
the garden’ ‘, and Leonardo da Vinci (1452-1519) speculated that the vasculature
developed like a tree from a seed (the heart) by sprouting roots (capillaiy network)
and a trunk with major branches (the aorta and arteries) 2 Indeed, the complexity of
the vascular system prompted the formulation of several hypotheses in an attempt to
understand its functioning and regulation. However, the defence of these postulates
was rendered difficuit by the absence of anatomic proof. William Harvey (157$-
1657) was the first physiologist to describe the circulation of blood in large vessels
yet he could flot explain how blood passed from the arteries to the veins. Thirty years
later, Malpighi (162$-1694) observed, through the newly developed microscope, the
interconnecting capillary network. Pioneering work conducted by Ruysch, (163$-
1731) enabled the development of techniques permitting the identification of the
micro- and macroscopic constituents of blood vessels enabling anatomic research to
progress.
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The ceilular monolayer carpeting the luminal aspect of blood vessels attracted
the attention of various researchers. The term endothelium was coined by His in
1865 who believed that this layer served solely as a physicai barrier to prevent blood
from flowing into the surrounding tissues . However, others beiieved that the
endothelium played a crucial foie in homeostasis, namely preventing the formation of
thrombi and the invasion of smooth muscle celis (SMC) into the vascular lumen .
Due to their direct contact with biood, endothelial cells perform a critical role in ail
aspects of tissue homeostasis. Endothelial cells regulate vascular tone through
interaction with components of the peripheral nervous system ami are involved in
thrombolysis and blood coagulation. Endothelial celis are aiso implicated in
inflammatory and immunological processes. The endothelial cells surface consists of
a layer of surface glycoprotein (glycocalyx) that provides flot only a local charged
barrier to the transendotheliai migration of blood celis and plasma proteins under
normai physiological conditions but is also physioiogicaily active 6 CeIls within the
vessel wall communicate with surrounding celis, can sense changes in pressure and
flow, and can secrete molecules that perform various functions. The beiief that
endothelial celis (EC) were merely barriers between blood and the interstitium was
revolved.
1.1.2 Role of the endothelium in the pathogenesis ofvascular disorders
Despite their role in the maintenance of vascular homeostasis, endothelial ceils may
aiso play a deleterious role under certain situations such as inflammation. British
2
surgeon John Hunter (172$-1793) reported that the characteristic redness associated
with inflammation is due to increased blood flow through dilated vessels. Early work
placed an emphasis on the fact that inflammation is characterized by an endothelium
dependent alteration in the vasculature. Furthermore, the endothelium was directly
associated with the accumulation and transmigration of leukocytes into underlying
tissues
Recent studies have demonstrated the crucial role played by the endothelium in the
development of various types of cancer. In fact, early studies reported that cancerous
tumours contain a high density network of blood vessels that supply the rapidly
growing cancerous celis with the necessary oxygen and nutrients and that the
disruption or inhibition of this vascular network may be a key in the treatment of
cancer . It is now commonly accepted that the unorganized growth of new blood
vessels is present in other pathologies such as atherosclerosis, retinopathies, psoriasis,
and rheumatoid arthritis 9-11 Thus, the endothelium possesses a dual nature. On one
hand, the endothelium plays a predominant role in the maintenance of homeostasis
yet it can regulate the progression ofvarious pathologies.
1.2 Angiogenesis
1.2.1 Overview
Angiogenesis is defined as the formation of blood vessets from pre-existing ones.
Tissue and ceils require blood to supply the nutrients and oxygen required for
homeostasis and growth. In 1935, Arthur Tremain Hertig (1904-1990) described
3
angiogenesis in the placenta of pregnant monkeys. Classic angiogenesis, or sprouting
angiogenesis, lias been extensively studied and its stepwise progression was initially
detailed by Dr. Folkman in 1971 ° Angiogenesis initiates with vasodilation and an
increase in vascular permeability in response to local hypoxia. Hypoxia is an
important stimulus for expansion of the vascular bed once tissues are no longer
oxygenated by simple diffusion. Hypoxia triggers angiogenesis tbrough the hypoxia
indicible factor (HIF-la). HIF is an c43 heterodimer initially identified as a DNA
binding factor implicated in erythropoietin hypoxia-inducible activity 12 HIf-la
subunits are inducible by hypoxia and are able to interact with hypoxia-responsive
element to induce transcriptional activity. Under normoxia, HIF-la is rapidly
inactivated by proteolysis but in a liypoxic environment, HIF-la mediates the
increase in expression of various angiogenic factors such as vascular endothelial
growth factor (VEGf) which increases vascular permeability. The ensuing protein
extravasation of plasma proteins lays down a provisional scaffold for migrating
endothelial cells 13 The increase in permeability is mediated by the formation of
fenestrations and a redistribution of platelet endothelial celi adhesion molecule
(PECAM) and vascular endothelial (VE)-cadherin. The intercellular junctions are
Ioosened and the endothelial ceils may disengage from supporting structures
(pericytes or smooth muscle ceils) in response to the degradation of the basement
membrane and the extracellular matrix. Pericytes, or perivascular ceils surround and
provide endothelial cells, which lack their own blood supply, with a balanced cellular
microenvironment. Liberated, the proliferating celis can then migrate to the site of
neovascularization and form tubular structures that mature through vessel
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remodelling. Once assembled into vessels, endothelial ceils become quiescent and
survive for years. A summary ofclassic angiogenesis appears in Figure 1.
1.2.2 Physiological angiogenesis
In the embryo, endothelial progenitors originating from the differentiation of
angioblasts, assemble in a primitive capillary plexus in a process termed
vasculogenesis. Afier the primary capillary plexus is formed, more endothelial celis
are generated and may form new capillaries through angiogenesis. Endothelial ceils
can differentiate into either arterial or venous cells in embryonic development
indicating remarkable phenotypic plasticity 14 Angiogenesis is a necessary
physiological process in embryonic development whereas neovascularization in the
adult occurs under specific conditions.
Angiogenesis is commonly observed during wound healing where sprouting induces
the formation of new capillaries from pre-existing ones. In aduits, endothelial ceils
differentiate from endothelial progenitor celis (EPC), mesoangioblasts, multipotent
aduit progenitor ceils, or side-population ceils in bone marrow During the
formation of new connective tissue, hypervascularization is observed and once the
injury repaired, most ofthe neovessels regress and normal vascularization is restored.
During prolonged physical efforts, localized hypoxia may occur in skeletal muscle in
response to the increased oxygen demand and this situation may be compensated for,
in the long-term, through the formation of new vessels 16 Lastly, the fernale
reproductive system consists of the only tissues whose vasculature undergoes regular
6
growth and regression. Upon ovulation and follicular rupture, the remaining ceils
form the corpus luteum and secrete estradiol and progesterone. The ensuing growth
and maturation of the corpus luteum resuits in an intense vascular development and at
the end of the menstrual cycle, this vascular network regresses. In unison, the uterine
lining also undergoes angiogenesis in preparation for the potential implantation of the
embryo. In absence of fertilization, the endometrial vasculature regresses.
1.23 Pathological angiogenesis
Dysregulated vessel growth may have a significant impact on health and contribute to
the pathogenesis of many disorders. Indeed, numerous disorders are characterized or
caused by excessive angiogenesis including cancer, psoriasis, rheumatoid arthritis,
retinopathies, and atherosclerosis t’ for review). Interestingly, a high fat diet has
been demonstrated to promote angiogenesis in adipose tissue and angiogenic factors
stimulate adipogenesis 17,18 Other disorders may be attributable to abnormal vessel
regression and maturation such as purpura, preeclampsia, nephropathy, and impaired
reendothelialization afier arterial injury j. If blood supply is impaired, tissue
ischemia may resuit leading to patient death or disability. Conversely, excessive
vessel growth could lead to increased tumour growth or inflammation. An in-depth
understanding of the molecular mechanisms of angiogenesis is of paramount
importance for the development of therapeutic strategies to combat inflammatory,
malignant, and ischaemic disorders. Natural inhibitors of angiogenesis, such as
angiostatin and endostatin 19,20 have been identified and soluble receptors of
angiogenic factors have been shown to efficiently block tumour angiogenesis and
7
growth 21,22 However, efforts to therapeutically generate new blood vessels have flot
been as successful as those to inhibit angiogenesis and strategies must be explored.
1.3 Regulation of angiogenesis
The aforementioned angiogenic processes are subject to a tight and rigorous control
at the molecular level. The consensus is that the regulated induction, stabilization,
and regression of the vasculature are the resuit of a balance between angiogenic and
angiostatic elements. Once the equilibrium is disrupted and the balance shifis,
angiogenesis is either induced or repressed. Until recently, vascular endothelial
growth factor (VEGf) was the only growth factor proven to be specific to and critical
for blood vessel formation 11,23 Other growth factors, such as fibroblast growth
factor (fGf) had effects in endothelial ccli assays 2 but also acted on many other celi
types. New growth factors, namely the angiopoietins, acting on the vascular
endothelium in a tightly regulated complementary and coordinated manner have
recently been identifled 24,25
1.3.1 Vascular endothelial growth factor (VEGF-A)
Initially identified as vascular permeability factor (VPf) in the 1 980s because tumour
growth is associated with increased microvascular permeabiÏity, VEGf is the most
important modulator of vascular formation. The gene coding for VEGf-A is
composed of 8 exons separated by 7 introns (figure 2). Altemate spiicing gives rise
8
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to 6 different isoforms ofVEGF-A respectively comprising 206, 189, 183, 165, 145,
or 121 amino acids 26-2$ These isoforms differ from one another by the presence or
absence of sequences encoded by exons 6 and 7, sequences responsible for binding to
heparin and the extracellular matrix. VEGf-A165, the most abundant and potent
isoform, does flot possess exon 6 and displays a moderate affinity for heparin which
explains why 50 to 70% of secreted VEGF-A165 remains bound to ceils or the
extracellular matrix 29 On the other hand, VEGf-A121 has neither exon 6 or 7 and
does flot bind heparin and is thus ftee to diffuse in the circulation °. In addition, the
lack of exon 7 also prevents VEGf-A121 from binding to the neuropilin-1 (NRP-1)
coreceptor and thus it is less powerful than VEGf-A165 at inducing biological effects.
In contrast, VEGF-A189 and —A206 possess exons 6 and 7 and thus are completely
sequestered with the extracellular matrix 31•
Other members of the VEGF family were identified based on their homology to
VEGF-A: placental growth factor (P1GF), VEGF-B, VEGF-C, VEGF-D, and VEGF
E 32-35 Placenta! growth factor and VEGF-B both play a predominant role in
embryonic development 32 P1Gf knockout mice do flot have an apparent phenotype.
However, these mice recover poorly from experimental myocardial infarction and
exhibit impaired collateral formation in response to hind limb ischemia 36
Overexpression of P1Gf in the skin of transgenic mice resuits in a hypervascular
phenotype with increased inflammatory and permeabitity responses while local
administration of P1Gf with recombinant adenoviruses or as a recombinant protein
induces the formation of mature, leakage-resistant vessels in a macrophage
10
dependent manner . The precise role of VEGf-B in vivo is flot known. Since
VEGF-B is highly expressed in striated muscle, myocardium and brown fat 40,41, its
function may be linked to high cellular energy metabolism.
On the other hand, VEGF-C and —D are synthesized as precursors that may be
metabolized into by-products with various properties 42,43• VEGf-C is expressed
predominantly in regions where lympliatic vessels develop The expression and
mice lacking both VEGF-C alleles fail to develop lymphatic vessels and succumb to
tissue edema at E15.5—E17.5 VEGF-D is present in most human tissues, most
abundantly in the lung and skin during embryogenesis 46• In experimental tumours
VEGF-D increases lymphatic vesse! growth and lymphatic metastasis “. VEGF-D is
expressed by melanoma ceils and has been proposed to have a ro!e in tumour
angiogenesis and !ymphangiogenesis in this tumour 48• VEGF-E, identified in the
genome of the Orf virus (0V), possesses similar mitotic and vascular permeability
effects as VEGF-A165 a!though it shows about 25% homology with mammalian
VEGF
VEGF-A165 possesses several biological fiinctions and it is produced by many
different celi types, including endothelial celis and vascular smooth muscle celis,
upon activation by various stimuli including hypoxia, oxidative stress, hormones and
other growth factors In angiogenesis, it is the key cytokine and p!ays a role
throughout the process. VEGf-A165 mediates vasodi!ation through nitric oxide (NO),
prostacyc!in (PGI2), and PAF synthesis which also modulates vascular permeability
55.56 NO synthesis is mediated by the activation ofnitric oxide synthase (NOS). Our
11
laboratory has recently demonstrated that the activation of endothelial NOS (eNOS)
by VEGf-A165 may occur through two pathways: a rapid, calcium-dependent one or a
delayed, Akt-dependent one The resulting vasodilation permits the induction of
morphological changes required to enhance the protiferative and mitogenic effects of
VEGf-A165 The breakdown of the basal membrane by the localized release of
MMPs from endothelial ceils is also mediated by VEGF-A165 as is the subsequent
celi proliferation, migration, and capillary-like tubule formation 60-62 VEGF-A165 is
also an inflammatory mediator 63,64 through its translocation and expression of
various ce!! adhesion molecules such as P-se!ectin, E-selectin, interce!!ular adhesion
molecu!e-1 (ICAM-l) and vascu!ar celi adhesion molecu!e-l (VCAM-l) which
favour the binding of leukocytes such as neutrophils and monocytes to the
endothe!ium 65,66 The mitogenic effects of VEGF-A165 are mediated by the
activation of the p42144 MAPK intracellular signalling pathway through a Ras
independent (favouring PLC and PKC) or a Ras-dependent pathway requiring
scaffolding proteins such as Sos, Grb2, and Shc leading to the transcription 67 The
ability of VEGF-A165 to mediate the migration of endothelia! celis is due to a rapid
interaction with VEGf receptor-2 (VEGfR-2) and integrins and the activation of the
p38 MAPK pathway. VEGF-A165 is also a celi survival factor through the expression
of anti-apoptotic mo!ecules such as Bd-2, Ai, survivin, and XIAP 68,69 VEGf-A165-
mediated ceil survival depends on the activation ofthe PI3K!Akt pathway which may
!ead to NO synthesis or inhibition of p38 MAPK-mediated apoptotic mechanisms 69-
71
12
1.3.1.1 Regulation of VEGf-A165 expression
The expression of VEGF-A165 is primarily induced under hypoxic conditions via
hypoxia inducible factor (HIF) regulated elements of the VEGF gene 72• The HIF-1
complex is composed of two subunits, HIF-la and HIF-1f3 Under normal
conditions (ie. when oxygen is present), HIF-1f3 is readily present within the ceil
whereas HIF- 1 ct is absent since it is rapidly degraded by the ubiquitin-proteosome
system by direct proline hydroxylation ‘7. This hydroxylation permits the
recruitment of the Von Hippel Lindau tumour suppressor gene product (pVHL)
which targets HIF-1Œ for proteosomal degradation 76,77 Constitutive degradation of
hypoxia inducible factor (HIF)- 1 a is blocked in hypoxia because of the oxygen
requirement of HIF-specific proline hydroxylases, promoting the stabilization of
HIF-1Œ and its heterodimerization with HIF-1f3, also called the aryl hydrocarbon
nuclear transiocator (ARNT). These complexes then bind hypoxia-responsive
elements (HREs) in the promoters of hypoxia inducible genes and initiate
transcription of approximately seventy genes, including genes involved in glucose
transport, glycolysis, and angiogenesis 72,78 Regulation of the expression of VEGF
A165 through oxygen levels may also occur in collaboration with other growth factors
such as epidermal growth factor (EGF), transforming growth factor (TGF-Œ and -3),
FGF, and platelet-derived growth factor and locally expressed inflammatory
cytokines, namely IL-1Œ, IL-113 and IL-6) 11,2$
13
1.3.1.2 VEGf receptors (VEGFR)
Three VEGf receptors, ail members of the receptor tyrosine kinase (RTK) family.
have been identified: VEGfR- 1, -2, and -3 with molecular weights ranging from 180
to 220 kDa. The expression of the three receptors at the ceil surface membrane is in
the monomeric form. However, in the presence of the ligand, dimerization of the
monomers occurs tbrough disulfide bonds forming homo- (R1/R1, R2/R2, or R3/R3)
or heterodimers (R1/R2 or R2/R3) VEGfR-1 and -2 were initially identified as
characteristic to endothelial celis $2,83 but studies have recently observed VEGFR-1 to
be present in monocytes, macrophages, and trophoblasts whereas VEGFR-2 is also
expressed on hematopoietic stem ceils, mesangial celis, and p1atelets 84• VEGFR-3 is
expressed in most embryonic endothelial ceils and primarily in the lymphatic
system in aduits ‘. Neuropilin-1 (NRP-1), a 140 kDa membrane protein originally
identified as a participant in neuronal growth 86, is also extensively expressed in
endothelial ceils and can interact with VEGFR-2 and potentiate the effects of VEGF
A165 65,80,87,88 A summary of the VEGF receptors and their respective Iigands
appears in Figure 3.
VEGf-A165 can bind to VEGFR-1 and R-2 but flot R-3. VEGFR-1 (fms-like tyrosine
kinase or Fit-1) is composed of seven extracellular immunoglobulin (1g) homology
domains, a single transmembrane region and an intracellular tyrosine kinase (TK)
domain that is interrupted by a kinase-insert domain VEGFR-1 was the flrst
receptor identified and its VEGf-A165 binding site is located within the second 1g
domain 90 A soluble form of VEGFR- I (sFlt- 1) exists and has neither the seventh
14
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1g domain, transmembrane domain, nor the kinase domain. Since VEGf-A165 binds
to this soluble form of VEGfR-1 with great affinity, sflt-1 sequesters VEGf-A165
and inhibits its various effects. Hypoxia increases VEGFR-1 expression, just like
VEGf-A165 through HIF-lu 91 In addition to binding VEGF-A165, VEGFR-1 may
also bind P1GF and VEGF-B 92,93• Binding of VEGf-A165 elicits only a weak
autophosphorylation and it was long believed that VEGFR- 1 was a decoy receptor
The role of VEGFR-1 in response to VEGF-A165 binding remains unclear 96-9$
The inactivation of the VEGFR-1 kinase domain (VEGFR-1 TKj in mice embryos
produced viable animais with no apparent vascular defects These observations
supported the suggestion that VEGFR- 1 was in fact a clearance receptor capable of
negatively regulating the mitogenic effects of VEGF-A165 by preventing its binding
to VEGFR-2 92 In mice deficient for the gene coding for VEGFR-1 (VEGFR-1j,
endothelial celis migrate and proliferate normally but the three-dimensional
arrangement ofthe vasculature is impaired and death occurs between embryonic days
$.5 and 9.5 (E$.5 and E9.5) In other instances, the kinase activity ofVEGFR-1 is
required, namely for the migration of monocytes and the release of plasminogen (tPA
and uPA) and matrix metalloprotease-9 (MMP-9) following treatment with VEGF
A165 We have demonstrated in vitro that a selective stimulation of VEGFR- 1 by
P1Gf only marginaiiy induced endothelial PAF synthesis and an intermediate
endothelial P-selectin transiocation 65 Furthermore, we reported that in vivo,
blocking the expression of VEGFR-1 reduced VEGF-A165-mediated angiogenesis by
85% 102 We have also recently reported that VEGF-A165-induced prostacyclin
(PGI2) synthesis requires the activation of VEGfR- 1 and -2 heterodimer Indeed,
16
pretreatment with antisense oligomers targeting VEGfR- 1 or R-2 mRNA reduced
PGI2 release mediated by VEGf-A165 and —A121 by up to 79% °. Based on the
aforementioned evidence, it would therefore appear that VEGfR- 1 is involved in
selective biological activities mediated by VEGf-A165.
Although the affinity of VEGF-A165 for VEGFR-1 is 10 times greater for than for
VEGfR-2, the latter is the primary mediator of VEGf-A165-induced angiogenic
activity. The overali structure of VEGfR-2 (kinase-insert domain receptor,
KDRJfetal liver kinase or f1k-1) is similar to that of VEGfR-1 103,104 Genetic
inactivation of VEGfR-2 (VEGfR-2j is lethal between embryonic days 8.5 (E8.5)
and 9.5 (E9.5) 105 In presence of its ligand, dimerization ofVEGFR-2 occurs which
leads to transphosphorylation of the receptor and the autophosphorylation of tyrosine
residues in the kinase domain 106 The affinity of the Src homology -2 (SH2) domain
for certain tyrosine residues favors the interaction of the receptor with phospholipase
C-y (PLC-’y) 107 In addition to a robust phosphorylation of VEGfR-2, VEGF-A165
activates several intracellular signalling pathways (figure 4). The chemotactic
properties of VEGf-A165 towards endothelial cells depend on the activation of the
p38 MAPK, an intracellular molecule responsible for the rearrangement of the
cytoskeleton 108 Cellular proliferation is under the control of the p42144 MAPK
pathway through the activation of nuclear transcription factors 108,109 Activation of
PLC-y and the subsequent hydrolysis of phosphatidylinositol 4,5 diphosphate (PIP2)
into diacylglycerol (DAG) and inositol
17
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1,4,5 triphosphate (1P3), an important regulator of intracellular calcium, also resultsin
the activation of VEGFR-2 by VEGf-A165 67,10$ The anti-apoptotic effects of
VEGF-A165 are mediated by the activation of the PI3K!Akt pathway 110 This
pathway is also capable of activating NO synthase (NOS) which is responsible for the
VEGf-A1 65-mediated NO synthesis 70,hhl•
The interaction between NRP-l and VEGFR-2 markedly increases VEGF-A165-
mediated phosphorylation of VEGFR-2 and ceil migration Initially, NRP-1 was
shown to participate in axonal growth through its ability to bind semaphorins and
collapsins $6 Subsequently, NRP-1 was described as capable of binding VEGf-A165
but flot VEGf-A121, which lacks exon 7 and thus cannot bind NRP-1 112 Strongly
expressed in endothelial ceils, NRP-1, when coexpressed with VEGfR-2, potentiates
the binding of VEGF-A165 and the ensuing biological effects . Genetic inactivation
(NRP-F’) resuits in severe defects in vascular development and overexpression
caused excess formation of dilated capillaries and blood vessels resulting in
embryonic death between E1O.5 and E12.5 $6,113 Together, these data confirm the
important role of neuropilin-1 in supporting VEGF-A165-mediated angiogenesis. We
have recently reported that NRP-1 increases the migration and proliferation of
endothelial ceils, platelet-activating factor (PAF) synthesis 88, endothelial P-selectin
translocation and adhesion of neutrophils onto endothelial cells 65 and prostacyclin
(PGI2) synthesis 80 induced by VEGF-A165.
19
1.3.2 Angiopoietins and the Tie2 receptor
In light of its critical role in angiogenesis, VEGf must nonetheless work in concert
with other factors to fine-tune vessel formation and regression. Indeed, early
therapeutic efforts based on the delivery of a single growth factor to favour
angiogenesis resulted in the formation of leaky and dysfunctional vessels 114
Recently discovered, the angiopoietins, namely Angi and Ang2, appear to be
important partners for VEGf-A165. Angiopoietins were discovered as ligands for the
lyrosine kinase with jmmunoglobulin and pidermal growth factor homology
domains (lie) receptor family 24,25 selectively expressed within the vascular
endothelium (and in other types such as haematopoietic celis) 11511$
1.3.2.1 The angiopoietins
The angiopoietin family of ligands is comprised of four members, numbered 1 to 4,
with similar molecular structures containing a fibrinogen-like domain which binds to
Tie2, a coiled-coil domain necessary for dimerization of angiopoietin monomers, and
a N-terminal that favors the formation of oligomeric structures essential to the
activation of Tie2 (figure 5) 119-122 Angi was isolated by screening conditioned
media from ceil unes for specific binding affinity for Tie2 24 and Ang2 was isolated
by screening a cDNA library using Angi cDNA as a probe 25 Angi and Ang2 bind
to the Tie2 receptor with similar specificity and affinity 24,25 Mgi
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has been characterized as a lie2 agonist, having the capacity to stabilize and promote
the maturation of unstable vessels in the presence of VEGf-A165 123 On the other
hand, Ang2 was initially described as a natural endogenous Tie2 antagonist, thereby
destabilizing existing vessels prior to VEGf-A165-induced angiogenic sprouting 25
However, recent findings have shown that Ang2 may, under certain circumstances
(concentration, autocrine or paracrine stimulation, duration of treatment, and
endothelial ceil type) induce Tie2 phosphorylation and biological activities such as
EC migration, and in vitro tubule capillary-like formation 124 12$ Angiopoietin-3
(mouse) and -4 (human) are interspecies orthologs identified through low stringency
hybridization screening using Angl and Ang2 cDNA 121 Ang4 is reported to be a
lie2 agonist whereas Ang3 inhibits Tie2 activation by Angi. However, as with
Ang2, agonist activities for Ang3 have recently been reported 129 although marginal
effects have been observed in human endothelial celis.
1.3.2.2 lie receptors
Identified in the early 1 990s, the lie receptors are a family of receptor tyrosine
kinases (RTK) containing two members, Tiel and Tie2. These two receptors share a
unique extracellular amino-terminal domain consisting of three epidermal growth
factor (EGf)-like domains, two Ig-like domains flanking the EGF-like repeats, and
three fibronectin-type III repeats located just above the transmembrane region
(figure 6). The intracellular domain of the lie receptors inctudes two conserved
tyrosine kinase domains 116,130,131 Although ligands for lie2 are well
22
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documented, ligands for Tiel have yet to be identified and thus, Tiel is considered an
orphan receptor. However, evidence is growing that Tie receptors can
heterotypicaliy associate through their intracellular domains, suggesting that Tiel
may modulate Tie2 signaliing 132 furthermore, Tiel has been shown to undergo
proteolytic cleavage by VEGF-A165, releasing a soluble extracellular domain capable
of forming a complex with Tie2 132-134 A recent study has reported that a chimeric
form of Tiel signais in the absence of Tie2 and activates the PI3K!Akt signalling
pathway 135
1.3.2.3 Role of angiopoietins and the Tie receptors in angiogenesis
Important observations on the biological significance of angiopoietins and the Tie
receptors have been made through the use of transgenic and knockout mice. Table 1
presents a summary of the various studies dissecting the role of the Tie receptors and
the angiopoietins. Embryos lacking Tie2 or Angi die in utero by embryonic days
10.5 (E10.5) and 12.5 (E12.5), respectively and display similar phenotypes 136,137
Both types of embryos display retarded cardiac growth 136,137 and the primary
capiiiary plexus fails to differentiate resulting in a vasculature of iow complexity.
Furthermore, the existing vessels appear dilated and dispiay dismpted connection of
endothelial ceils to the extracellular matrix 136,137 These resuits suggest that Ang
recruits and sustains periendothelial support ceils and is needed for the maturation of
blood vessels during embryonic development. In comparison, the deletion of a single
allele ofVEGF-A165 is sufficient to induce lethality at E 11.5 and these embryos show
severe defects in their vascuiar networks 138,139
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Interestingly, one can gain insight into the chronology of vessel formation by
comparing the phenotype of Tie 2 (Tie2 j and VEGFR-2 (VEGfR-2 j kuockouts.
Deletion of the gene coding for VEGFR-2 resuits in lethality between E$.5 and E9.5
and these embryos are characterized by an absence of blood islands and primary
capiliary plexi which illustrates the critical role of VEGfR-2 signalfing in vascular
deveiopment 105rn
Embryos lacking Tiel die between E13.5 and birth, with prominent edema in various
internai organs, resulting in haemorrhages due to impaired endothelial integrity in the
microcirculation 136 Although flot lethal during embryonic development, Ang2
knockout mice rarely exceed 14 days of postnatal life due in part to impaired
lymphatic organization and angiogenic defects 126 In these mice, the lymphatic
defects may be resolved upon gene repiacement with cDNA encoding for Angi,
suggesting that Ang2 behaves as a Tie2 agonist in lympliatic tissue 126
Transgenic mice overexpressing Angi under the control of the human keratinocyte
promoter (Ki 4-Ang 1) present a hypervascularization characterized by an increased
number, branching, number of endothelial ceils, and diameter of dermal blood
vessels 123,137 As with K14-Angl mice, K14-VEGf-A164 (VEGF-A164 in mice is the
equivaient of VEGf-A165 in humans) mice appear normal and show an increased
redness of the skin due to the hypervascularization 123,137 However, analysis of the
phenotype of these animais shows an increased vascular penneabiiity, leukocyte
infiltration, and the dermal biood vessels resemble capiiiaries 123,137 Interestingly,
26
mice overexpressing Angi and VEGF-A164 display a markedly increased dermai
vascularization characterized by greater redness, vesseis are more numerous and
possess characteristics of both phenotypes although no leukocyte infiltration was
observed 123,137 In addition, mice overexpressing Ang2 display a phenotype similar
to what was described for AngF’ animais. Indeed, overexpression of Ang2 induces
iethality between E9 and ElO due to a discontinuous vascular network devoid of
capiilary branching as welI as cardiac malformations 25 Taken together, these
observations suggest that Angi inhibits certain inflammatory actions of VEGf-A165
and stabilizes the vasculature whereas Ang2 behaves like a Tie2 antagonist during
embryonic development (Figure 7).
Although Mgi does flot stimulate endothelial cell proliferation 24 it can nonetheless
induce endothelial ceii migration 140 tubule formation 141 and sprouting 142,143 and
survival from a variety of apoptotic insuits 144-146 in vitro. Taken together, these
observations and the resuits of the above animal studies demonstrate that Angi is a
potent proangiogenic factor. Angi can aiso interact directly with integrins at the
surface of endotheiial celis to favour their adhesion and, in the event of angiogenesis,
their migration through its chemotactic effects 140,147• In addition, prolonged
treatment with Mgi reduces VEGF-A165-mediated neutrophil adhesion and the
expression of certain adhesion molecules (ICAM- 1, VCAM- 1, and E-selectin) 148
27
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The role ofAng2 in blood vessel regulation, on the other hand, is quite complex. The
expression of Ang2 in endothelial ceils suggests that Ang2 may act in an autocrine
manner to control endothelial ceil quiescence and responsiveness. As mentioned
above, transgenic overexpression of Ang2 is lethal, suggesting that it behaves as a
Tie2 antagonist 25 Initially, in vitro experiments confirmed this by demonstrating
that Ang2 prevented Angl-mediated Tie2 phosphorylation 25 and migration I4O
However, Ang2 was shown to activate ecotopically-expressed Tie2 on fibroblasts 25
Furthermore, recent studies have demonstrated that under certain circumstances,
Ang2 may induce, following Tie2 activation, biological activities such as endothelial
cel! (EC) migration, neutrophil activation, vascular permeability, and in vitro tubule
capillary-like formation 124,125,127,149,150 Ang2 also promotes endothelial ce!! survival
through activation of the PI3KIAkt signalling pathway 127 In addition, HUVEC and
fibrob!asts plated on various surfaces coated with Ang2 were shown to adhere and
spread. In the presence of VEUF, Ang2 induces the pro!iferation and migration of
endothelial celis and promotes the sprouting of new vessels in vivo whereas vessel
regression occurs when the activity of endogenous VEGF is inhibited 151• Ang2 has
a!so recently been shown to be stored in endothelial celis within organelles ca!!ed
Weibel-Palade bodies (WPB) from which it can be rapidly secreted, suggesting that
Ang2 may be implicated in other processes besides angiogenesis 152
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1.3.2.4 Regulation ofthe expression of angiopoietins
Angi mRNA is primarily expressed in periendothelial ceils (pericytes and vascular
smooth muscle celis) 146 whereas Ang2 mRNA is selectively expressed in endothelial
ceils in aduit tissues that undergo vascular remodelling such as the ovaries, uterus,
and placenta 25
In the aduit, Angi is expressed in many tissues such as the reproductive system,
skeletal muscle, and small quantities in the heart and liver. A recent study reports
that hypoxia modulates the expression levels of Angi in pericytes but flot in
endothelial celis 153 The presence of a hypoxia-responsive element (HRE) on the
Angi promoter has yet to be determined. This upregulation may also be mediated in
collaboration with other growth factors, namely VEGF-A165 which can double Angi
mRNA expression in pericytes 153 However, TNF-a has been shown, depending on
the study and ceil type used to either increase or decrease Angi mRNA expression
levels
154,155
Hypoxia also increases Ang2 expression in macro- and microvascular endothelial
ceils 156,157 furthermore, VEGF-A165, bfGf, and TNf-a increase Ang2 mRNA
expression in endothelial celis 156-15$ In a rat ovary model of angiogenesis, Ang2 and
VEGF mRNA were coexpressed at the front of invading sprouts during active
angiogenesis whereas Ang2, but flot VEGF, was upregulated during vessel regressiofi
25 Studies show that tyrosine kinase, MAPK, and PKC-dependent pathways play a
crucial role in VEGF-induced Ang2 expression 157 TNf-cx increases Ang2
30
expression in part through Nf-icB activation in human umbilical vein endothelial
ceils (HUVEC) It has also been demonstrated that angiotensin II induces Ang2
expression but flot Mgi in cardiac and microvascular celis 159,160 High levels of
Ang2 are expressed in a wide variety of highly vascular tumours (161 for review)
suggesting that Ang2 plays an important role in the initiation oftumour angiogenesis.
1.3.2.5 Signalling pathways activated by angiopoietins
Previous studies reported that Angi is capable of activating p38 and p42144 MAPKs
162
as well as the PI3KIAkt signal transduction pathways 146 Prior to our study, liffle
was known with regards to potential intracellular events following the activation of
Tie2 by Ang2. A summary of the signalling pathways activated upon angiopoietin
binding to Tie2 appears in figure 8. In addition, other studies have reported that Tie2
activates signal transducers and activators of transcription-3 and -5 (STATs) 163
known to play a role in celi proliferation, differentiation, migration, and survival.
Phosphorylated Tie2 interacts cytoplasmically with the Grb family of scaffolding
proteins and the p85 subunit of PI3K via their SH2 domains 164 The interaction of
p85 and Tie2 resuits in the activation of PI3K and the subsequent activation of Akt
165 Angl is implicated in ceil survival 144,145 and this activitiy is mediated by the
PI3KJAkt pathway 146,166 furthermore, the activation of p42/44 MAPK signalling by
Mgi regulates apoptosis in endothelial celis through the phosphorylation of
transcription factors favouring the inhibitory action of caspases -
31
D-
I..
1I
\jI
Iç1
I\1
r1
IJ
I
i
L
.’
M
ig
ra
tio
n
Tr
an
sc
rip
tio
n f
ac
to
rs
In
hi
bi
tio
n
o
f a
po
pt
os
is
Fi
gu
re
8:
In
tr
ac
el
lu
la
r
si
gn
al
lin
g
pa
th
w
ay
s
a
c
tiv
at
ed
by
th
e
a
n
gi
op
oi
et
în
s.
St
im
ul
at
io
n
o
f
Ti
e2
w
ith
A
ng
i a
ct
iv
at
es
th
e
p3
8
M
A
PK
,
p4
2/
44
M
A
PK
, a
n
d
PI
3K
/A
kt
pa
th
w
ay
s.
A
ng
2
ha
s
be
en
sh
ow
n
to
ac
tiv
at
e
th
e
PI
3K
JA
kt
pa
th
w
ay
w
hi
ch
m
ed
ia
te
s
ce
li
su
rv
iv
al
.
Si
gn
al
lin
g
by
th
e
Ti
el
re
ce
pt
or
re
m
ai
ns
to
be
de
sc
rib
ed
.
D
A
ng
i
A
ng
2
A
po
pt
os
is
4,
€
4
M
A
P
K
IL
_
_
_
_
_
_
Ce
il
A
kt
su
rv
iv
al
R
el
ax
at
io
n
3, -7, and 162 The promotion of ce!! survival contributes to the quiescence and
stability of endotheliai ceils. Another function of Angi is the recruitment of
pericytes. This activity requires the activation of the p38 MAPK pathway 167 Ang2
has also been shown to be a ceil survival factor through the activation of the
PI3KIAkt signalling pathway 127 However, littie is known with respect to the
signalling pathways activated by Ang2 in endothelial celis.
1.3.2.6 Angiopoietins in pathologicai angiogenesis
Angiogenesis plays an important foie in severai beneficial biologicai events such as
embryonic development, wound healing and, regulation of the femaie reproductive
cycle. However, angiogenesis is aiso a component of various pathologies. Recent
insight into the angiogenic process has determined that the complex sequence of
events leading to the formation of neovessels requires the collaboration of various
angiogenic mediators, namely VEGF and the angiopoietins. In addition, recent
studies have begun defining roies for the angiopoietins in inflammation. Therefore, it
is important to present the contribution of angiopoietins to pathoiogical angiogenesis.
1.3.2.6.1 Angiopoietins in tumour vascuiarization
In addition to a genetic component, tumour progression and propagation requires the
induction of tumour vascularization, termed the ‘angiogenic switch’ (168 for review).
Induction of the angiogenic switch depends on the balance between anti-angiogenic
and pro-angiogenic factors and can be induced at various stages of tumour
development. Tumours have lost the appropriate balance between positive and
33
negative regulatory mechanisms that characterize normal, physiological
angiogenesis. The switch begins with perivascular detachment and vessel dilation
folÏowed by angiogenic sprouting, new vessel formation and maturation to provide
the hypoxic regions of the tumour supplied with oxygen and nutrients 168 Tumour
blood vessels are irregularly shaped, dilated, torturous, may have dead ends, and are
ofien leaky and haemorrhagic due to an overproduction of VEGF. It has been
suggested that cancer ceils initially encroach upon existing microvessels (co-option)
followed by destabilization and regression of the vessels in the center of the tumour,
and initiation of new capillary growth at the periphery of the tumour 15$. In certain
cases, tumours may recruit endothelial precursor celis from bone marrow which
become incorporated into the walls of growing vessels through the action of VEGf
A165, PIGF, and Angi 169,170 However, the number of circulating endothelial
precursors is low and although some tumours have been shown to progress in this
manner
171
most tumour neovascularization occurs through angiogenesis.
The role of Angi in tumour angiogenesis is not clear. Overexpression of Angi has
been observed in malignant glioblastoma 172,173, neuroblastoma 174 non-small cell
lung cancer 175 and variably in other tumours as well 161• However, certain studies
using xenograft models demonstrate ectopic expression of Angi in breast 176 and
colon 177 cancer ceils resuits in decreased tumour proliferation and angiogenesis. In
addition, a similar tumour inhibitory role for Angi has been observed in squamous
ceil carcinoma (SCC) models overexpressing Angi’ The explanation for this
apparent paradox may lie in the ability of Angl to recruit mural celis to stabilize
34
vessels since vessels in the aforementioned tumours ail displayed increased pericyte
recniitment, suggesting that mature blood vessels functionally inhibit tumour
angiogenesis through enhanced celi-celi junctions, rendering the vessel iess prone to
angiogenesis 161 In reviewing the literature, what becomes apparent is that although
absolute levels of either Angi or Ang2 increase or decrease depending on the type of
tumoural mode!, the ratio of Angi to Ang2 within tumours shifis in favour of Ang2
179 High !evels ofAng2 mRNA are observed in highly vascularized tumours such as
g!ioblastoma, Kaposi’s sarcoma. cutaneous angiosarcoma, hemangioma, thyroid
tumours, as weil as gastric and colorectal cancer 172,180-184 The overexpression of
Ang2 in tumours is ofien accompanied by that of VEGf 161 suggesting that the
destabilization of vesse!s by Ang2 permits VEGf-mediated angiogenesis to proceed.
It would therefore appear that Ang2 plays an important role in the initiation of
tumour angiogenesis through its ability to antagonize Angl-induced vesse!
stabi!ization. The abi!ity of tumours to shift the angiogenic balance towards a pro
angiogenic state by altering the balance between angiopoietins may impiicate Ang2
as a candidate for the angiogenic switch
1.3.2.6.2 Angiopoietins in inflammation
The ro!e of Angi in inflammation is current!y under investigation and in light of the
anima! studies demonstrating the abi!ity of Angi to inhibit certain inflammatory
actions of VEGF-A165, recent reports indicate that Angi possesses anti-inflammatory
abi!ities. Indeed, Angi was shown to reduce VEGf-A165-stimu!ated !eukocyte
adhesion to HUVEC through a reduction in the expression of adhesion molecules,
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namely intercellular adhesion molecule-l (ICAM-1), vascular ccli adhesion
molecule-l (VCAM-1), and E-selectin 148 In this study, Angi by itselfhad no effect
on leukocyte adhesion or the expression of adhesion molecules within 4 hours but it
counteracted VEGF-induced inflammation. The antiinflammatory effects of Angi
were further demonstrated when endotheliai permeability, neutrophil adhesion to
endothelial ceils, and interleukin-8 (IL-8) production by endothelial ceils were
inhibited following at least 1 hour of treatment with Angi 185 In addition,
polymorphonuclear neutrophil (PMN) migration across endothelial monolayers
stimulated by TNF-a was atso reduced in response to treatment with angiopoietin-1
186 Moreover, the localization of proteins such as platelet endothelial ce!! adhesion
molecu!e-1 (PECAM-1) into junctions between endothelia! ceils was enhanced as
evidenced by a decrease in basal permeability and inhibition of permeabiiity
responses to thrombin and vascular endothelial growth factor 186 VEGf-mediated
permeabi!ity is associated with the disruption of endothelial celi junctionai
complexes, dissociation of f3-catenin from vascular endothelial (VE)-cadherin, and
accumulation of f3-catenin in the cytosol 187,188 and this pathway requires the
activation of protein kinase C-f3 (PKCf3) isoforms which is b!ocked by Angi ‘.
Taken together, the above in vitro studies appear to confirm that Angi inhibits the
proinflammatory effects ofVEGF-A165.
Until recently, !ittle was known about the potential role of Ang2 in inflammatory
processes. However, Ang2 has been shown in vivo to induce edema formation in the
mouse paw in a dose-dependent marmer which is blocked by administration of
36
soluble Tie2 receptor or Angi 150 In addition to edema, a weak stimulatory effect on
leukocyte migration was observed in the mouse paw following treatment with Ang2
Similarly, Ang2 injected into the mouse air pouch produced a modest effect on
leukocyte migration ‘° The recent identification of Ang2 as a stored, rapidly
secreted molecule in endothelial celis strongly suggests that Ang2 may play a role in
rapid vascular homeostatic reactions such as inflammation 152 Stimulation of
endothelial ceils with thrombin, phorbol myristate acetate (PMA), or histamine
induced a rapid release of Ang2 (within 5 minutes) from Weibel-Palade bodies
whereas treatment with VEGF-A165, Angi, bFGF, or transforming growth factor f3
(TGF-f3) did flot induce Ang2 release 152 The released Ang2 could, in mm, modulate
the destabilization of the vasculature in the presence of VEGf-A165 or act in an
independent manner and promote proinflammatory events.
1.4 The inflammatory response and angiogenesis
It is now well established that the inflammatory response and angiogenesis are
mutually inclusive based on observations that tumours demonstrate increased
vascular permeability and the presence of inflammatory ceils such as neutrophils and
macrophages at angiogenic sites 8,23,190 During inflammation, new vessels provide
essential oxygen and nutrients to inflamed tissues. furthermore, the vasculature
enables inflammatory ceils, namely neutrophils and monocytes/macrophages, to
reach the affected site and secrete cytokines, growth factors (ie. VEGf-A165) 191 and
proteases (ie. MMP-2 and MMP-9) 192,193 to regulate the angiogenic response.
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Inflammation can be divided into two major categories, chronic or acute. Chronic
inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and
inflammatory bowel disease are characterized by a prolonged duration (weeks to
years) and infiltration of monocytes and fibrosis in which active inflammation, tissue
destruction, and attempts at tissue repair are occurring simultaneously 194 Acute
inflammation is of relatively short duration (minutes to days) and is characterized by
vasodilation which facilitates the local delivery of soluble mediators and
inflammatory celis, the exudation of protein-rich plasma, and the migration of
neutrophils to the site of injury ‘. The vasodilatory response is mediated by nitric
oxide (NO) throught the action of nitric oxide synthase (NOS) and prostaglandins
mostly PGI2 produced from arachidonic acid through the action of cyclooxygenases
196 The exudation of plasma into the surrounding tissues is termed edema and is
representative of an increase in vascular permeability resulting from the actions of
inflammatory mediators such as VEGF-A165, histamine, bradykinin, leukotrienes, and
PAF which act on intercellular junctions between endothelial ceils. The inflamed
region swells and displays a characteristic redness and warmth.
1.4.1 PAF, an inflammatory mediator
Initially identified in rabbit leukocytes, platelet-activating factor (PAF; l-O-alkyl-2-
acetyl-sn-glycero-3-phosphocholine) has now been shown to possess a variety of
biological activities 197 PAF has been shown to participate in embryogenesis and
angiogenesis through its ability to induce endothelial ceil migration 19$ Studies have
also reported that PAF can act as both an inter- and intracellular messenger 199, can
3$
modulate cardiac function by acting on cardiornyocytes, and reduce blood pressure
200,201 PAF may also mediate both an acute and chronic inflammatory response 202
The increase in vascular permeability observed upon treatment with PAF is the resuit
of PAF binding to its extra- and intracellular receptors (PAFR) and inducing an
increase in intracellular calcium which in tum favours the contraction of the actin
skeleton, shrinkage of the ceil and the formation of gaps between adjoining celis
201,203,204 PAF may also be colocalized at the endothelial ceil surface with P-selectin
and mediate leukocyte rolling, activation, and adhesion onto the endothelium 205,206
1.4.1.1 PAF synthesis
PAF may be synthesized through two distict pathways. Physiological amounts of
PAF are synthesized via the de novo pathway in the kidney and central nervous
system 207,20$ whereas PAF synthesis in stimulated inflammatory cells is regulated by
the ‘remodelling pathway’. This pathway rapidly generates large quantities of PAF
and regulates ‘very early’ (2 to 5 minutes) and ‘early’ (10 to 40 minutes) PAF
synthesis and its activity is controlled by cytosolic calcium (Ca2) and the activation
of either a phospholipase A2 (PLA2) or a coenzyme A (CoA)-independent
transacyclase to generate lyso-PAF, a biologically inactive PAF precursor 197 for
review). Lyso-PAF is in tum converted into PAF by the action of lyso-PAF
acetyltransferase (lyso-PAF AT) which mediates the transfer of the acetyl group from
acetyl-CoA to the free hydroxyl moiety at the sn-2 position of
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lyso-PAF 209,2 10 A summary of the ‘remodelling pathway’ leading to PAF synthesis
is presented in Figure 9.
1.4.1.2 Role of PAF in angiogenesïs
Growing evidence demonstrates that PAF is directly implicated in angiogenesis.
PAF has been shown to mediate endothelial celi migration in vitro 198 and budding of
new vessels in mice subjected to sustained release of PAF 197,211,212 The angiogenic
potential of PAF is also mediated by its effects on adhesion properties of endothelial
celis which enhance leukocyte adherence and ultimately their ability to release
angiogenic mediators 213 The role of PAF in pathological angiogenesis has also been
examined. PAF released by certain tumours into the extracellular environment has
been reported to act in a paracrine fashion and promote budding of new vessels,
increasing the potential malignancy ofthese tumours 197,214 Several types oftumours
also express PAF receptors (PAFR) 197,215 and in vivo overexpression of PAFR has
been shown to favour tumour development 216 Taken together, these observations
demonstrate the role of PAF in tumourigenesis.
The role of PAF in angiogenesis may be linked to VEGF-A165. It has been
demonstrated that VEGF-A165 increases vascular permeability through the synthesis
of PAF in endothelial celis 56• An increase in vascular permeability is one of the
characteristic elements of acute inflammation. In an inflammatory sefting, activated
neutrophils and other leukocytes release inflammatory mediators such as VEGF and
PAF which, besides acting on vascular permeability through the release of
41
metalloproteases from the endothelium to favour detachment of endothelial celis
from the basal membrane 59,217, promote P-selectin transiocation to the surface of
endothelial celis 65,205 and favour adhesion onto activated endothelial ceils as
discussed above.
1.4.2 The phospholipase A2 family
The phospholipase A2 (PLA2) superfamily consists of a broad range of enzymes
defined by their ability to catalyze the hydrolysis of the middle (sn-2) ester bond of
substrate phospholipids to liberate arachidonic acid (AA) and lysophospholipids 218-
220 This action is important for the synthesis of eicosanoids such as prostaglandins
and leukotrienes from AA precursors and for the synthesis of PAF from
phospholipids as described in the previous section. Initially isolated from cobra
venom and then from various other sources, PLA2 are categorized into eleven (11)
classes (I — XI) 218,221 and four families: cytosolic (cPLA2), secreted (sPLA2),
caïcium-independent (iPLA2), and PAF-acetylhydrolases (220 for review).
Located within the cytosol of resting celis, cPLA2 is a high molecular weight ($5
kDa) PLA2 that shows a marked preference for AA over other fatty acids and
requires submicromolar concentrations of Ca2 for activation 222 Ubiquitously and
constitutively expressed in most celis and tissues 223 cPLA2 plays an essential role in
the initiation of stimulus-induced AA liberation from phospholipids, supplying
cyclooxygenase and lipoxygenases which synthesize eicosanoids. Evidence from
studies utilizing celis from cPLA2-null mice show that animais lacking cPLA2 are
42
unable to generate these lipid mediators 224 In addition, cPLA2 bas been shown to
mediate PAF synthesis from phospholipids in neutrophils 225 Activation of cPLA2 is
tightly regu!ated by cytosolic Ca2 levels and sustained phosphorylation of Ser505 by
p42144 or p38 MAPKs 226
The secretory PLA2 (sPLA2) family, which contains 10 isozymes, consists of low
molecular weight (14-19 kDa), secretory enzymes implicated in various biological
processes such as the modification of eicosanoid synthesis, inflammation, host
defense, and atherosclerosis 219 sPLA2 hydrolyze the sn-2 ester bond of
glycerophospholipids in the presence of millimolar Ca2 concentrations with no
particular fatty acid specificity 219 Inflammatory celis such as neutrophils,
macrophages, and mast ceils store sPLA2-IIA in secretory granules and release it
promptly upon ce!! activation 227 Large amount of sPLA2-IIA are detected in
exudated fluids and plasma of patients and animal models with inflammatory
conditions 228,229 Type V sPLA2 (5PLA2-V) is the primary secreted PLA2 in the
mouse but its !eve!s are also markedly e!evated in human diseases such as cardiac
dysfunction and inflammation 220 We have recently reported that VEGF-A165-
230mediated endotheha! PAF synthesis 15 mediated by sPLA2-V
Fully active in the absence of Ca2, iPLA2 shows no strict sn-2 fatty acid
preference. The specific contributions of iPLA2 isoforms to biological events have
yet to be ful!y defined a!though it has been suggested that they partake in
phospholipids remodelling through the deacylation of phospholipids 23 t
43
Finally, PAF-AH, also referred to as group VIIA PLA2, is a 45 kDa secreted protein
which hydrolyzes the ester bond in the sn-2 position of PAF to liberate acetate and its
inactive intermediate, lysoPAF 220
1.4.3 Adhesion of leukocytes to the endothelium
The first step towards the extravasation of circulating inflammatory celis into the
extravascular tissues involves the induction of leukocyte rolling on the endothelium.
In response to inflammation, adhesion molecules are expressed at the surface of
endothelial celis and leukocytes favouring the transient aftachment (rolling) of
leukocytes to the endothelium. Rolling elicits a priming response which favours the
siowing down of circulating leukocytes and their subsequent firm adhesion to
endothelial celis. firm adhesion leads to diapedesis followed by migration into the
interstitium towards the site of inflammation or angiogenesis where leukocytes can,
in tum, secrete a plethora of inflammatory and angiogenic mediators. The sequence is
graphically represented in Figure 10. Three main families of adhesion molecules,
each possessing distinct molecular structures, participate in the overlapping steps of
the leukocyte adhesion cascade: the selectins, the integrins, and the immunoglobulin
(1g) superfamily.
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1.4.3.1 The selectins
The selectins play a critical role in the initial capture from the bloodstream and
rolling of leukocytes on the vascular endothelium. The selectin family of adhesion
molecules consists of three members. The expression of E-selectin is induced upon
endothelial ce!! activation, L-selectin is constitutively expressed on the surface of
leukocytes, and P-selectin is stored within the alpha (Œ) granules of platelets and the
Weibel-Palade bodies (WPB) of endothelia! ceils and trans!ocated to the celi surface
membrane upon ce!! activation.
The se!ectins are Type 1 transmembrane glycoproteins and possess an extracellu!ar
domain composed of a lectin domain, an epidermal growth factor-like (EGF) domain,
and short consensus repeats (SCR) a!so referred to as complement binding (CB)
e!ements. The !ectin domain is responsible for ligand recognition and binding
whereas the EGf domain stabilizes the conformation of the lectin domain 232
Tmncating the number of SCR has been shown to impair the efficiency with which
P-selectin could support ro!ling of leukocytes suggesting that these domains are
important in extending P-selectin a sufficient length from the plasma membrane 233
Moreover, the number of SCR varies from two (2) in L-selectin to nine (9) in P
selectin and accounts for the size variation amongst the three selectins 234 Ail three
selectins are anchored in the membrane by a single transmembrane region followed
by a short cytoplasmic tail 234,23 as presented in Figure 11.
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E-selectin is only expressed at the surface of activated endothelial ceils in response to
inflammatory mediators such as lippopolysaccharide (LP$) or interleukin (IL)- 1 3
235,236 and induction achieved through transcription with 3 to 4 hours 237 E-selectin is
implicated in the rolling of leukocytes primarily during transition ftom rolling to firm
adhesion 23$ through interactions with its ligands present at the surface of leukocytes,
E-selectin ligand-1 (ESL-1) 239 and P-selectin glycoprotein ligand-1 (PSGL-1) 24O
L-selectin is constitutively expressed on the surface of leukocytes 241 and has been
shown to slow rolling leukocytes to allow for their activation by mediators such as
IL-8 and PAF 242 In addition, activation of leukocytes resuits in the rapid
downregulation of L-selectin within minutes 243 by proteolytic activity through the
action of metalloprotease cleaving L-selectin at an extracellular site proximal to the
celi membrane 243,244 This phenomenon, termed L-selectin shedding facilitates
detachment of leukocytes from the endothelial ceils as they start migrating through
the endothelial ceil layer 234 and is indicative or leukocyte activation. Certain studies
have suggested intracellular signalling resulting from the binding of L-selectin to its
ligands, expressed at the surface of endothelial ceils, increases J32 integrin-mediated
adhesion 242,245,246
In endothelial celis, P-selectin is stored within Weibel-Palade bodies, translocated to
the ce!! surface upon activation by inflammatory mediators such as histamine,
thrombin and phorbol esters, or hypoxia 247 Following transiocation, P-selectin may
be recyc!ed back into the celi by endocytosis 248 although it lias recently been
4$
suggested that P-seiectin may be cleaved and a portion of the P-selectin measured in
the plasma may be of endothelial origin 249,250 Endothelial P-selectin translocation is
rapid and transient, maximal within 10 minutes and returning to baseline by 3 hours
251-253
although additional synthesis may be brought about within 2 hours by
cytokines such as IL-1, tumour necrosis factor-Œ (TNF-a), and by LPS or thrombin
252-254 P-selectin binds to P-seiectin glycoprotein iigand-1 (P$GL-1) iocated on the
surface of leukocytes. Studies using knockout mice deficient for the gene coding for
P$GL-1 have demonstrated that leukocyte rolling is defective in these animais 255-25$
1.4.3.2 The Integrins
The steps following ieukocyte rolling govem the firm adhesion of inflammatory celis
to the endothelium, their movement through the inter-endotheiial junctions and their
migration into the inflamed region. The integrins iocated on the surface of
leukocytes play a critical role in this series ofevents.
Structurally, the integrins are type I transmembrane glycoproteins comprised of non
covalently associated alpha (Œ) and beta (f3) subunits. The integrins are a large
family, 19 alpha subunits and 8 beta subunits have been identified comprising 25
known integrins 259 Leukocytes express the f32 integrin (CD1$) subfamiiy in
association with (XL (OEL f32, CD11aJCD18, or LFA-1) and OEM (OEM f32, CD11b/CD18, or
Mac-1) subunits 260,261 and these integrins play an important role in the firm adhesion
of leukocytes to endotheliai celis. The primary ligand for the f32 integrins is
intercellular adhesion molecule- 1 (ICAM- 1) present at the surface of activated
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endothelial ceils. LFA-1 may also bind to ICAM-2 and -3, albeit with a lower
affinity than to ICAM-1 262 whereas Mac-1 binds to a wide variety of ligands 263
The integrins may be activated by inflammatory mediators such as PAF and
leukotriene B4 (LTB4) and chemotactic agents like IL-8 binding to their respective G
protein-coupled receptors (GPCR) on the surface of leukocytes. Signalling pathways
associated with GPCR act on the cytoplasmic tau of 32 integrins and through a
conformational change, increase their affinity for their ligand 264 Within seconds of
activation by chemokine receptor binding or tethering on E- or P-selectins, CD 18
expression and affinity is increased on leukocytes 264-266rn
1.4.3.3 The 1g superfamily
Completion of the process of leukocyte recruitment follows the development of
strong interactions between integrins and Ig-superfamily members 267 1g-
superfamily members are characterized by their extracellular 1g domain analogous to
the immunoglobulin light and heavy chains. Certain members of this family, namely
ICAM-1 and -2 expressed on endothelial ceils are counter-receptors to leukocyte
borne integrins. ICAM- 1, which possesses 5 1g domains, is only weakly expressed
on the surface of endothelial celis under normal conditions 26$ However, its
expression is greatly increased in the presence of IL-1, TNF-a, and LPS 269-271
ICAM-2 has only 2 1g domains and contrary to ICAM-1, it is constitutively
expressed on the endothelium and its expression level is flot affected by cytokines 272
Diapedesis also requires the action of platelet endothelial adhesion molecule-1
(PECAM-1) which is expressed along the borders ofendothelial celis 273
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1.5 Rationale
Over the course of the last several years, work conducted in our iaboratory has
centered on the inflammatory foie of VEGF-A165 in angiogenesis. Indeed, our
laboratory has deiineated the foie of VEGfR-2 and the celi signaliing pathways
implicated in VEGF-A165-mediated endotheiiai PAF synthesis 95,230,274 In addition,
we have recently demonstrated the implication of endogenous PAF in the VEGF
A165-mediated transiocation of P-selectin and the adhesion of neutrophils onto
activated HUVEC 65 Since angïopoietins act in concert with VEGF-A165 to
moduiate vascuiar piasticity during postnatal neovascularization 275 we therefore
sought to investigate the role of these recentiy characterized angiogenic factors in
mediating proinflammatory events.
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1.6 Purpose
Based on previous observations with regards to VEGf-A165 and on the capacity of
angiopoietins to regulate vascular integrity, we sought to investigate whether Angi
and/or Ang2 could modulate endothelial PAF synthesis and if so, to define the
intracellular signalling pathways. Furthermore, we recently demonstrated that Angi
and Ang2 are also both capable of promoting endothelial P-selectin transiocation and
neutrophil adhesion onto endothelial celis 149 Thus, we also sought to dissect the
cellular mechanisms implicated in angiopoietin-mediated endothelial P-selectin
transiocation and assess the role of PAF in this process. Together, these two
objectives would allow us to delineate the role of angiopoietins in acute
inflammation.
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2.1 SUMMARY
Vascular endothelial growth factor (VEGF) is the only angiogenic growth factor
capable of inducing an inflammatory response and we have recently demonstrated that
its inflanimatory effect is mediated by the endothelial synthesis of platelet-activating
factor (PAF). Recently discovered, Angi and Ang2, upon binding to Tie2 receptor,
modulate vascular permeability and integrity, contributing to angiogenesis. Angi was
initially identified as a Tie2 agonist whereas Ang2 can behave as a context-dependent
Tie2 agonist or antagonist. We sought to determine if Angi andlor Ang2 could
modulate PAF synthesis in bovine aortic endothelial celis (BAEC) and if so, through
which intracellular signalling pathways. Herein, we report that Angi and Ang2 (1
nM) are both capable of mediating a rapid Tie2 phosphorylation and a rapid,
progressive and sustained endothelial PAF synthesis maximal within 4 hours (1695%
and 851% increase, respectively). Angiopoietin-mediated endothelial PAF synthesis
requires the activation of the p38 and p42144 MAPKs, PI3K intracellular signalling
pathways, and a secreted phospholipase A2 (sPLA2-V). Furthermore, angiopoietin
mediated PAF synthesis is partly driven by a relocalization of endogenous VEGF to
the celi surface membrane. Our resuits demonstrate that the angiopoietins constitute
another class of angiogenic factors capable of mediating PAF synthesis which may
contribute to proinflammatory activities.
Key words: angiopoietins, Tie2 receptor, platelet-activating factor, inflammation
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2.2 INTRODUCTION
Angiogenesis plays a criticai foie in several pathological conditions, namely
atheroscierosis, proiiferative retinopathies and tumor growth [1]. Previous studies
established the contribution of vascular endothelial growth factor (VEGF-A165) and
the ceil signalling mechanisms by which it ieads to angiogenesis [1]. Nameiy, it has
been reported that inflammation precedes and accompanies pathological angiogenesis
as evidenced by increased vascular permeability, monocytes/macrophages and
neutrophiis recruitment at angiogenic sites [2]. During inflammatory processes,
newly formed vesseis suppiy inflamed tissue with oxygen and nutrients as well as
facilitate the transport of inflammatory ceiis. Recently, we have shown that VEGF
A165 increases vascular permeability through the synthesis of a potent inflammatory
mediator, platelet-activating factor (PAF) by endothelial ceils (EC) [3]. VEGF
mediated endotheiiai PAF synthesis occurs via a remodeling pathway in which
membrane phospholipids are converted by a phospholipase A2 (sPLA2-V) into lyso
PAF which is in tum acetyiated into PAF by acetylCoA:iyso-PAF acetyltransferase
(lyso-PAF AI) [4]. Furthermore, we have recently demonstrated that in bovine
aortic endotheiial celis (BAEC), VEGF-A165 activation of both p38 and p42144
mitogen-activated protein kinases (MAPK) are crucial to VEGF-mediated endotheiial
PAF synthesis whereas phosphatidyl inositol-3-phosphate kinase (PI3K) activation is
not required [5]. Moreover, newly synthesized PAF is essential for VEGF-A165-
mediated endothelial P-selectin transiocation and neutrophii adhesion onto activated
EC [3, 6, 7], essential events in the induction ofacute inflammatory processes.
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Recently, a new class of angiogenic factors, angiopoietins (Angi and Ang2), was
defined as ligands for the tyrosine kinase receptor Tie2 [8, 9] to which they bind with
similar specificity and affinity [8, 9]. Angi has been characterized as a Tie2 agonist,
having the capacity to stabilize and promote the maturation of unstable vessels in the
presence of VEGF-A165 [10]. On the other hand, Ang2 was initially described as a
natural endogenous Tie2 antagonist, thereby destabilizing existing vessels prior to
VEGf-A165-induced angiogenic sprouting [9]. However, recent findings have shown
that Ang2 may, under certain circumstances, induce Tie2 phosphorylation and
biological activities such as EC migration, and in vitro tubule capillary-like formation
[11, 12]. In addition, we recently demonstrated that both angiopoietins can promote
endothelial P-selectin transiocation, directly activate neutrophils through Tie2
signalling as well as modulate PAF synthesis and f32-integrin functional upregulation
thereby promoting the acute recruitment of leukocytes and conferring a
proinflammatory capacity to angiopoietins [13].
Based on our previous observations with regards to VEGF-A165 and on the potential
capacity of angiopoietins at regulating vascular integrity, we sought to investigate
whether Angi and/or Ang2 modulate endothelial PAF synthesis and if so, to define
the intracellular signalling pathways.
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2.3 MATERIAL & METHODS
CelÏ culture
Bovine aortic endothelial celis (BAEC) were isolated from freshly harvested aortas,
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Pickering
ON) containing 5% fetal bovine serum (FBS; Medicorp Inc., Montreal, QC) and
antibiotics (Sigma, St. Louis, MO). BAEC were characterized as previously
described and used between passages 3 and 7 [3, 14].
Western blot analysis ofTie2 and VEGfR-2 phosphorylation
Confluent BAEC were serum-starved in DMEM with antibiotics overnight, rinsed
with Hank’s balanced sait solution (HBSS; Life Technologies, Burlington, ON), then
stimulated in a solution of HBSS/HEPES (10 mM, pH 7.4), bovine serum albumin
(BSA; 1 mg/mL; Sigma), and CaC12 (10 mM). Celis were placed on ice for 30
minutes then stimulated with Dulbecco’s phosphate-buffered saline (PBS), Angl, or
Ang2 (1 nM; R&D Systems, Minneapolis, MN) at 37°C for up to 2 hours. In another
set of experiments, BAEC were pretreated with selective inhibitors of VEGfR- 1 and
VEGFR-2 (VTK; 10 iM; 1C50 = 2.0 and 0.1 iM respectively) [15, 16], or VEGFR-2
(5U1498; 5 iM; 1C50 = 0.7 tM) [7, 16, 17] (Calbiochem, La Joua, CA), 15 minutes
prior to stimulation with Mgi or Ang2 (1 nM). In a third set of experiments, we
assessed the capacity of angiopoietins (Angl and Ang2) to transactivate VEGfR-2 in
function of time. Cells were solubilized with lysis buffer, scraped, and the protein
concentration determined by Bradford assay. Celi lysates were immunoprecipitated
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with rabbit polyclonal anti-mouse Tie2 IgG or with anti-mouse VEGfR-2 IgG (Santa
Cruz Biotecbnology, $anta Cruz, CA) and separated by SD$-PAGE. Proteins were
transferred onto a polyvinylidene difluoride (PVDf) membrane and probed with
mouse monoclonal anti-phosphotyrosine 1gO (clone 4010, 1:1 000 dilution; Upstate
Biotechnology Inc., Lake Placid, NY). Membranes were stripped using Re-Blot Plus
Strong stripping solution (Chemicon International, Temecula, CA) and reprobed with
rabbit polyclonal anti-mouse Tie2 1gO or VEGfR-2 1gO (1:1 000 dilution; Santa
Cruz Biotechnology). Bands were visualized using LumiGloTM (New England
Biolabs, Pickering, ON). The density of the bands was determined using Quantity
One software (Bio-Rad, Mississauga, ON) [7].
Western blot analysis ofp38, p42/44, andAkt activation by angiopoietins
Confluent BAEC were serum-starved overnight, rinsed, and stimulated with Angi or
Ang2 (1 nM) for various time durations. In another series of experiments, BAEC
were pretreated with either a p38 MAPK inhibitor ($B203580, 10 j.iM), MAPK
kinase (MAPKK) inhibitor (PD98059, 10 tM), or inhibitors ofthe PI3KJAkt pathway
(LY294002, 5 jiM; Wortmannin, 500 nM) (Calbiochem) prior to stimulation with
Angi or Ang2 (1 nM). As positive control, BAEC were treated with VEGf-A165 (1
nM; Peprolech Inc., Rocky Hill, NJ) for 7.5 minutes after pretreatment with the
aforementioned pathway inhibitors. Ceil lysates were separated by $DS-PAGE and
proteins transferred onto a PVDF membrane. Activation of p38, p42144 and Akt was
determined by probing membranes with antibodies for their respective
phosphorylated forms (1:1 000 dilution; New England Biolabs). Membranes were
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subsequently stripped and reprobed to visualize corresponding total protein
expression.
Measurement ofPAF synthesis
Confluent BAEC were rinsed, then stimulated in HB$$/HEPES containing CaC12 (10
mM) and {3HJ-acetate (25 1iCi) (New England Nuclear, Boston, MA) with
angiopoietins (Angi or Ang2; 0.1 to 10 nM) or VEGf-A165 (1 nM) for 7.5 to 360
minutes. In another series of experiments, BAEC were pretreated with VTK (10
iM), SU1498 (5 tM), SB2035$0 (10 1iM), PD9$059 (10 iM), LY294002 (5 tM) or
Wortmannin (500 nM) prior to stimulation with Angl, Ang2, or VEGF-A165. BAEC
were also pretreated with either a selective cPLA2 and iPLA2 inhibitor (AACOCF3;
10 jiM; Calbiochem), a non-specific sPLA2 inhibitor (scalaradial; 10 jiM;
Calbiochem), or a selective sPLA2-V inhibitor (LY3 11727; 100 jiM; kindly provided
by Dr. Jerome Fleisch, Lilly Research Laboratories, Indianapolis, IN) for 15 minutes
prior to stimulation with Angi or Ang2 (1 nM) for 240 minutes or VEGF-A165 for 15
minutes. The reaction was halted by addition of acidified methanol, polar lipids
isolated, evaporated under N2 gas, and purified by HPLC as described previously [3-
5]. Fractions corresponding to [3H]-PAF were quantified with a B-counter. The
authenticity of synthesized PAF was confirmed by an identical elution pattem to
standard [3H]-PAF (New England Nuclear) [3, 14].
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VEGF ELJ$A
The content of VEGF protein in BAEC supernatant and whole ce!! extract was
quantified using a commercial ELISA kit (Peprolech Inc.). Confluent ceils grown
in 6-well plates were serum-starved overnight in DMEM containing antibiotics prior
to stimulation with Mgi or Ang2 (1 nM) in HBSS-HEPES containing CaCl2 (10
mM) for various time periods. Upon stimulation, ceil supernatant was collected, the
cells scraped, and gently sonicated in P35 (pH 7.4) in ice. The ELISA protocol was
carried out according to the manufacturer’ s instructions.
Confocal Microscopy: Image acquisition, deconvolution and image rendering
BAEC were grown to confluence on glass coverslips coated with 1.5% gelatin,
serum-starved ovemight, rinsed, and incubated with rabbit polyclonal anti-human
VEGF IgG (1:100 dilution; Santa Cruz Biotechnology) in the presence of Angi or
Ang2 (1 nM; 7.5 to 240 minutes) in serum-free DMEM. following stimulation, the
cells were rinsed and fixed with a 1% paraformaldehyde-PBS solution for 20
minutes. Nonspecific binding of primary antibodies was prevented by preincubating
live BAEC with 4% serum from the species used to raise the secondary antibodies.
Cells were rinsed and incubated with donkey anti-rabbit Alexa 555 conjugated IgG
(1:400 dilution; Molecular Probes, Eugene, OR) for 90 minutes. Glass coverslips
were mounted using 1 ,4-diazabicyclo-2-2-2octane (DABCO/glycerol (1:1) solution.
BAEC were observed on a Zeiss Axiovert 100M microscope equipped with a
63X11 .4 Plan-Apochromat oil objective lens (Zeiss, Oberkochen, Germany) adapted
with an LSM 510 confocal system and saved as L$M files. Donkey anti-rabbit
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conjugated to Alexa 555 IgG was visualized using a 543 nm Helium-Neon laser.
Voxel size is 143 nm X 143 nm X 160 nm (X, Y, Z). Z stacks were deconvolved
with the Huygens Pro 2.6.5a ($cientific Volume Imaging, SVI, Alexanderlaan, The
Netherlands) using the Maximum Likelihood Estimation (MLE) algorithm. Signal
to-noise ratios were quantified for each Z stacks and added to the MLE algorithm.
Point spread function (PSf) was derived from Z stacks of 15 fluorescent (540-560
nm) beads of 170 nm in diameter (Invitrogen). PSf was acquired the same way as
the images of interest. Deconvolutions were applied until reaching 0.01% quality
change threshold (QCT) between iterations. Deconvolved Z stacks were saved in
Tiff files format series. Transparent projections were produced using the projection
tool of the L$M 510 sofiware. VEGf levels at the celi surface membrane was
assessed by quantifying the summation of voxels intensity of the deconvolved Z
stacks volume using the Huygens Pro 2.6.5a software. The relative intensity (RI) of
VEGF at the celi surface membrane was set at 1 for the PBS-control treated celis.
$tatistical analysis
Data are mean ± SEM. Comparisons were made by analysis of variance followed by
a Bonferroni t-test. Data were considered significantly different if values of p<O.OS
were observed.
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2.4 RESULTS
Activation of Tie2 receptor by angiopoietins
We first assessed the capacity of both angiopoietins (Angi and Ang2) to modulate
Tie2 phosphorylation in function of time. Treatment of confluent BAEC with Angl
(1 nM) induced a rapid and transient phosphorylation of Tie2, which was maximal
within 15 minutes, and corresponding to a 21-fold increase over PBS-treated celis
(Figure lA). Treatment with Ang2 (1 nM) aiso induced a rapid and transient
activation of Tie2 leading to an 8-fold increase in phosphorylation within 7.5 minutes
(Figure lB).
Activation ofp38 MAFK p42/44 M4FK, andAkt by angiopoietins
Previous studies reported that Angl is capable of activating p38 and p42144 MAPKs
[181 as well as the PI3KIAkt signal transduction pathways [19J. Prior to our study,
littie was known with regards to potential intracellular events following the activation
of Tie2 by Ang2. Herein, we demonstrate that Ang2, like Angl, can activate p42144
and p38 MAPK as well as PI3K in a time-dependent manner (Figure 2). In our
study, stimulation of BAEC with Angl (1 nM) activates p42144 MAPK and Akt in a
time-dependent manner (Figure 2A and E) with maximal effects at 7.5 minutes
maintained through 30 minutes of stimulation. Treatment with Angl induces a rapid
and transient activation of p38 MAPK with a maximal phosphorylation at 7.5
minutes (figure 2C). $imiiarly, Ang2 (1 nM) activates ail three pathways but with
slight variations in its kinetics. firstly, maximal activation of p42144 MAPK occurs
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within 10 minutes of stimulation (Figure 2B) but as with Ang 1, this activation is
maintained 30 minutes post-stimulation. $econdly, activation of PI3KIAkt by Ang2
is delayed compared to Angl and flot sustained (20 minutes versus 7.5 minutes;
figure 2F). Ang2 activation of p38 MAPK produces a pattem similar to what was
observed with Angi (Figure 2D). As a positive control, BAEC were also stimulated
with VEGF-A165 (1 nM; 7.5 minutes).
Regulation ofPAF synthesis by Ang] andAng2
We previously reported that VEGF-A165 induces a rapid and transient (within 15
minutes) endothelial PAF synthesis [3, 14]. Therefore, we assessed the capacity of
angiopoietins to mediate endothelial PAF synthesis. The induction of PAF synthesis
by the angiopoietins was very rapid (significant increase within 7.5 minutes),
maximal at 4 hours and sustained for at least 6 hours post-treatment (Figure 3A-B).
Angiopoietin-mediated endothelial PAF synthesis is characterized by a biphasic
response profile. An initial rapid and moderate synthesis is observed from 7.5
minutes to 30 minutes followed by a “burst” phase culminating at 4 hours. The peak
values of PAF synthesis mediated by Angi and Ang2 correspond to a 1695% and
851% increase, respectively, compared to PBS-treated ceils. Basal levels of PAF
synthesis in PBS-treated ceils did flot change significantly throughout the time course
of the experiments (data flot shown). In addition, VEGF-A165 (1 nM) was used as
positive control and induced maximal PAF synthesis within 15 minutes (788%
increase over PBS values) and was degraded within 30 minutes, as previously
described [3, 14]. We also assessed the potential of Angi and Ang2 to mediate
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endothelial PAF synthesis in a concentration-dependent manner. Celis were treated
with Angi or Ang2 (0.1 to 1 nM) at an intermediate time period (2 hours) to ensure
that we were flot reaching a saturation plateau of PAF synthesis. PAF synthesis
mediated by Angi at 0.1 nM was almost as potent as at 1 nM whereas Ang2 at 0.1
nM did flot significantly increase PAF synthesis but at 1 nM, Ang2 had an equivalent
agonistic activity, compared to Angl at mediating endothelial PAF synthesis afier 2
hours (Figure 3C). Interestingly, at a higher concentration (10 nM), both Angl and
Ang2 almost completely lost (86% and 75%, respectively) their capacity of
mediating PAF synthesis in comparison to 1 nM (Figure 3C).
Role ofendogenous VEGF in angiopoietin-mediated PAF synthesis
Since the stimulation of BAEC with VEGF-A165 induces PAF synthesis and that EC
express VEGF [20-23], we hypothesized that VEGF may contribute to angiopoietin
mediated endothelial PAF synthesis. Therefore, we pretreated BAEC with inhibitors
of both VEGFR-1 and VEGFR-2 (VTK; 10 1iM) or VEGFR-2 ($U149$; 5 tM) for
15 minutes prior to stimulation with Ang 1 or Ang2 (1 nM) for 4 hours. Inhibition of
VEGFR-1 and VEGFR-2 with VTK prompted a 51% and 43% decrease in PAF
synthesis mediated by Angl and Ang2, respectively (Figure 4). When only VEGFR
2 activity was inhibited, Angi and Ang2-mediated PAF synthesis was diminished by
42% and 26%, respectively (Figure 4). As a positive control, the above inhibitors
were added individually prior to VEGF-A165 stimulation and completely abrogated
VEGF-A165-mediated PAF synthesis at 15 minutes (Figure 4). In addition, to assess
that these inhibitors of VEGF receptors were not interfering with Tie2
6$
phosphorylation mediated by angiopoietins, we pretreated BAEC with VTK or
SU 1498 15 minutes prior to stimulation with angiopoietins (1 nM) for 7.5 minutes.
Such pretreatment with the aforementioned inhibitors did flot alter angiopoietin
mediated Tie2 phosphorylation (data flot shown).
We then investigated whether VEGF was released from BAEC to promote its
autocrine activity on PAF synthesis. We performed an ELISA assay and detected
negligible amounts of VEGF in the supematant of BAEC treated with Ang 1 or Ang2
from 15 minutes to 6 hours, whereas most endogenous VEGf was quantified from
BAEC lysates (Figure 5). Confocal microscopy was then employed to visualize the
distribution of VEGF within BAEC. Labeling live celis with primary antibodies
targeting VEGF prior to stimulation allowed us to observe the relocalization of
endogenous VEGF to the celi surface membrane. In control PBS-treated celis, the
relative intensity (RI) of VEGF protein detection on celi surface membrane was set to
1 (Figure 6A), and was slightly higher than negative control in which PBS-treated
celis were incubated with isotypic rabbit IgG instead of primary VEGF IgG (RI =
0.9; Figure 6B). Treatment with Angl (1 nM) for 7.5 minutes resulted in a marked
redistribution of VEGF on cell surface membrane (RI = 10.2; Figure 6C), which
remained noticeable up to 4 hours post-stimulation (RI = 1.97; Figure 6D).
Treatment of BAEC with Ang2 (1 nM) induced as well an acute but less intense
relocalization of endogenous VEGF within 7.5 minutes (RI = 2.81; Figure 6E), but
which was sustained up to 4 hours (RI = 3.56; Figure 6F).
Since angiopoietins mediate VEGF relocalization to the cell surface
membrane of endothelial celis, and that VEGf-A165 mediates PAF synthesis through
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VEGFR-2 activation, we then sought to assess whether angiopoietins can promote
VEGFR-2 transactivation. We observed that a treatment with Angi or Ang2 (1 nM)
mediated a rapid and transient VEGFR-2 phosphorylation, which was maximal
within 15 and 30 minutes (6.3 and 9.2-fold increase) respectively (figure 7A and B).
Treatment with VEGF-A165 (1 nM) for 7.5 minutes was used as positive control
(Figure 7C).
Contribution ofp38 M4PK p42/44 MAPK and PI3K to angiopoietin-mediated FAF
synthesis
We recently reported that endothelial VEGf-A165-mediated PAF synthesis by BAEC
involves p38 and p42144 MAPKs activation whereas PI3K activation does flot lead to
PAF synthesis [5]. Subsequently, in order to determine the intracellular pathways by
which the angiopoietins promote EC PAF synthesis, we pretreated BAEC with
selective inhibitors of the corresponding signalling pathways. Pretreatment of BAEC
with a MAPKK inhibitor (PD98059; 10 jiM), a p38 MAPK inhibitor (SB203580; 10
or two unrelated selective PJ3K inhibitors (LY294002; 5 tM and Wortmannin;
500 nM) 15 minutes prior to treatment with Arigi (1 nM) for 4 hours, decreased EC
PAF synthesis by 65, 93, 93, and 100%, respectively (figure sA). Similarly, Ang2-
mediated EC PAF synthesis at 4 hours was reduced by 73% to 100% following
pretreatment with the aforementioned inhibitors (Figure sA). As positive control,
these inhibitors were used prior to VEGF-A165 stimulation and PAF synthesis was
completely blocked following pretreatment with PD98059 and SB203580 whereas
pretreatment with PI3K inhibitors did flot reduce PAF synthesis (data flot shown).
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We also performed Western blot analyses to confirm that the selective inhibitors at
corresponding concentrations prevented the phosphorylation of p42144 MAPK, p38
MAPK and PI3K (data flot shown).
The effect of angiopoietins on endotheÏiaÏ PAF synthesis is attenuated by sPLA2
inhibitors
We have previously demonstrated the role of sPLA2-V in VEGF-mediated EC PAF
synthesis [4] and therefore sought to determine which phospholipase A2 is implicated
in angiopoietin-mediated EC PAF synthesis. We observed that inhibition of cPLA2
and iPLA2 using AACOCF3 (10 tM) failed to reduce angiopoietin-mediated EC PAF
synthesis (Figure $B). However, pretreatment with a broad-range sPLA2 inhibitor,
scalaradial (10 1iM), inhibited Angi and Ang2-mediated EC PAF synthesis by 57%
and 51%, respectively (Figure $B). We also treated BAEC with LY31 1727 (100
an inhibitor of sPLA2-V 15 minutes prior to stimulation with Angi or Ang2 (1
nM; 4 hours) and observed a reduction of 43 and 55% in PAF synthesis, respectively
(Figure $3). In addition, we performed a positive control study in which the
corresponding inhibitors were added prior to VEGF-A165 wherein we observed that
EC PAF synthesis was almost totally abrogated (97% inhibition) following
pretreatment with both non-specific (scalaradial) and specific (LY3 11727) sPLA2-V
inhibitors whereas the inhibition of cPLA2 (AACOCF3; 10 !IM) did flot attenuate
endothelial PAF synthesis (data flot shown).
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2.5 DISCUSSION
In the present study, we observed that Angl and Ang2 are both capable of mediating
a rapid Tie2 phosphorylation, as well as a rapid, progressive and sustained
endothelial PAF synthesis. This angiopoietin-mediated PAF synthesis, maximal at
240 minutes is mediated in part by a relocalization of endogenous VEGF to the cdl
membrane and through the activation of the p38 MAPK, p42144 MAPK, and
PI3KJAkt intracellular signalling pathways acting on a secreted phospholipase A2
(sPLA2-V).
Ang] andAng2 both act as T1e2 agonists
Our data showed that Angl and Ang2 are both capable of mediating a rapid and
transient phosphorylation of Tie2 receptor, which is in agreement with previous
reports [8, 11, 12, 1$, 24J. One ofthe major characteristics ofour study is that Angi
and Ang2 at 1 nM were able to phosphorylate Tie2 in a manner corresponding to 21-
and 8-fold increase compared to PB$-treated ceils, and at such concentration, both
had their maximal agonistic effect on PAF synthesis, increasing it by 1695% and
851% respectively. Our results suggest that Ang2 might serve as a partial Tie2
agonist on PAF synthesis, and are in agreement with a recent study demonstrating
that the potency of Ang2 to support Tie2 activation is lower than Angi [25].
Interestingly, at a higher concentration (10 nM), Angi- and Ang2-mediated PAF
synthesis was almost completely lost. This can be explained by the fact that the
binding of a ligand to a receptor tyrosine kinase (RTK) induces receptor homo- or
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heterodimerization, which is essential for the autophosphorylation of tyrosine
residues and the initiation of downstream signalling events [261. However, an
overabundance of ligand impedes receptor dimerization [27]. Considering that
numerous studies reported the use of angiopoietins, in some cases, at concentrations
exceeding 10 nM, our study demonstrates the importance of performing a dose
response curve to establish the suitable concentration to achieve selective biological
activities thereby avoiding potentially false interpretations with respect to the
biological activities of the angiopoietins.
Recent reports indicate that Tie2 dimerization may be induced to distinctly
different extents by Angl or Ang2 [28, 29], thus it is possible that Angi and Ang2,
upon binding to Tie2, induce conformational changes in Tie2 resulting in different
activation pattems, namely the phosphorylation of different tyrosine residues or
activation of different signalling pathways, explaining the differential response
between Angl and Ang2. Furthermore, we demonstrate that the activation ofTie2 by
Angi activates p38 and p42144 MAPKs in a rapid and transient manner and
PI3KJAkt for a prolonged period of time. Our data are in line with a previous report
demonstrating that upon binding to Tie2, Angi activates both p38 and p42144
MAPKs [18] as well as Akt [30]. Most studies investigating signalling downstream
of Tie2 mainly focused on PI3KJAkt [19, 31-33] due to the ability of Angi to
stabilize the vasculature. The ability of Angl to activate both proapoptotic (p38
MAPK) and antiapopototic (p42744 MAPK and PI3K) pathways is not unique since
endothelial cell-specffic mitogens, such as VEGF, are also capable of activating
multiple pathways including p38 and p42744 MAPKs, and PI3K [34]. Interestingly,
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we aiso obseiwed the capacity of Ang2 to activate p38 and p42144 MAPKs, which
had yet to be documented, in addition to PI3KJAkt which had previously been
described [24, 25]. Our observations demonstrate the complex dual nature of Ang2
by its ability to similarly activate p38 and p42144 MAPK as Angi. However, Ang2
did flot activate Akt in the sustained manner observed with Ang 1. This difference
may expiain in part the ability of Ang2 to destabilize vesseis due to an inability to
sufficiently activate PI3K and in tum, Akt and focal adhesion kinase (FAK), two
crucial elements in the signailing pathway leading to ccli survivai and migration [35].
Angi andAng2 induce endothelial PAF synthesis
Our data demonstrate that the angiopoietins constitute a second class of tyrosine
kinase receptor ligands with proangiogenic activities. In the present study, we
demonstrate that both Angi and Ang2 induce endothelial PAF synthesis, however,
the profile of PAF synthesis mediated by the angiopoietins is strikingly different to
that seen with VEGF-A165. In contrast to what we have previously reported with
respect to VEGF-A165-mediated PAF synthesis [3], both angiopoietins induce a rapid,
progressive, and sustained endothelial PAF synthesis (maximal within 4 hours)
whereas VEGF-A165 induces a rapid and transient synthesis of PAF [3]. In activated
endothelial ceils, acute PAF synthesis is mediated through the remodeling pathway
and can occur in a very early (2 - 5 minutes), early (10 - 40 minutes), or delayed (4 -
8 hours) [36] manner. The kinetics observed in the current study follow a biphasic
response during which angiopoietins induce an early response which is not as robust
as that seen with VEGF-A165. This initial synthesis is followed by a “burst” phase
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where maximal PAF synthesis is twice as high as the peak observed with VEGF
A165. Based on the kinetics observed, angiopoietin-mediated endothelial PAF
synthesis may be complementary to VEGF-mediated PAF synthesis. Perhaps, under
inflammatory conditions, VEGF-mediated PAF synthesis provides an initial rapid
and transient synthesis followed by the prolonged angiopoietin-mediated response
sustaining neutrophil and EC activation leading to endothelial P-selectin transiocation
and neutrophil adhesion onto EC.
The maximal PAF synthesis observed at 4 hours is dependent upon the activation of
the p38 MAPK, p42144 MAPK, and PI3K/Akt signalling pathways. Indeed,
pretreatment of BAEC with pharmacological inhibitors for each of the
aforementioned pathways resulted in similar inhibition pattems of PAF synthesis
mediated by both Angi and Ang2. We have recently suggested that the ability ofthe
MAPKK inhibitor to completely block VEGF-A165-mediated endothelial PAF
synthesis resides in its ability to prevent PLA2 activation [5]. Based on our data, it
appears that this inhibitor elicits a similar response with respect to angiopoietin
mediated PAF synthesis in BAEC since pretreatment with this inhibitor substantially
reduced PAF synthesis. Since p38 MAPK has been shown to directly activate lyso
PAF AT [37], an enzyme essential for PAF synthesis, it is flot surprising to observe
that p38 MAPK inhibition almost completely abrogated angiopoietin-mediated PAF
synthesis. The observation that the PI3KIAkt pathway regulates angiopoietin
mediated PAF synthesis in a positive manner is in stark contrast to what we have
previously reported with respect to VEGF-A165-mediated PAF synthesis [51. Future
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smdies will be required to delineate how the activation of PI3K!Akt pathway
modulates downstream effectors involved in both VEGF- and angiopoietin-mediated
PAF synthesis.
The phospholipase A2 family has been implicated in a number of cellular responses
and several isoforms of cytosolic (cPLA2), calcium-independent (iPLA2) and secreted
(sPLA2) have been identified ([3$] for review). As mentioned above, the remodeling
pathway of EC PAF synthesis requires the contribution of a PLA2 to convert
membrane phospholipids into lyso-PAF. Having demonstrated that the angiopoietins
activate three intracellular signalling pathways known to participate in EC PAF
synthesis, the next step was to determine which PLA2 was implicated in angiopoietin
mediated PAF synthesis. Cytosolic PLA2 is expressed in most ce!! types and p42144
and p38 MAPKs have been implicated in its activation [39-41]. The iPLA2s are the
most recent!y identified members of the PLA2 superfamily and share the size,
intrace!lular localization, and cata!ytic mechanisms with cPLA2 [3$]. It is apparent
that angiopoietin-mediated PAF synthesis is flot dependent on cPLA2 and iPLA2 as
pretreatment with a specific cPLA2 and iPLA2 inhibitor, AACOCF3 did not prevent
but even slightly increased EC PAF synthesis by both Angl and Ang2 at 4 hours.
We have previously reported that sPLA2-V is implicated in VEGF-A165-mediated EC
PAF synthesis [4] and thus opted to target this particu!ar sPLA2 isoform. Using
pharmacological inhibitors, we demonstrated that pretreatment of BAEC with a non
specific sPLA2 inhibitor, scalaradial, b!ocked angiopoietin-mediated PAF synthesis
by approximately 50%. In addition, LY3 11727 at a concentration (100 iM) known
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to specifically block sPLA2-IIA and -v activity similarly inhibited angiopoietin
mediated PAF synthesis. Since sPLA2-IIA is not expressed in BAEC [4], this
suggests the essential contribution of sPLA2-V in angiopoietin-mediated PAF
synthesis. Therefore, it is interesting to note that although angiopoietins have a
different PAF synthesis profile than VEGF-A165, both require the same
phospholipase, thereby bestowing a critical role upon sPLA2-V in EC PAF synthesis.
The peak in angiopoietin-mediated PAF synthesis, could 5e representative of a
“delayed” PAF production as described previously ([36] for review) and hence
require newly synthesized proteins for celi activation. Since BAEC stimulation with
VEGF-A165 induces PAF synthesis and that EC express VEGF [20-23], we sought to
investigate whether VEGF was implicated in angiopoietin-mediated PAF synthesis.
First, we did flot detect an upregulation of VEGF mRNA by RT-PCR analysis when
BAEC were stimulated with Angi or Ang2 (data not shown) nor did we see
significant fluctuations in the quantity of endogenous VEGF by ELISA. We also
observed that no or marginal amounts of VEGF were released into the supernatant.
However, when BAEC were pretreated with VEGF receptor inhibitors prior to
stimulation with Angi or Ang2, angiopoietin-mediated EC PAF synthesis was
inhibited by approximately 50%. This partial reduction of PAF synthesis was flot
due to a non-specific inhibition of Tie2 activation by VTK and SU149$, since we
observed by Western blot analysis that these inhibitors of VEGF receptors did flot
alter Tie2 phosphorylation mediated by angiopoietins but prevented VEGF-A165-
mediated VEGFR-l and R-2 activation [7, 16] and PAF synthesis. We then
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postulated that endogenous VEGF was being shuffled from the intracellular
compartment to the endothelial celi surface membrane to interact with its ce!! surface
membrane receptors and contribute to angiopoietin-induced PAF synthesis. This
hypothesis was confirmed by confoca! microscopy whereby we observed the
presence of a significant amount of endogenous VEGF at the celi surface within 7.5
minutes of stimulation with Angl and to a !esser extent with Ang2, and which
remained noticeab!e up to 4 hours post-stimulation with both angiopoietins.
Furthermore, we observed that a treatment with Angi or Ang2 were both capable of
mediating VEGfR-2 phosphorylation. The reduced capacity of Ang2 to promote
PAF synthesis may be related to its less intense activation of Tie2 and VEGF
relocalization on endothe!ia! ceil surface membrane. Our data are in !ine with
previous studies reporting that a treatment of bovine aortic endothelial cel!s, name!y
with sphingosine 1-phosphate (S1P), can !ead to VEGFR-2 phosphory!ation and
activation of downstream effectors [42]. b the best of our knowledge, our study is
the first one to demonstrate the capacity of angiopoietins to induce VEGFR-2
phosphory!ation and bio!ogical activities such as PAF synthesis.
Based on our current observations as wel! as previous studies, it appears that under
specific conditions, both Angi and Ang2 are capable of mediating proinflammatory
events. We have recent!y reported that the angiopoietins are capable of promoting
endothelial P-selectin trans!ocation and the adhesion of neutrophils onto activated
human umbilical vein endothelial celis (HUVEC) as well as activating Tie2 receptors
on neutrophils leading to PAF synthesis promoting a rapid upregulation of the f32-
7$
integrin complex (CD 11 lCD 1$) and contributing to an increase in neutrophil
adhesion onto activated EC thereby demonstrating that the angiopoietins should be
considered as acute proinflammatory mediators [13]. However, in the
aforementioned study, angiopoietins did flot induce PAF synthesis in HUVEC [13]
whereas we demonstrate their powerfiul capacity to mediate PAF synthesis in BAEC,
thereby suggesting tissue specificity. We have previously observed that BAEC
induce a more robust endothelial PAF synthesis than HUVEC [4]. Recent studies
reported that Angi possesses anti-inflammatory properties. For instance, under in
vivo conditions, Angi has been shown to prevent VEGf-mediated vascular
permeability [10, 43, 44] and in vitro it reduces the basal activation of vascular
endothelial cadherin (VE-cadherin) and 13-catenin, concomitantly with a reduction of
VEGF-mediated endothelial ce!! permeability [45, 46]. Interestingly, the above
studies utilized HUVEC and it is therefore possible that the anti-inflammatory effects
attributed to Angi under in vitro conditions stem from the inabi!ity of angiopoietins
to promote PAF synthesis in this endothelia! subtype.
In summary, our study demonstrates for the first time that Angi and Ang2 are both
capable of inducing endothe!ial PAF synthesis and this in a temporal resolution
different than the rapid and transient PAF synthesis induced by VEGF-A165.
Furthermore, this synthesis requires the activation ofthe p38 MAPK, p42144 MAPK,
and PI3KJAkt intrace!!u!ar signalling pathways as well as the induction of sPLA2-V.
In addition, angiopoietin-mediated endothelial PAF synthesis is partly regulated by a
redistribution of endogenous VEGF to the celi surface membrane which may
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subsequently potentiate endothelial PAF synthesis (Figure 9). In our study, Ang2
behaved as a partial to full Tie2 agonist in function of its concentration, further
strengthening the current view of tissue and context specificity with respect to Ang2
activity. Taken together, our resuits demonstrate that the angiopoietins, like VEGF,
constitute another family of angiogenic growth factors capable of promoting
proinflammatory events.
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2.8 FIGURE LEGENDS
FIGURE 1: Activation and expression of Tie2 in BAEC. Confluent BAEC were
treated with Angi (A), or Ang2 (B) for up to 2 hours. Ce!! lysates were prepared
and immunoprecipitated (IP) with rabbit polyclonal anti-mouse Tie2 IgG from 500
tg of !ysate. Following resolution by SDS-PAGE and transfer, PVDf membranes
were probed with mouse monoclonal antiphosphotyrosine IgG and immunoreactive
bands were visualized by chemiluminesence. Membranes were subsequently
stripped using ReBlot Plus Strong stripping solution and Tie2 protein expression was
determined following incubation with rabbit polyclonal anti-mouse Tie2 IgG. IP
designates immunoprecipitation and WB represents Western blot.
FIGURE 2: Angi and Ang2 activate p38 MAPK, p42144 MAPK, and PI3K
pathways. Confluent BAEC were stimulated with Angi, or Ang2 (1 nM) for up to
30 minutes. BAEC were also stimulated with VEGF-A165 for 7.5 minutes as positive
control. Ce!! lysates equivalent to 100 ig total proteins were loaded in each lane.
Signalling pathway activation was determined by probing PVDF membranes with
antibodies for the phosphory!ated form of p42/44 MAPK, p38 MAPK, or PI3KIAkt.
Angi and Ang2 activate p42/44 MAPK (A and B, respectively), p38 MAPK (C and
D, respectively), and PT3K!Akt (E and f, respective!y). Membranes were then
stripped and corresponding protein expression determined.
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FIGURE 3: Angi and Ang2 are both capable of inducing endothelial PAF
synthesis in a time and concentration-dependent manner. Confluent BAEC were
stimulated with Angi or Ang2 (1 nM) for time periods ranging from 7.5 to 360
minutes in the presence of [3HJ-acetate. As positive control BAEC were treated with
VEGF-A165 for 15 minutes. Angl (A) and Ang2 (B) mediate endothelial PAF
synthesis with maximal values observed following 4 hours of stimulation. Maximal
angiopoietin-mediated endothelial PAF synthesis is observed when Angi and Ang2
are used at a concentration of 1 nM (C). Data are expressed as thousands (10g)
disintegrations per minute (DPM) and represent the incorporation of tritiated acetate;
[3H]-acetate into lyso-PAF. Values are means ± SEM ofat least 12 experiments. ‘
p < 0.00 1 vs. PBS.
FIGURE 4: Pretreatment with VEGF receptor (VEGFR) inhibitors attenuates
angiopoietin-mediated endothelial PAF synthesis at 4 hours. Confluent BAEC
were pretreated with a selective VEGFR-2 inhibitor (SU 1498; 5 jiM) or a VEGFR
1 /R-2 inhibitor (VTK; 10 tM) for 15 minutes prior to stimulation with Ang 1 or Ang2
(1 nM) for 4 hours in the presence of [3H]-acetate. Values are means ± SEM of at
least three experiments. ** p <0.01 and p <0.001 vs. PBS ; t p <0.05 and 1-t p
<0.01 vs. agonist.
FIGURE 5: Endothelial distribution of VEGF upon stimulation with
angiopoietins. Confluent BAEC were stimulated in serum-free DMEM with Angi
or Ang2 (1 nM) for up to 6 hours. Supematants were collected, concentrated and
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VEGf protein quantified by sandwich ELISA. Ceil membranes were gently scraped
in cold PBS (pH = 7.4), disrupted by sonication, and VEGf protein measured in the
same ELISA as the corresponding supernatants. Values are means ± SEM
corresponding to three experiments.
FIGURE 6: Treatment of BAEC with angiopoietins induces a relocalization of
endogenous VEGF to the celi surface membrane. Subconfluent BAEC were
grown on gelatin-coated glass siides, rinsed with PBS, lefi untreated (A and B) or
treated with Angi or Ang2 (both 1 nM) for 7.5 minutes (C and E, respectively) or 4
hours (D and f, respectively). Prior to angiopoietin stimulation, celis were incubated
with rabbit polyclonal anti-human VEGf antibody (A, C-f) or with isotypic IgG (B)
and then fixed with 1% paraformaldehyde. The presence of VEGf on the ccli
surface membrane was observed by confocal microscopy. Relative intensity (RI) for
each image represents the summation of voxel intensities compared to that of PBS
which was normalized to 1. Bar represents 20 11m.
FIGURE 7: Treatment of BAEC with Angi or Ang2 promotes VEGFR-2
phosphorylation. Confluent BAEC were stimulated with Angl or Ang2 (1 nM) for
7.5 minutes to 4 hours. Ceil lysates (1 mg) were prepared and immunoprecipitated
(IP) with rabbit polyclonal anti-mouse VEGfR-2 IgG. following resolution by SDS
PAGE and transfer, PVDF membranes were probed with mouse monoclonal
antiphosphotyrosine IgG and immunoreactive hands were visualized by
chemiluminesence. Membranes were subsequently stripped and VEGfR-2 protein
$8
expression was determined following incubation with rabbit polyclonal anti-mouse
VEGFR-2 IgG.
FIGURE 8: Angiopoietin-mediated endotheliai PAF synthesis requires the
activation of p38 MAPK, p42144 MAPK, and PI3KJAkt signalling pathways and
sPLA2-V. (A) Confluent BAEC were pretreated with either PD9$059 (10 tM),
SB203580 (10 tM), LY294002 (5 iM), or Wortmannin (500 nM) 15 minutes prior to
4 hours of stimulation with Angi or Ang2 (1 nM). (B) Confluent BAEC were
pretreated with selective PLA2 pharmacological inhibitors AACOCF3 (10 jiM),
scalaradial (10 1iM), or LY3 11727 (100 jiM) 15 minutes prior to 4 hours of
stimulation with Angi or Ang2 (1 nM). Values are means ± SEM of 3 experiments.
** p < 0.01 and p < 0.001 vs. PBS ; t p < 0.05 vs. agonist.
FIGURE 9: Proposed mechanism by which angiopoietins mediate endothelial
PAF synthesis. Stimulation of tyrosine kinase Tie2 receptor by Angi or Ang2 (1)
activates PI3K, p42144 MAPK, and p38 MAPK pathways (2). These intracellular
signalling pathways, through the action of sPLA2-V, induce endothelial PAF
synthesis (3). Concurrently, Tie2 activation, through a mechanism yet to be defined,
promotes the relocalization of endogenous VEGF to the ceil membrane (4) where it
can bind to one of its receptors, VEGFR-2 (5). Activation of VEGFR-2 leads to p38
and p42144 MAPKs activation and endothelial PAF synthesis (6) which in tum
potentiates angiopoietin-mediated PAF synthesis.
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Titie: Angiopoietin-mediated endothelial P-selectin transiocation is
calcium-dependent
Cellular Signalling
Dear Dr Sirois,
Reviewers have now commented on your paper. You will see that they
are advising that you revise your manuscript. If you are prepared ta
undertake the work required, I would lie pleased ta reconsider my
decis ion.
If you decide ta revise the work, please submit a list af changes or
a rebuttal against each point which is being raised when you submit
the revised manuscript.
Yaurs sincerely,
Susan Pyne, PhD
Co-Editor
Cellular Signalling
Reviewers comment s:
This study details evidence of the angiapoietin-induced
transiocatian of P-selectin ta the surface of 3AEC celis. Bath Angi
and Ang2 are able ta produce this et f ect which is shown ta be
dependent upan phospholipase C and Ca2+/calmadulin whereas the
p42/p44 MAPK, p38 MPK and PI3K pathways do flot appear ta lie
invalved. However, the authors need ta validate that PLCgamma is
activated (rather than relying exclusively an the inhibitary et fect
of U73122) and ta demonstrate that the variaus kinase inhibitars
that have been used are indeed exerting the reguired effects under
the conditions used.
1. Fig 1 is nat canvincing and should be amended. Firstly, which af
the (apparently) three bands in the Tie2 blot (Fig lA and Fig 13) is
Tie2? How lias this been canfirmed given that multiple
immunareactive bands migrate very similarly? Secandly, the
‘phospho blat in Fig 13 appears ta show marked phospharylatian at 5
mm, fallowed by a decline ta 15 min. This trend is not reflected
in the histagram (Fig 1C), even af ter taking inta account the total
Tie2 amount (Fig 13, lower panel) which appears ta increase with
time.
2. Since the ceil surface ELISA results are heavily reliant on the
selectivity of the P-selectin antibady, the specificity af this
reagent in BAEC should lie confirmed by Western blatting.
3. It is nat sufficient ta rely exclusively an the reparted
selectivity and published 1C50 values far the variaus inhibitars
used. The authors need ta substantiate their daim that Angi and
Ang2 activate PLCgamma (e.g. by Western blatting far phasphar
PLCgamma) and ta confirm (e.g. by Westerns) that the kinase
inhibitars are indeed exerting the required et fect under the
conditions used. This is particularly important when making daims
about the exclusion af certain pathways (p42/p44 MZPK, p38 MAPK and
PI3K) from the transiacation of P-selectin ta the plasma membrane.
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3.1 ABSTRACT
Recently identified, angiopoietin-1 (Angi) and -2 (Ang2) bind to the tyrosine kinase
receptor Tie2 and contribute to orchestrate blood vesse! formation during
angiogenesis. Angi mediates vesse! maturation and integrity by favouring the
recruitment of pericytes and smooth muscle ceils. Ang2, initia!ly identified as a Tie2
antagonist may, under certain circumstances, induce Tie2 phosphorylation and
biological activities. Since inflammation exists in a mutually-dependent association
with angiogenesis, we sought to detennine if Angi and/or Ang2 could modulate
proinflammatory activities, namely P-selectin transiocation, in bovine aortic
endothelia! celis (BAEC) and dissect the mechanisms implicated. P-selectin, an
adhesion molecule found in the Weibel-Palade bodies (WPB) of endothelial celis
(EC), is rapidly translocated to the ccli surface upon EC activation during
inflammatory processes. Herein, we report that Angi and Ang2 (1 nM) are both
capable of mediating a rapid Tie2 phosphorylation as well as a rapid and transient
endothelia! P-selectin transiocation maximal within 7.5 minutes (125% and 100%
increase, respectiveiy over control values). In addition, we demonstrate for the first
time that angiopoietin-mediated endothelial P-selectin transiocation is calcium
dependent and regulated through phospholipase C-y (PLC-y) activation.
Key words: angiopoietins, P-selectin, Tie2, calcium, and inflammation,
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3.2 INTRODUCTION
Angiogenesis, the formation of new blood vessels from preexisting vasculature, is a
tightly regulated process requiring the action of various growth factors, namely,
vascular endothelial growth factor (VEGF) and angiopoietins ([1] for review).
Angiogenesis plays a critical role in several pathological conditions, including
atherosclerosis, proliferative retinopathies, and tumour growth [1]. It has been
reported that inflammation precedes and accompanies pathological angiogenesis as
evidenced by increased vascular permeability as well as monocyte/macrophage and
neutrophil recruitment at angiogenic sites [2]. During inflammatory processes, newly
formed vessels supply inflamed tissue with oxygen and nutrients and facilitate the
transport ofinflammatory celis.
Recently identified, the angiopoietins (Angi and Ang2), are defined as
ligands for the tyrosine kinase receptor Tie2 [3, 4] to which they bind with similar
specificity and affinity [3, 4]. Mgi has been characterized as a Tie2 agonist, having
the capacity to stabilize and promote the maturation of unstable vessels in presence of
VEGF-A165 [5J. On the other hand, Ang2 was initially described as a natural
endogenous Tie2 antagonist, thereby destabilizing existing vessels prior to VEGF
A165-induced angiogenic sprouting [41. However, under certain circumstances, Ang2
may induce Tie2 phosphorylation and biological activities such as endothelial celi
(EC) migration, neutrophil activation, vascular permeability, and in vitro tubule
capillary-like formation [6-101.
Neutrophils are the first celis recmited to the site of inflammation and provide
cytokines, growth factors, and proteolytic enzymes, which together, contribute to
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trigger and support angiogenic activities [11, 12]. The recruitment of neutrophils
implies overlapping succession of adhesive events encompassing neutrophil
tethering, rolling, and firm adhesion onto EC. These processes require the interaction
of various adhesion molecules located on the surface of EC and neutrophils.
Stimulation of EC with inflammatory mediators such as thrombin, histamine, and
VEGf-A165, can promote a rapid and transient translocation of P-selectin contained
in Weibel-Palade bodies (WPB) to the ce!! surface [13, 14]. P-selectin is then able to
interact with its high affinity counterreceptor, P-selectin-glycoprotein-ligand- 1
(PSGL-1) expressed on neutrophils and promote their rolling and transient adhesion
[13-15]. Inflammatory mediators may also lead to an equivalent rapid and transient
synthesis of platelet-activating factor (PAF) by EC and/or neutrophils. Newly
synthesized PAF can then bind to its receptor expressed on neutrophils, and induce a
rapid functional upregulation of the 2-integrin complex (CD 11 lCD 1$) favouring the
binding to its endothelial counterreceptor, intracellular adhesion molecules -1 and -2
(ICAM-1 and ICAM-2). This latter interaction increases the adhesion ofneutrophils
onto activated EC, which is critical in the initiation of the inflammatory process at
injury sites [13, 16, 17] ([1$] for review).
We have recently reported that VEGF-A165 inflammatory effects are mediated
tbrough the synthesis of platelet activating factor by endothelial celis [19] and that
PAF contributes to the induction of endothelial P-se!ectin transiocation and
neutrophil adhesion onto activated EC [15]. Furthermore, our !aboratory
demonstrated that Angl and Ang2 are also both capable of promoting endothelial P
selectin translocation and neutrophil adhesion onto EC [9]. Since angiopoietins act in
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concert with VEGF to modulate vascular plasticity during postnatal
neovascularization [20], we therefore sought to investigate the cellular mechanisms
implicated in angiopoietin-mediated endothelial P-selectin transiocation and assess
the role of PAF in this process.
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3.3 MATERIAL & METHODS
Reagents
BN 52021, CV-3988, PD9$059, SB203580, Wortmannin, U73 122, Caiphostin C, and
W-7 were purchased from Calbiochem (La Joua, CA, USA). BAPTA-AM was
purchased from Sigma (Oakville, ON, Canada). LAU 8080 was a generous gifi from
Dr. Nicolas G. Bazan (Department of ophtalmology and Neuroscience Center of
Excellence, Louisiana State University, New Orleans, LA, USA).
Ceil Culture
Endothelial celis were isolated from fresh bovine aortas (BAEC) and seeded in flat
bottom 96-well plates (fisher Scientific, Nepean, ON, Canada) and cultured in
Dulbecco’s modified Eagle medium (DMEM; Life Technologies, Burlington, ON,
Canada) containing 5% fetal bovine serum (f35; Medicorp Inc., Montreal, QC,
Canada) and 1% antibiotics (Penicillin and Streptomycin; Sigma). BAEC were
characterized as previously described [19, 21] and used between passages 2 and 5.
Western blot analysis ofTie2 phosphorylation
Confluent BAEC in 100 mm culture plates were serum-starved in DMEM with
antibiotics overnight, rinsed with Hank’s balanced salt solution (HBSS; Life
Technologies), placed on ice for 30 minutes, and then stimulated in a solution of
HBSS/HEPES (10 mM, pH 7.4), bovine serum albumin (BSA; 1 mg/mL; Sigma),
and CaCl2 (1 mM) containing Angi or Ang2 (1 nM) at 37°C. Cells were solubilized
with lysis buffer, scraped, and the protein concentration determined by Bradford
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assay. Ce!! !ysates were immunoprecipitated with rabbit polyclonal anti-mouse Tie2
IgG (Santa Cruz Biotechno!ogy, $anta Cruz, CA, USA) and separated by $DS
PAGE. Proteins were transferred onto a polyvinylidene difluoride (PVDF)
membrane and probed with mouse monoclonal anti-phosphotyrosine IgG (clone
4Gb, 1:1000 dilution; Upstate Biotechnology Inc., Lake Placid, NY, USA).
Membranes were stripped using Re-Blot Plus Strong stripping solution (Chemicon
International, Temecula, CA, USA) and reprobed with rabbit polyclonal anti-mouse
Tie2 IgG (1:1000 dilution; Santa Cruz Biotechnology). Bands were visualized using
LumiGloTM (New England Biolabs, Pickering, ON, Canada). The density of the
hands was determined using Quantity One software (Bio-Rad, Mississauga, ON,
Canada).
Celi surface ELISA
Endothelial P-selectin translocation was measured by celi surface enzyme-linked
immunosorbent assay (ELISA) as described previously [9, 15], following stimulation
of BAEC with angiopoietin -1 or -2. Briefly, BAEC were seeded and grown up to 1
day post-confluence in flat-bottom 96-well plates. Prior to stimulation, BAEC were
incubated overnight in sernm-free DMEM containing 1% antibiotics. BAEC were
rinsed with Dulbecco’s phosphate buffered saline (DPBS; Life Technologies) at 37°C
and, in fimction ofthe experiments, pretreated with a DPBS-CaC12 (10 mM) solution
with or without selective antagonists or inhibitors 15 minutes prior to stimulation
with angiopoietins (R&D Systems, Minneapolis, MN, USA) or VEGF-A165
(PeproTech Inc., Rocky Hill, NJ, USA). Reactions were stopped by removing
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stimulation medium and adding 1% paraformaldehyde for 20 minutes. Following a
rinse with DPBS, ceils were incubated with blocking solution (5% B$A in DPBS) for
15 minutes. Ceils were then incubated with rabbit polyclonal anti-human P-selectin
IgG (Research Diagnostics mc; Flanders, NJ, USA; 1:1000 dilution) for 90 minutes,
rinsed with DPBS, and then incubated with HRP-conjugated goat anti-rabbit IgG
(Santa Cruz Biotechnologies; 1:5000 dilution) for 45 minutes. Peroxidase activity
was quantified at 450 nm using a plate reader. Nonspecific binding was assessed by
substituting primary antibodies with normal rabbit IgG (Santa Cruz Biotechnologies).
Due to slight variations of basal P-selectin transiocation between experiments, data
were reported as relative P-selectin translocation [9, 15J.
Confocal Microscopy
Immunoflorescence: BAEC were grown on glass coverslips, rinsed with DPBS
(37°C), stimulated with VEGf-A165, Angl, Ang2 (1 nM) or phorbol myristate acetate
(PMA; 1 jiM) and fixed with 1% paraformaldehyde-DPBS solution. Following
fixation, the celis were incubated for 60 minutes in the dark with wheat germ
agglutinin (WGA) conjugated to Alexa 488 (1:200 dilution; Invitrogen) to label the
cell surface membrane. Following a rinse with DPBS, ceils were incubated with
blocking solution (4% normal donkey serum in DPBS) for 15 minutes. Cells were
incubated with rabbit polyclonal anti-human P-selectin antibodies (1:100 dilution;
Research Diagnostics mc) and nonspecific binding was assessed by substituting
primary antibodies with normal rabbit IgG (Santa Cruz Biotechnologies) for 90
minutes. Cells were rinsed with DPBS and incubated with donkey anti-rabbit
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conjugated to Alexa 555 IgG (1:600 dilution; Invitrogen) for 60 minutes. Glass
coverslips were mounted using 1 ,4-diazabicyclo-2-2-2-octane (DABCO)/glycerol
(1:5) solution.
Image acquisition, deconvolution and image rendering: Z stacks of BAEC were
acquired with a LSM 510 confocal microscope (Zeiss. Oberkochen, Germany) and
saved as LSM files. Donkey anti-rabbit conjugated to Alexa 555 IgG and WGA
conjugated to Alexa 48$ were visualized using a 543 nm Helium-Neon laser and a
488 mi Argon laser respectively. A 63x11 .4 Plan-Apochromat objective (Zeiss) was
used for magnification. Voxel size is 71 nm X 71 nm X 160 nm (X, Y, and Z). Z
stacks were deconvolved with the Huygens Pro 2.6.5a (Scientific Volume Imaging,
SVI, Alexanderlaan, The Netherlands) using the Maximum Likelihood Estimation
(MLE) algorithm. Signal-to-noise ratios were quantified for each Z stacks and added
to the MLE algorithm. Point spread functions (PSFs) were derived from Z stacks of
15 fluorescent (540-560 nm and 500-515 nm) beads of 170 nm in diameter
(Invitrogen). PSFs were acquired the same way as the images of interest.
Deconvolutions were applied until reaching 0.01% quality change threshold (QCT)
between iterations. Deconvolved Z stacks were saved in Tiff files format series or
ICS files and transferred to the LSM 510 or SFP ($imulated fluorescence Process,
$VI) software, respectively. front view transparent projections were made using 4
suces (0.64 im total thickness) from their respective Z stacks. A two (2 im)-wide
rectangle volume was extracted from the Z stacks to produce transverse transparent
projections. These projections were executed with the projection tool from the LSM
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510 software. The totality of suces from the Z-stacks was used to produce the $FP
projections. final images were saved as Tiff files.
Statistical AnaÏysis
Data are mean ± SEM. Comparisons were made by analysis of variance followed by
a Bonferroni t-test using GraphPad Instat version 3.05 (GraphPad Software Inc.).
Data were considered significantly different if values ofp<0.05 were observed.
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3.4 RESULTS
Ang] andAng2 activate Tie2
In an initial series of experiments, we assessed the capacity of both angiopoietins
(Angl and Ang2) to modulate Tie2 phosphorylation in fiinction of time. Treatment
of confluent BAEC with Angi (1 nM) induced a rapid Tie2 phosphorylation within
7.5 minutes, corresponding to a 2.2-fold increase upon 15 minutes of treatment
versus control DPB$-treated celis (Figure lA). Similarly, treatment with Ang2 (1
nM) also induced within 7.5 minutes Tie2 phosphorylation and corresponding to a
4.1 -fold increase following a 15 minute treatment compared to control DPBS-treated
ceils (figure lB).
Ang] andAng2 induce P-selectin transiocation in BAEC
We have previously reported that VEGF-A165 requires endothelial PAF synthesis to
promote P-selectin transiocation in human umbilical vein endothelial ceils (HUVEC)
[15]. In addition, we observed that both Angi and Ang2 are capable of inducing P
selectin transiocation in HUVEC, and this, in absence of endothelial PAF synthesis
[9]. More recently, we demonstrated that Angl and Ang2 are capable of mediating
PAF synthesis in BAEC [22] and thus, we sought to determine whether angiopoietins
can mediate P-selectin transiocation in BAEC, and the potential contribution of PAF.
Stimulation of BAEC with Angi induced endothelial P-selectin transiocation in a
time- (O-15 minutes) and concentration-dependent manner (1 pM — 5 nM). Peak
values (125% increase) were observed within 7.5 minutes and at 1 nM as compared
to control DPBS-treated celis (Figure 2A and B). Similarly, treatment of BAEC with
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Ang2 (1 nM) induced a 100% increase in endothelial P-selectin transiocation within
7.5 minutes at (figure 2C and D). As positive control, BAEC were stimulated with
VEGf-A165 (1 nM) for 7.5 minutes increasing by 200% basal endothelial P-selectin
transiocation (figure 2).
To confirm the ability of angiopoietins to promote endothelial P-selectin
transiocation, we used a confocal microscopy approach. Transiocation of P-selectin
to the non-permeabilized endothelial celi surface membrane was visualized by dual
labeling of celi membrane with WGA conjugated to Alexa 488 and with antibodies
conjugated to Alexa 555 against P-selectin. Negative control experiment was
performed by replacing P-selectin primary antibodies with purified preimmune rabbit
IgG which did not reveal detectable staining of P-selectin (figure 3A1 -A3). In
control DPBS-treated BAEC, we observed a basal level of P-selectin at the ceil
surface membrane (Figure 3B1-B3). Treatment with positive controls (PMA; 1 tM
and VEGf-A165; 1 nM), or with Angi or Ang2 (1 nM), for 7.5 minutes induced P
selectin transiocation along the cytoplasmic membrane (figure 3C1-C3 to 3f 1-3F3,
respectively).
Non-permeabilized celis were used so as to eliminate the signal emanating
from P-selectin located in cytoplasmic WPB and thus enabling the visualization of P
selectin at the celi surface in front view (Figure 3A1-3F1), and transverse (figure
3A2-3f2) transparent projections. In these projections, P-selectin transiocation
within the ce!! surface membrane is detected upon stimulation with angiopoietins and
positive controls as evidenced by the presence of a yellow signal. To visualize the
extracellular P-selectin translocated domain, confocal images were cumulated to
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provide a three (3)-dimensional projection of the celis in which the extracellular P
selectin domain appears in red (figure 3A3-3F3).
Angiopoietin-mediated P-selectin transiocation requires PLC-y signal transduction.
A recent study reported that VEGF-A165 triggers exocytosis of WPB in part through
PLC-7 signal transduction [23]. We thus sought to determine the role played by
PLC-y in angiopoietin-mediated endothelial P-selectin transiocation by pretreating
BAEC for 15 minutes with pharmacological inhibitors of PLC-y (U73 122; 10 1iM)
and protein kinase C (PKC; Caiphostin C; 100 nM) prior to stimulation with Mgi or
Ang2 (1 nM; 7.5 minutes). Angiopoietin-mediated endothelial P-selectin requires the
activation of PLC-7 since pretreatment with U73 122 reduced Angi- and Ang2-
mediated P-selectin transiocation by 56% and 88%, respectively (Figure 4).
Similarly, inhibition of PKC, activated immediately downstream of PLC--y, also
reduced endothelial P-selectin translocation in BAEC treated with Angi and Ang2
both by 62% (figure 4). As positive control, BAEC were pretreated with U73 122
and Caiphostin C prior to stimulation with VEGf-A165 (1 nM; 7.5 minutes). U73 122
and Caiphostin C diminished VEGF-A165-mediated endothelial P-selectin
transiocation by 78% and 74%, respectively (Figure 4).
Angiopoietins mediate endotheliaÏ P-selectin transiocation independently of p38
M4PK p42/44 MAPK, PI3K activation, and PAF synthesis.
Activation of PKC may lead to the activation of p42144 mitogen-activated protein
kinase (MAPK). Furthermore, we and others have reported that Tie2 receptor
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autophospho-rylation following stimulation with Angi or Ang2 can in tum activate
p38 MAPK, p42144 MAPK, and PI3KJMt intracellular signaling pathways [6, 22,
24-2$]. Pretreatment of BAEC with selective inhibitors for MAPKK (PD9$059; 10
1iM), p38 MAPK (SB2035$0; 10 jiM), or PI3K (Wortmannin; 500 nM) prior to
stimulation with angiopoietins did flot significantly reduce P-selectin transiocation
(Figure 5A). However, pretreatment with the aforementioned inhibitors reduced P
selectin transiocation foilowing 7.5 minutes of stimulation with VEGF-A165 by 55 to
57% (figure 5A).
In addition, we have previously reported on the foie of endothelial PAF in
VEGF-A165-mediated P-selectin transiocation in HUVEC [15]. To assess the
contribution of endotheliai PAF to angiopoietin-mediated P-selectin translocation,
BAEC were pretreated with selective antagonists for either intraceilular (LAU 8080;
100 nM), extracellular (BN 52021; 10 1iM) or both intra- and extraceilular (CV-3988;
10 jiM) PAF receptors (PAFR) 15 minutes prior to stimulation with either Angi or
Ang2 (1 nM) for 7.5 minutes. Pretreatment with PAFR antagonists had no effect on
angiopoietin-mediated P-selectin translocation (Figure 5B). However, pretreatment
of BAEC with the aforementioned PAFR antagonists (LAU $080, BN 52021, or CV
3988) prior to stimulation with VEGf-A165 reduced endothelial P-selectin
transiocation by 59%, 39%, and, 43%, respectively (Figure 5B).
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Angiopoietin-mediated endothelial P-seÏectin transiocation is Ca2-dependent.
Angiopoietin-mediated endothelial P-selectin translocation does flot appear to be
regulated by the activation of p38 MAPK, p42144 MAPK, or PI3K intracellular
signalling pathways nor by PAF. However, exocytosis of WPB and the subsequent
transiocation of P-selectin has been shown to be calcium-dependent following
stimulation of EC with VEGF-A165 [23]. b determine which calcium stores are
mobilized during angiopoietin-mediated P-selectin transiocation, BAEC were
pretreated with an intra- and extracellular calcium chelator (BAPTA-AM; 10 rM) or
stimulated in Ca2-free DPBS. Chelation of intra- and extracellular calcium
completely abrogated endothelial P-selectin translocation. In addition, in an
extracellular Ca2-free environment, we observed that the release of Ca2 from
intracellular pools was insufficient to support endothelial P-selectin translocation
(Figure 6A). No significant statistical differences were observed between BAPTA
AM-treated and Ca2-free DPBS groups for each ofthe three growth factors studied.
In order to determine the role of the calciumlcalmodulin complex (Ca27CaM)
on angiopoietin-mediated endothelial P-selectin transiocation, we disrupted its
formation with a selective inhibitor (W-7; 10 mM). The blockade ofthe Ca2/CaM
complex completely abolished angiopoietin-mediated endothelial P-selectin
transiocation (Figure 6B). Similarly, VEGF-A165-mediated endothelial P-selectin
translocation was also completely inhibited in response to pretreatment with W-7
(Figure 6B).
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3.5 DISCUSSION
In the present study, we demonstrate that Angi and Ang2 are both capable of
mediating Tie2 phosphorylation resulting in a rapid and transient endothelial P
selectin translocation. In addition, we delineate that angiopoietin-mediated
endothelial P-selectin translocation is calcium-dependent through PLC-y signal
transduction. However, as opposed to VEGF-A165, P-selectin transiocation mediated
by Angi or Ang2 is independent of endothelial PAF synthesis.
Angi and Ang2 promote Tie2 phosphoryÏation and endothelial P-selectin
transiocation.
Early studies identified that Angi can induce a rapid activation of Tie2 receptor [3, 4,
7, 25], whereas Ang2 was described as a natural Tie2 antagonist in EC [4]. However,
other studies reported that the use of high concentrations or prolonged treatment with
Ang2 can induce Tie2 activation, support endothelial cell survival and EC tubule
capillary-like formation [6, 7]. More recently, we and others reported that Ang2 can
also promote a rapid Tie2 phosphorylation (within minutes) [8, 9, 22], mediate tubule
capillary-like formation in immortomouse brain endothelial celis [8], endothelial P
selectin transiocation, and neutrophil adhesion onto activated FRJVEC [9]. Herein,
we report that both angiopoietins activate Tie2 with a similar kinetic pattem,
resulting in a rapid and transient endothelial P-selectin transiocation in BAEC as
demonstrated by celi surface ELISA and confocal microscopy. Our observations are
consistent with reports indicating that endothelial P-selectin is translocated from
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Weibel-Palade bodies (WPB) upon stimulation with various inflammatory mediators
as rapidly as 2 minutes afier stimulation with a peak within 10 minutes [29, 301
whereupon P-selectin is removed from the ceil surface either by enzymatic cleavage
or by endocytosis to be recycled back into WPB [31]. In addition, we demonstrate
that endothelial P-selectin translocation mediated by angiopoietins is concentration
dependent. Indeed, maximal P-selectin transiocation was attained at 1 nM, and
interestingly, at a higher concentration (5 nM), the capacity of Angi and Ang2 to
mediate P-selectin transiocation was reduced. We also observed this phenomenon
under other experimental conditions, namely VEGf-A165 and angiopoietin-mediated
P-selectin transiocation in HUVEC, angiopoietin-mediated PAF synthesis in BAEC
as well as VEGF-A165-mediated prostacyclin (PGI2) synthesis in BAEC [9, 15, 22,
32]. This can be explained by the fact that the binding of a ligand to a receptor
tyrosine kinase (RTK) induces receptor homo- or heterodimerization, which is
essential for the autophosphorylation of tyrosine residues and the initiation of
downstream signalling events [33]. However, an overabundance of ligand impedes
receptor dimerization [34]. Considering that numerous studies reported the use of
angiopoietins, in some cases, at concentrations exceeding 10 nM, our study
demonstrates the importance of performing a dose-response curve to establish the
suitable concentration to achieve selective biological activities thereby avoiding
potentially false interpretations with respect to the biological activities of the
angiopoietins and other tyrosine kinase receptor ligands.
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IntracelluÏar signalling impÏicated in angiopoietin-mediated P-selectin transiocation.
In previous studies, we defined that the inflammatory properties of VEGF-A165
requires endothelial PAF synthesis. In addition, we reported that VEGF-A165-
mediated PAF synthesis implies the dual activation of PLC-’y/PKC/p42/44 MAPK
and MLKJMKK-3, 6/p38 MAPK signalling pathways [35]. We also reported that
VEGf-A165 induces P-selectin translocation through endogenous PAF synthesis in
HUVEC [15]. furthermore, we recently observed that both Angi and Ang2 can
promote P-selectin transiocation in absence of PAF synthesis in HUVEC [9].
However, we recently observed that Angi and Ang2 as VEGF-A165 can mediate PAF
synthesis in BAEC [22]. Finally, recent findings indicate that VEGF-A165-mediated
WPB exocytosis is regulated in part through PLC--y signal transduction [23]. We
therefore sought to dissect the signalling pathways implicated in angiopoietin
mediated P-selectin transiocation and the role of endogenous PAF in BAEC using
VEGF
-A165 as a positive control.
In the current study, we demonstrate that angiopoietin-mediated endothelial
P-selectin translocation requires PLC and PKC activation. Indeed, treatment of
BAEC with selective inhibitors of PLC-y (U73 122) or PKC (Caiphostin C) prior to
stimulation with Angi or Ang2 reduced P-selectin transiocation. Similarly, VEGF
A165-mediated P-selectin transiocation is also dependent on the activation of PLC-y
and PKC. PLC-’y is an important regulator of calcium signalling and PKC,
immediately downstream, is implicated in p42144 MAPK activation which in tum
regulates endothelial PAF synthesis. Taken together, these observations prompted us
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to investigate calcium signalling and intracellular signalling pathways leading to
endothelial PAF synthesis.
Since Angi and Ang2, upon binding to Tie2, have been shown to activate
p42144 MAPK, p38 MAPK, and PI3K intracellular signalling pathways [6, 22, 24-
28] leading to a rapid and sustained synthesis of PAF in BAEC [22], we wished to
determine whether these pathways and PAF were implicated in angiopoietin
mediated P-selectin transiocation. In the current study, we demonstrate that the
aforementioned pathways are flot implicated in angiopoietin-mediated endothelial P
selectin transiocation and neither is endothelial PAF. On the other hand, VEGF-A165-
mediated transiocation requires the activation of p38 MAPK and p42744 MAPK, both
capable of mediating endothelial PAF synthesis and PI3K which, although activated,
has been shown not to increase PAF synthesis [35]. When we pretreated BAEC with
selective PAFR antagonists, we observed a reduction in translocation, although not as
pronounced as what we had previously reported in HUVEC [15]. Taken together,
our data demonstrates that the angiopoietins and VEGF-A165, two different classes of
tyrosine kinase receptor ligands, induce endothelial P-selectin translocation in BAEC
through different mechanisms. Furthermore, the contribution of endothelial PAF to
VEGF-A165-mediated P-selectin transiocation may account for the ability of VEGF
A165 to induce greater levels ofP-selectin transiocation than Angi or Ang2.
The transiocation of P-selectin and constituents of WPB requires the movement of
the WPB from the cytoplasm to the cell membrane and the fusion of these vesicles
120
with the plasma membrane. Increased levels of cytosolic free Ca2 concentration
([Ca2j1) levels have been implicated in the mechanism of exocytosis for a number of
agonists including thrombin and histamine [36]. The cellular responses to increased
[Ca2j are most likely mediated through calmodulin and small GTP-binding proteins
[37-39]. In our current study, treatment of BAEC with an intracellular calcium
chelator (BAPTA-AM) or a calmodulin inhibitor (W-7) prior to stimulation with
Angi or Ang2 completely abrogated P-selectin transiocation. furthermore, P
selectin transiocation was absent in celis treated with Angi or Ang2 in calcium-free
DPBS. Together, these data confirm the importance of Ca2 in P-selectin
transiocation mediated by angiopoietins. It has been established that elevation of
Ca2 over basal levels (100 nM) is required for regulated exocytosis [40, 41J and that
this elevation may be due to influx of calcium across the plasma membrane [42],
from intemal stores, or both [43, 44]. The endoplasmic reticulum tER) is the best
characterized Ca2 store in mammalian cells [45] and release of Ca2 from the ER can
be triggered by activation of inositol triphosphate (1P3) [46] which can also modulate
calcium release from the Golgi complex [47]. In our current study we show that
PLC-y, which can act on PIP2 to produce 1P3 and hence trigger Ca2 release from
intracellular stores, regulates angiopoietin-mediated endothelial P-selectin. Once
released, calcium may form a complex with calmodulin. This complex has been
shown to interact with a small GTP-binding protein, Rai, in a calcium-dependent
manner and play an important role in regulating WPB exocytosis in EC [36]. In fact,
we observed that chelation of intra- and extracellular calcium completely abrogated
endothelial P-selectin translocation. furthermore, we observed that the release of
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Ca2 from intracellular pools was insufficient to support endothelial P-selectin
translocation in an extracellular Ca2-free environment. Taken together, these
observations demonstrate the critical role of calcium in angiopoietin-mediated
endothelial P-selectin translocation. Using another approach, namely inhibiting the
formation of the Ca2/calmodulin complex with W-7 and this, regardless of intra- or
extracellular levels of calcium, reduces transiocation to levels below control values
confirming the importance of calcium in P-selectin transiocation. Similarly, calcium
also contributes to mediate VEGF-A165-induced endothelial P-selectin transiocation.
Recent studies have reported that Angl possesses anti-inflammatory properties in
vitro, namely by reducing VEGF-induced leukocyte adhesion onto HUVEC and E
selectin expression [48] and thrombin-mediated neutrophil adhesion onto EC [49].
Upon initial review, these resuits may appear contradictory to what we report herein
as well as what we have previously demonstrated [9] but both of the above studies
[48, 49] were perfonned for extended periods of time that are well in excess of the
timeframe of P-selectin activity. Until recently, the role of Ang2 in inflammation
was unknown. In addition to our recent demonstration that Ang2 (as well as Angl)
promotes neutrophil PAF synthesis, endothelial P-selectin transiocation, and
neutrophil adhesion onto EC [9], Ang2 has been shown to promote vascular leakage
in vivo [10]. Furthermore, Ang2 has been shown to be stored exclusive of P-selectin
and rapidly released from WPB upon stimulation with PMA and calcium ionophores
but flot with VEGF or Angl [50]. Taken together, these observations demonstrate
that the angiopoietins should be considered as acute proinflammatory mediators.
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In summary, we demonstrate that in BAEC, Angi and Ang2 induce a rapid and
transient transiocation of P-selectin dependent on calcium entry and PLC-y
activation. However, contrary to VEGF-A165-mediated P-selectin transiocation,
angiopoietins do flot require the synthesis of endogenous PAF. P-selectin
transiocation plays a preponderant role in neutrophil rolling, an important event in
acute inflammation. This study allowed us to gain a better understanding of the
intracellular mechanisms mediating angiopoietin-induced endothelial P-selectin
transiocation.
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3.8 FIGURE LEGENDS
Figure 1: Angi and Ang2 activate Tie2 in a time-dependent manner. Confluent
BAEC were treated with Angl (A), or Ang2 (B) from 5 to 15 minutes. Ce!! lysates
(500 fig) were prepared and immunoprecipitated (IP) with rabbit po!yc!onal anti
mouse Tie2 IgG. Following resolution by $DS-PAGE and transfer, PVDF
membranes were probed with mouse monoclonal antiphosphotyrosine IgG and
immunoreactive bands were visualized by chemiluminesence. Membranes were
subsequently stripped using ReBlot Plus Strong stripping solution and Tie2 protein
expression was determined by Western blot (WB) analysis fo!lowing incubation with
rabbit polyclonal anti-mouse Tie2 IgG. Relative Tie2 phosphory!ation over Tie2
total protein expression under various experimental conditions was calculated by
normalizing DPBS contro! optical density (OD) values to 1 (C).
Figure 2: Angi and Ang2 induce endothelial P-selectin transiocation in a time
and concentration-dependent manner. Confluent BAEC were treated with Angi
or Ang2 and P-selectin trans!ocation was measured by ce!! surface enzyme-linked
immunosorbent assay (ELISA). Solution buffer (DPBS) was used as contro! and the
basal !evels of P-selectin translocation were norma!ized to 1. Maxima! P-selectin
trans!ocation was observed at 7.5 minutes (A) at a concentration of 1 nM (B).
Simi!ar!y, Ang2-mediated endothe!ial P-se!ectin trans!ocation was maximal at 7.5
minutes (C) and at 1 nM (D). As positive contro!, BAEC were stimu!ated with
VEGf-A165 (1 nM; 7.5 minutes). Data are expressed as relative absorbance measured
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at 450 nm. Values are means + SEM ofat least 3 experiments. ** and denote p <
0.01 and 0.001 vs. DPB$, respectively.
Figure 3: Angi and Ang2 mediate endothelial P-selectin transiocation.
Confluent BAEC were stimulated with DPBS, PMA (1 tM), VEGF-A165, Angl, or
Ang2 (1 nM) for 7.5 minutes. Ceils were fixed, labe!ed with antisera, and visualized
by confocal microscopy. Ce!! surface membranes were labeled with WGA
conjugated to A!exa 48$ and appear in green. P-selectin distribution was detected by
using rabbit polyclonal anti-human P-se!ectin IgG fo!!owed by incubation with a
secondary antibody conjugated to Alexa 555 IgG and appears in red. Presence of P
selectin within the celi surface membrane appears in yellow. Front view transparent
projections (Al-Fi) were made using 4 suces (0.64 tm thick) from respective Z
stacks. A 2 iim-wide rectangular volume from the Z stacks was extracted to produce
transverse transparent projections (A2-F2) executed using the LSM 510 software.
Three (3)-dimensiona! representation of the ce!!s (A3-F3) was performed by using
the $imulated Fluorescence Process (SfP) software, projections were created using
ail the suces ofthe Z stacks. Magnification = 63x; digital zoom = 2x, Bar 5 im.
Figure 4: Endothelial P-selectin transiocation mediated by Angi or Ang2
requires PLC-y and PKC signal transduction. Confluent BAEC were pretreated
with selective pharmacological inhibitors for phospholipase C-y (PLC-y; U73 122; 10
iM) and protein kinase C (PKC; Caiphostin C; 100 nM) for 15 minutes prior to 7.5
minutes of stimulation with Angl or Ang2 (1 nM). BAEC were also stimu!ated with
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VEGf-A165 (1 nM) for 7.5 minutes as positive control. Endothelial P-selectin was
measured by celi surface ELISA and data are expressed as relative absorbance
measured at 450 nm. Values are means ± SEM ofat least 3 experiments. ** and
denote p < 0.01 and p < 0.001 vs. PBS, respectively; f, if, and tif represent p<
0.05, p< 0.01, and p< 0.001 vs. agonist, respectively.
Figure 5: p38 MAPK, p42144, and PI3K signalling is not required for
angiopoietin-mediated endothelial P-selectin transiocation. (A) Confluent BAEC
were pretreated with selective inhibitors against MAPKK (PD98059; 10 jiM), p38
MAPK ($B203580; 10 jiM), or PI3K (Wortmannin; 500 nM) for 15 minutes prior to
7.5 minutes of stimulation with Angi or Ang2 (1 nM). (B) In a separate series of
experiments, confluent BAEC were pretreated with antagonists targeting either the
intracellular (LAU 8080; 100 nM), extracellular (BN 52021; 10 1iM) or both intra
and extracellular (CV-3988; 10 1iM) PAF receptors (PAFR) for 15 minutes prior to
stimulation with either Angl or Ang2 (1 nM) for 7.5 minutes. BAEC were
stimulated with VEGF-A165 (1 nM) for 7.5 minutes as positive control. Values are
means ± SEM of at least 3 experiments. ** and denote p < 0.01 and p <0.001
vs. PB$, respectively; tt and tif represent p< 0.01 and p< 0.001 vs. agonist,
respectively.
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Figure 6: Angiopoietin-mediated endothelial P-selectin requires calcium.
Confluent BAEC were pretreated with an intracellular calcium chelator (BAPTA
AM; 10 tM) prior to stimulation with Angi or Ang2 (1 nM) or stimulated with
angiopoietins in Ca2-free DPBS (A). In a separate series of experiments, EC were
treated with a selective calmodulin inhibitor (W-7; 10 mM) prior to treatment with
Angi or Ang2 (1 nM). VEGF-A165 (1 nM; 7.5 minutes) is present as positive
control. Endothelial P-selectin was measured by celi surface ELISA and data are
expressed as relative absorbance measured at 450 nm. Values are means + SEM of at
least 3 experiments. * and denote p <0.05 and p < 0.001 vs. PBS, respectively;
,
j, and ff represent p< 0.05, p< 0.01, and p< 0.00 1 vs. agonist, respectively.
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4.0 Discussion
Our !aboratory has reported that the effect of VEGF-A165 on vascular permeability is
mediated through the synthesis of platelet activating factor (PAF) by endothelial celis
56 In addition, we have delineated the intracellular signalling pathways leading to
VEGF-A165-mediated endothelial PAF synthesis 95,230,274 in BAEC. Furthermore, we
have recently demonstrated that VEGF-A165 induces endothelial P-selectin
transiocation and the subsequent adhesion of neutrophils onto activated endothelial
ceils through the synthesis ofendogenous PAF 65 in HUVEC.
Recently identified, the angiopoietins (Angi and Ang2), are defined as ligands for
the tyrosine kinase receptor Tie2 24,25 to which they bind with similar specificity and
affinity 24,25 Angi has been characterized as a Tie2 agonist, having the capacity to
stabilize and promote the maturation of unstable vessels in presence of VEGF-A165
123 On the other hand, Ang2 was initially described as a natural endogenous Tie2
antagonist, thereby destabilizing existing vessels prior to VEGf-A165-induced
angiogenic sprouting 25 However, under certain circumstances, Ang2 may induce
Tie2 phosphorylation and biological activities such as endothelial ce!! (EC)
migration, neutrophi! activation, vascular permeability, and in vitro tubu!e capillary
like formation 124,125,127,149,150 We have recently reported that Angi and Ang2 are
both capab!e of promoting endothelia! P-se!ectin transiocation and neutrophil
adhesion onto activated HUVEC in the absence of PAF synthesis 149 However, in
neutrophils, Angi and Ang2 activated Tie2 receptors leading to PAF synthesis,
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functional up-regulation of the 32-integrin complex, and a subsequent increase in
neutrophils adhesion 149
Therefore, building upon the numerous studies performed in our laboratory
investigating the role of VEGF-A165 on the regulation, synthesis, and signalling
pathways associated with endothelial PAF and knowing that angiopoietins act in
concert with VEGF to modulate vascular plasticity during postnatal
neovascularization 275 we set out to determine whether the angiopoietins could
modulate proinflammatory events, namely PAF synthesis and P-selectin
transiocation, in BAEC and identify the intracellular mechanisms implicated.
Herein, we report that Angi and Ang2 are both capable of mediating a rapid Tie2
phosphorylation, as well as a rapid, progressive and sustained endothelial PAF
synthesis. This angiopoietin-mediated PAF synthesis, maximal at 240 minutes is
mediated in part by a relocalization of endogenous VEGF to the ceil membrane and
through the activation of the p38 MAPK, p42144 MAPK, and PI3KIAkt intracellular
signalling pathways acting on a secreted phospholipase A2 (sPLA2-V). In addition,
we demonstrate that the angiopoietins are also capable of mediating a rapid and
transient endothelial P-selectin transiocation. Moreover, angiopoietin-mediated
endothelial P-selectin transiocation is calcium-dependent and regulated tbrough
phospholipase C-y (PLC-y) activation and contrary to VEGF-A165, this transiocation
does flot require endothelial PAF synthesis.
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4.1 Angi and Ang2 behave as T1e2 agonists in BAEC
Early studies reported that Angi can induce a rapid activation of Tie2 receptor
24,25,124,164
whereas Ang2 was described as a natural Tie2 antagonist in EC 25
However, other groups reported that the use of high concentrations or prolonged
treatment with Ang2 can induce Tie2 activation, support endothelial ceil survivat and
EC tubule capillary-like formation 124,125,127 Our data showed that Angi and Ang2
are both capable of mediating a rapid and transient phosphorylation of Tie2 in
endothelial ceils.
When determining whether the angiopoietins induced either endothelial PAF
synthesis or P-selectin transiocation, we set out to identify the optimal concentration
with which to conduct future experiments. Hence, we observed that endothelial PAF
synthesis and P-selectin transiocation mediated by Angi and Ang2 proceed in a dose
dependent manner. Angi and Ang2 at i09 M had their maximal agonistic effect on
PAF synthesis, increasing it by 1695% and 851%, respectively, suggesting that Ang2
might serve as a partial Tie2 agonist with respect to PAF synthesis. At a higher
concentration (i08 M), Angi- and Ang2-mediated PAF synthesis was also almost
completely lost. Similarly, we demonstrate that endothelial P-selectin transiocation
mediated by angiopoietins was also attained at I O M, and interestingly, at a higher
concentration (5x109 M), the capacity of Angi and Ang2 to mediate P-selectin
transiocation was also reduced. We have also observed this phenomenon under other
experimental conditions, namely for VEGF-A165 and angiopoietin-mediated P-
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selectin transiocation in HUVEC, as well as VEGF-A165-mediated prostacyclin
(PGI2) synthesis in BAEC 65,80,149 These observations can be explained by the fact
that the binding of a ligand to a receptor tyrosine kinase (RTK) induces receptor
homo- or heterodimerization, which is essential for the autophosphorylation of
tyrosine residues and the initiation of downstream signalling events 276 However, an
overabundance of ligand impedes receptor dimerization 277 Considering that
numerous studies reported the use of angiopoietins at concentrations exceeding 1 O
M 127,143,146,148,185 and draw conclusions that differ somewhat from ours, our study
demonstrates the importance of performing a dose-response curve to establish the
suitable concentration to achieve selective biological activities thereby avoiding
potentially false interpretations with respect to the biological activities of the
angiopoietins.
In this study, we also demonstrated that the activation of Tie2 by Angi activates p38
and p42144 MAPKs in a rapid and transient manner and PI3KJAkt for a prolonged
period of time. Our data are in une with a previous report demonstrating that upon
binding to Tie2, Angl activates both p38 and p42144 MAPKs 162 as well as Akt 165
Most studies investigating signalling downstream of Tie2 mainly focused on
PI3KIAkt 143,146,164,278 due to the ability of Angl to stabilize the vasculature. The
ability of Angl to activate both proapoptotic (p38 MAPK) and antiapopototic
(p42144 MAPK and PI3K) pathways is not unique since endothelial cell-specific
mitogens, such as VEGF, are also capable of activating multiple pathways including
p38 and p42144 MAPKs, and PI3K 279 Interestingly, we also observed the capacity
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of Ang2 to activate p38 and p42/44 MAPKs, which had yet to be documented, in
addition to PI3KJAkt which had previously been described by others 127,280 Our
observations demonstrate the complex dual nature of Ang2 by its ability to similarly
activate p38 and p42/44 MAPK as Mgi. However, Ang2 did not activate Akt in the
sustained manner observed with Angl. This difference may explain in part the ability
of Ang2 to destabilize vessels due to an inability to sufficiently activate PI3K and in
tum, Akt and focal adhesion kinase (FAK), two crucial elements in the signalling
pathway leading to ce!! survival and migration 114
4.2 Angi and Ang2 induce PAF synthesis in BAEC
Angiogenesis p!ays a critical ro!e in severa! patho!ogical conditions, namely
atherosc!erosis, proliferative retinopathies and tumour growth 13 $evera! studies have
reported that inflammation precedes and accompanies pathological angiogenesis as
evidenced by increased vascular permeability, monocytes/macrophages and
neutrophi!s recruitment at angiogenic sites 23,190 During inflammatory processes,
newly formed vessels supp!y inflamed tissue with oxygen and nutrients as well as
faci!itate the transport of inflammatory celis. We have shown that VEGF-A165
increases vascu!ar permeability through the synthesis of a potent inflammatory
mediator, plate!et-activating factor (PAF) by endothelial cel!s (EC) 56 VEGF
mediated endothe!ial PAF synthesis occurs via a remodelling pathway in which
membrane phospho!ipids are converted by a phospho!ipase A2 (sPLA2-V) into lyso
PAF which is in tum acety!ated into PAF by acetylCoA:lyso-PAF acetyltransferase
(lyso-PAF AT) 230 Furthermore, we have demonstrated that in bovine aortic
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endothelial celis (BAEC), VEGF-A165-mediated PAF synthesis implies the dual
activation of PLC-’/PKC/p42/44 MAPK and MLKIMKK-3,-6/p38 MAPK signalling
pathways whereas phosphatidyl inositol-3-phosphate kinase (PI3K) activation is not
required 274 Therefore, based on our previous observations with regards to VEGF
A165 and on the capacity of angiopoietins at regulating vascular integrity, we sought to
investigate whether Angi and/or Ang2 modulate endothelial PAF synthesis and if so,
to define the intracellular signalling pathways.
Our data demonstrate that the angiopoietins constitute a second class of tyrosine
kinase receptor ligands capable of mediating endothelial PAF synthesis. In the
present study, we demonstrate that both Angl and Ang2 induce endothelial PAF
synthesis in a time-dependent manner, however, the profile of PAF synthesis
mediated by the angiopoietins is strikingly different to that seen with VEGF-A165. In
contrast to what we have previously reported with respect to VEGF-A165-mediated
PAF synthesis 56, both angiopoietins induce a rapid, progressive, and sustained
endothelial PAF synthesis (maximal within 4 hours) whereas VEGF-A165 induces a
rapid and transient synthesis of PAF (maximal within 15 minutes) 56• In activated
endothelial celis, acute PAF synthesis is mediated through the remodelling pathway
and cari occur in a very early (2
- 5 minutes), early (10 - 40 minutes), or delayed (4 -
8 hours) 197 manner. The kinetics observed in the current study follow a biphasic
response during which angiopoietins induce an early response which is flot as robust
as that seen with VEGF-A165. This initial synthesis is followed by a “burst” phase
where maximal PAF synthesis is twice as high as the peak observed with VEGF
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A165. Based on the kinetics observed, angiopoietin-mediated endothelial PAF
synthesis may be complementary to VEGf-mediated PAF synthesis. Perhaps, under
inflammatory conditions, VEGF-mediated PAF synthesis provides an initial rapid
and transient synthesis followed by the prolonged angiopoietin-mediated response
sustaining neutrophil and EC activation leading to endothelial P-selectin transiocation
and neutrophil adhesion onto EC. We demonstrate herein that Angi and Ang2 are
both capable of inducing PAF synthesis in BAEC whereas in a previous study, we
reported that angiopoietins did not induce PAF synthesis in HUVEC 149 At first
glance, this may appear contradictory, but it may in fact be indicative of tissue
specificity. Indeed, we have previously observed that VEGF-A165 induces a more
robust endothelial PAF synthesis in BAEC as compared to HUVEC 230 Therefore,
the effect of angiopoietins on PAF synthesis is more evident in aortic than in venous
endothelial ceils.
The maximal PAF synthesis observed at 4 hours is dependent upon the activation of
the p38 MAPK, p42144 MAPK, and PI3KIAkt signalling pathways. Indeed,
pretreatment of BAEC with pharmacological inhibitors for each of the
aforementioned pathways resulted in similar inhibition pattems of PAF synthesis
mediated by both Angi and Ang2. We have recently suggested that the ability ofthe
MAPKK inhibitor (PD98059) to completely block VEGF-A165-mediated endothelial
PAF synthesis resides in its ability to prevent PLA2 activation 274rn Based on our data,
it appears that this inhibitor elicits a similar response with respect to angiopoietin
mediated PAF synthesis in BAEC since pretreatment with this inhibitor substantially
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reduced PAF synthesis. Since p3$ MAPK has been shown to directly activate lyso
PAF AT 2$1 an enzyme essential for PAF synthesis, it is flot surprising to observe
that p38 MAPK inhibition almost completely abrogated angiopoietin-mediated PAF
synthesis. The observation that the PI3K/Akt pathway regulates angiopoietin
mediated PAF synthesis in a positive mariner is in stark contrast to what we have
previously reported with respect to VEGF-A165-mediated PAF synthesis 274rn Future
studies will be required to delineate how the activation of PI3KJAkt pathway
modulates downstream effectors involved in both VEGF- and angiopoietin-mediated
PAF synthesis.
The phospholipase A2 family lias been implicated in a number of cellular responses
and several isoforms of cytosolic (cPLA2), calcium-independent (iPLA2) and
secreted (sPLA2) have been identified (282 for review). As mentioned above, the
remodelling pathway of EC PAF synthesis requires the contribution of a PLA2 to
convert membrane phospholipids into lyso-PAF. Having demonstrated that the
angiopoietins activate three intracellular signalling pathways known to participate in
EC PAF synthesis, the next step was to determine which PLA2 was implicated in
angiopoietin-mediated PAF synthesis. Cytosolic PLA2 is expressed in most celi
types and p42144 and p38 MAPKs have been implicated in its activation 226,283,284
The iPLA2s are the most recently identified members of the PLA2 superfamily and
share the size, intracellular localization, and catalytic mechanisms with cPLA2 282 It
is apparent that angiopoietin-mediated PAF synthesis is not dependent on cPLA2 and
iPLA2 as pretreatment with a specific cPLA2 and iPLA2 inhibitor, AACOCF3 did not
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prevent but even slightly increased EC PAF synthesis by both Angi and Ang2 at 4
hours. We have previously reported that sPLA2-V is implicated in VEGF-A165-
mediated EC PAF synthesis 230 and thus opted to target this particular sPLA2 isoforrn.
Using pharmacological inhibitors, we demonstrated that pretreatment of BAEC with
a non-specific sPLA, inhibitor, scalaradial, blocked angiopoietin-mediated PAF
synthesis by approximately 50%. In addition, LY3 11727 at a concentration of 1 O
M, known to specifically block sPLA2-IIA and -v activity, similarly inhibited
angiopoietin-mediated PAF synthesis. Since sPLA2-IIA is flot expressed in BAEC
230 this suggests the essential contribution of sPLA2-V in angiopoietin-mediated PAF
synthesis. Therefore, it is interesting to note that although angiopoietins have a
different PAF synthesis profile than VEGF-A165, both require the same
phospholipase, thereby bestowing a critical role upon sPLA2-V in EC PAF synthesis.
The peak in angiopoietin-mediated PAF synthesis could be representative of a
“delayed” PAF production (197 for review) and hence require newly synthesized
proteins for ceil activation. Since BAEC stimulation with VEGF-A165 induces PAF
synthesis and that EC express VEGf 285-28$ we sought to investigate whether VEGF
was implicated in angiopoietin-mediated PAF synthesis. First, we did flot detect an
upregulation of VEGF mRNA by RT-PCR analysis when BAEC were stimulated
with Angi or Ang2 (data flot shown) nor did we see significant fluctuations in the
quantity of endogenous VEGF by ELISA. We also observed that no or marginal
amounts of VEGF were released into the supematant. However, when BAEC were
pretreated with VEGF receptor inhibitors prior to stimulation with Angi or Ang2,
14$
angiopoietin-mediated EC PAF synthesis was inhibited by approximately 50%. We
then postulated that endogenous VEGF was being shuffled from the intracellular
compartment to the endothelia! ce!! surface membrane to interact with its ce!! surface
membrane receptors and contribute to angiopoietin-induced PAF synthesis. This
hypothesis was confirmed by confocal microscopy whereby we observed the
presence of a significant amount of endogenous VEGF at the ce!! surface within 7.5
minutes of stimulation with Angi and to a lesser extent with Ang2. The reduced
response observed with Ang2 may be re!ated to its !ess intense activation of Tie2 and
may also explain why Ang2 is !ess potent at mediating PAF synthesis than Angi.
Figure 12 represents a summary of the purported intrace!!ular signa!!ing pathways
imp!icated in angiopoietin-mediated PAF synthesis.
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4.3 Angiopoietin-induced P-selectin transiocation in BAEC is calcium-dependent
We have reported that VEGF-A165 induces P-selectin transiocation through
endogenous PAF synthesis in HUVEC 65 We have also recently observed that both
Angl and Ang2 can promote P-selectin transiocation in absence of PAF synthesis in
HUVEC 149 However, in this study, we observed that Angi and Ang2 as VEGF
A165 can mediate PAF synthesis in BAEC. We therefore sought to dissect the
signalling pathways implicated in angiopoietin-mediated P-selectin translocation and
detennine the contribution of endogenous PAF in BAEC using VEGF-Al65 as a
positive control. Herein, we report that both angiopoietins mediate a rapid and
transient endothelial P-selectin transiocation in BAEC as demonstrated by ceil
surface ELISA and confocal microscopy. Our observations are consistent with
reports indicating that endothelial P-selectin is translocated from Weibel-Palade
bodies (WPB) upon stimulation with various inflammatory mediators as rapidly as 2
minutes afier stimulation with a peak attained within 10 minutes 25 1,252 whereupon P
selectin enzymatic cleavage or endocytosis and is recycled back into WPB 248
In the current study, we demonstrate that angiopoietin-mediated endothelial P
selectin translocation requires PLC and PKC activation. Indeed, treatment of BAEC
with selective inhibitors of PLC-y (U73 122) or PKC (Caiphostin C) prior to
stimulation with Angl or Ang2 reduced P-selectin transiocation. Similarly, VEGF
A165-mediated P-selectin translocation is also dependent on the activation of PLC-’y
and PKC. PLC-y is an important regulator of calcium signalling and PKC,
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immediately downstream and is implicated in p42/44 MAPK activation which in tum
regulates endothelial PAF synthesis. Taken together, these observations prompted us
to investigate calcium signalling and intracellular signalling pathways leading to
endothelial PAF synthesis.
Since we and others have reported that Angi and Ang2, upon binding to Tie2, have
been shown to activate p42144 MAPK, p38 MAPK, and PI3K intracellular signalling
pathways 127,146,162,164,166,278 leading to a rapid and sustained synthesis of PAF in
BAEC as reported above, we wished to determine whether these pathways and PAF
were implicated in angiopoietin-mediated P-selectin transiocation. In the current
study, we demonstrated that the aforementioned pathways are not implicated in
angiopoietin-mediated endothelial P-selectin transiocation and neither is endothelial
PAF. On the other hand. VEGF-A165-mediated transiocation requires the activation
of p38 MAPK and p42144 MAPK, both capable of mediating endothelial PAF
synthesis and PI3K which, although activated, has been shown not to increase PAF
synthesis 274 When we pretreated BAEC with selective PAF receptor antagonists
prior to stimulation with VEGF-A165, we observed a reduction in P-selectin
translocation, although not as pronounced as what we had previously reported in
HUVEC 65 Taken together, our data demonstrates that the angiopoietins and VEGF
A165, two different classes of tyrosine kinase receptor ligands, induce endothelial P
selectin transiocation in BAEC through different mechanisms. Furthermore, the
contribution of endothelial PAF to VEGF-A165-mediated P-selectin translocation may
account for the ability of VEGF-A165 to induce greater levels of P-selectin
translocation than Angi or Ang2.
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The translocation of P-selectin and constituents of WPB requires the movement of
the WPB from the cytoplasm to the celi membrane and the fusion of these vesicles
with the plasma membrane. Increased levels of cytosolic free Ca2 concentration
([Ca2J) levels have been implicated in the mechanism ofexocytosis for a number of
agonists including thrombin and histamine 289 The cellular responses to increased
[Ca2] are most likely mediated through calmodulin and smali GTP-binding proteins
290-292 In our current study, treatment of BAEC with an intra- and extracellular
calcium chelator (BAPTA-AM) or a calmodulin inhibitor (W-7) prior to stimulation
with Angi or Ang2 compietely abrogated P-selectin translocation. Furthermore, P
selectin transiocation was absent in celis treated with Angi or Ang2 in calcium-free
DPBS. Together, these data confirm the importance of Ca2 in P-selectin
transiocation mediated by angiopoietins. It has been established that elevation of
Ca2 over basal levels (iO M) is required for regulated exocytosis 293,294 and that this
elevation may be due to influx of calcium across the plasma membrane 295 from
internai stores, or both 296,297 The endoplasmic reticulum tER) is the best
characterized Ca2 store in mammalian ceils 298 and release of Ca2 from the ER can
be triggered by activation of inositol triphosphate (1P3) 299 which can also modulate
calcium release from the Golgi complex °°. In our current study we show that PLC
y, which can act on PIP2 to produce 1P3 and hence trigger Ca2 release from
intracellular stores, regulates angiopoietin-mediated endothelial P-seiectin. Once
released, calcium may form a complex with caimodulin. This complex has been
shown to interact with a small GTP-binding protein, Rai, in a calcium-dependent
153
manner and play an important foie fl regulating WPB exocytosis in EC 289 In fact,
we observed that chelation of intra- and extracellular calcium completely abrogated
endotheiiai P-selectin transiocation. furthermore, we observed that the release of
Ca2 from intracellular pools was insufficient to support endotheliai P-selectin
transiocation in an extracellular Ca2-free environment. Using another approach,
namely inhibiting the formation of the Ca2/calmoduiin complex with W-7 and this,
regardless of intra- or extracellular leveis of calcium, reduces transiocation to levels
below control values confirming the importance of calcium in P-seiectin
translocation. Similarly, calcium also contributes to mediate VEGf-A165-induced
endothelial P-seiectin translocation. Taken together, these observations demonstrate
the critical roie of calcium in VEGF-A165 and angiopoietin-mediated endothelial P
selectin translocation. In figure 13, a summary of the signaiiing pathways reguiating
both VEGf-A165 and angiopoietin-mediated P-selectin translocation in BAEC is
presented.
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4.4 Angiopoietins are intlammatory mediators
Based on our current observations as well as what we have reported in previous
studies, it appears that under specific conditions, both Angi and Ang2 are capable of
mediating proinflammatory events. We have recently reported that the angiopoietins
are capable of promoting endothelial P-selectin transiocation and the adhesion of
neutrophils onto activated human umbilical vein endothelial celis (HUVEC) as well
as activating Tie2 receptors on neutrophils leading to PAF synthesis promoting a
rapid upregulation of the 2-integrin complex (CD 11 lCD 1$) and contributing to an
increase in neutrophil adhesion onto activated EC thereby demonstrating that the
angiopoietins should be considered as acute proinflammatory mediators 149 Recent
studies reported that Angi possesses anti-inflammatory properties. for instance,
under in vivo conditions, Angi has been shown to prevent VEGf-mediated vascular
permeability 301 and in vitro it reduces the basal activation of vascular endothelial
cadherin (VE-cadherin) and t3-catenin, components of intercellular junctions 189
concomitantly with a reduction of VEGf-mediated endothelial ce!! permeability
185,186 Interestingly, the above studies utilized HUVEC and it is therefore possible
that the anti-inflammatory effects attributed to Angi under in vitro conditions stem
from the inability of angiopoietins to promote PAF synthesis in this endothelial
subtype. In addition, Angi mediated a reduction of VEGf-induced leukocyte
adhesion onto HUVEC and E-selectin expression 148 and thrombin-mediated
neutrophil adhesion onto EC 185 Upon initial review, these resuits may appear
contradictory to what we report herein as well as what we have previously
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demonstrated 149 but both of the above studies 148,185 were performed for extended
periods oftime that are well in excess ofthe timeframe ofP-selectin activity.
One would expect Ang2 to readily induce PAF synthesis if one considers its ability to
disrupt vessel integrity. Surprisingly, until recently, the role ofAng2 in inflammation
was unknown. In addition to our recent demonstration that Ang2 (as well as Angi)
promotes neutrophil PAF synthesis, endothelial P-selectin transiocation, and
neutrophil adhesion onto EC 149 Ang2 has been shown to promote vascular leakage
in vivo without displaying the full features of a true proinflammatory mediator since
it only weakly promoted leukocyte migration 150 The authors of the aforementioned
study observed that administration of Angi did flot inhibit VEGF-induced vascular
permeability. Citing our work 149 Roviezzo et 150 postulate that the presence of
other inflammatory celis expressing Tie2 within the airpouch environment modified
the response to Ang 1 and thus Mgi activation of neutrophil Tie2 receptors increases
their adherence and release of PAF. Furthermore, Ang2 has been shown to be stored
exclusive of P-selectin and rapidly released from WPB upon stimulation with PMA
and calcium ionophores but flot with VEGF or Mgi 152• This ability to be rapidly
released upon stimulation suggests that Ang2 is an important component of rapid
vascular responses such as inflammation. Taken together, these observations
demonstrate that the angiopoietins should be considered as acute proinflammatory
mediators.
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4.5 Perspectives
In light of our observations with respect to the potential proinflammatory properties
of Ang 1, one may be prompted to conclude that our observations are partly due to
our experimental model. Indeed, as mentioned above, previous studies have reported
on the anti-inflammatory nature ofAngl using other cell types (HUVEC) 148,185,186,189
or its vessel-stabilizing nature in animal models 123,137,301-303 Our data suggests tissue
specificity with respect to the proinflammatory abilities of Angi since we have
demonstrated that Angl can induce P-selectin translocation but not PAF synthesis in
another ceil type, namely HUVEC 149 The ability of BAEC to produce greater
amounts of PAF than HUVEC has been documented by our laboratory 230 and
prompted us to select this experimental model. Thus, to better define the role of
Angi in endogenous PAF synthesis, in vivo studies should be performed.
In order to verify our in vitro data, models of localized inflammation could be
utilized. One potential approach is the murine air pouch 150,304 where sterilized air is
injected subcutaneously into the back ofthe animal six (6) and three (3) days prior to
the injection ofthe desired substance into the air pouch. Angi, for example, could be
injected into the air pouch for various time periods, the pouch exudates collected and
screened for the presence of various inflammatory mediators. Due to its rapid
degradation, endothelial PAF could not be directly measured and thus its role could
be delineated by the use of PAF receptor antagonists. An increase in vascular
permeability brought upon by an increase in endothelial PAF synthesis could be
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observed by quantifying Evans blue exudation into surrounding tissue. In addition,
specific pathway inhibitors and Tie2 blocking antibodies could, for example, be
injected into the air pouch to delineate the signalling pathways implicated. Similarly,
the mouse paw edema model 150 may prove to be an attractive model with which to
determine the role of Angi in endogenous PAF synthesis in vivo. In this model,
animais receive subpiantar administrations of various agents and paw volume is
determined using a hydroplethysmometer modified for small volumes 150 PAF
synthesis would be observed through an increase in limb volume due to local edema
brought upon by an increase in vascular permeability. In addition to using
pharmacological antagonists and inhibitors, our laboratory has access to PAF-R and
sPLA2-V nuli mice which could in tum be utilized to determine the effect ofAngi on
endogenous PAF synthesis.
Recent sttidies have reported on the proinflammatory role of Ang2 in vivo 150,305,306
and these observations, at first glance, seem to be in une with our in vitro work. Ail
of the animal studies proposed above to investigate the role of Angi in endogenous
PAF synthesis should be performed with Ang2 as well.
The ability to measure endothelial P-selectin transiocation in vivo proposes to be
technically challenging. Initially, a flow chamber apparatus could be used to assess
the ability to label endothelial P-selectin in a dynamic (non-static) environment. In
an intact animal, however, two-photon microscopy, because of its resolving power,
may allow the observation of P-selectin translocation in vivo. In such an experiment,
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an artery (ie. carotid) could be isolated from surrounding anatomical structures in an
anaesthetized animal. A P-selectin antibody coupled to a chromophore could then be
injected upstream of the area of interest to allow it to bind to EC lining the artery.
Promoters of P-selectin transiocation such as PMA, thrombin, and angiopoietins
could then be injected into the animal.
Another potential study would entail the determination of the role of Tiel in
endogenous PAF synthesis and endothelial P-selectin transiocation. There is some
evidence that under certain circumstances, Tiel forms a complex with Tie2 132,133 and
in addition, Tiel may also signal through PI3K!Akt However, littie is known
about the ability of Tiel to modulate Tie2 activity. On another scale, ex vivo
experiments could also be conducted in an organ bath using isolated vessels to
explore the role of angiopoietins in modulating acute inflammatory responses.
Our data demonstrate in vitro the ability of angiopoietins to behave as
proinflammatory mediators. However, the inftammatory response is a complex
process and a better understanding is complemented through in vivo studies. Our
work has delineated the intracellular signalling pathways implicated in angiopoietin
mediated endothelial PAF synthesis and P-selectin transiocation but animal studies
are necessary to validate these observations.
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5.0 Conclusion
In light ofthe objectives ofthis study, we can conclude the following:
(1) Our study demonstrates for the first time that Angi and Ang2 are both capable of
inducing endothelial PAF synthesis and this in a temporal resolution different
than the rapid and transient PAF synthesis induced by VEGF-A165.
(2) Angiopoietin-mediated endothelial PAF synthesis requires the activation of the
p38 MAPK, p42144 MAPK, and PI3KIAkt intracellular signalling pathways as
well as the induction of sPLA2-V. In addition, it is partly regulated by a
redistribution of endogenous VEGF to the celi surface membrane which may
subsequently potentiate endothelial PAF synthesis.
(3) Angi and Ang2 induce a rapid and transient transiocation of P-selectin dependent
on calcium and modulated through PLC-y activation. In addition, contrary to
what we have observed with respect to VEGF-A165, angiopoietin-mediated P
selectin transiocation does not require the synthesis ofendogenous PAF.
Taken together, our resuits demonstrate that the angiopoietins, like VEGF-A165,
constitute a second family of angiogenic growth factors capable of promoting
proinflammatory events, namely endothelial PAF synthesis and P-selectin
transiocation. This study allowed us to gain a better understanding of the
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intracellular mechanisms mediating angiopoietin-induced endothelial PAF synthesis
and P-selectin transiocation. By identifying and delineating the intracellular
mechanisms goveming endothelial PAF synthesis and P-selectin transiocation
mediated by angiopoietins in vitro, we establish a platform for future studies and
development of novel anti-inflammatory and/or antiangiogenic therapies.
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Angiopoietins-1 and -2 are both capable of mediating endothelial PAF
synthesis: Intracellular signalling pathways
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Vascular endothelial growth factor (VEGF) is the only angiogenic growth factor capable of inducing an inflammatoiy response and we have
recently demonstrated that ils inflammatory effect is mediated by the endothelial synthesis ofplatetet-activating factor (PAF) Recently discovered,
Angi and Ang2, upon binding te Tie2 receptor, modulate vascular permeability and integdty. contributing to angiogenesis. Angi was initially
identified as a Tie2 agonist whereas Ang2 can behave as a context-dependent Tie2 agonist or antagonist. We sought te determine ifAng I and/or Ang2
could modulate PAF synthesis in bovine aortic endothelial ceils (BAEC) and if sa, through which intracellular signalling pathways. Kerein, we report
that Arigi and Ang2 (1 nM) are bath capable ofmediating a rapid Tie2 phosphoiylation and a mpid, progressive and sustained endotheliat PAF
synthesis maximal within 4 h (1695% and 851% increase, respectively). Angiopoietin-mediated endothelial PAF synthesis requires the activation of
the p38 and p42144 MAPKs, PI3K intracellular signalling pathways, and a secreted phospholipase A2 (sPLA2-V). Furthennore, angiopoietin
mediated PAF synthesis is partly driven by a relocalization ofendogenous VEGF to the ceil surface membrane. Our resu]ts demonstrate that the
angiopoietins constimte anotherclass ofangiogenic factors capable ofmediating PAF synthesis which may contribute ta proinflammatory activities.
Crown Copyright © 2006 PuNished by Elsevier Inc. Alt rights reserved.
Kevwords: Angiopoietins; Tie2 receptor Platelet-activating factor; Inflammation
1. Introduction
Angiogenesis plays a critical rote in several pathological
conditions, namely atherosclerosis, proliferative retinopathies,
and tumor growth [1]. Previous studies established the
contribution of vascular endothelial growth factor (VEGF
A165) and the ceil signalling mechanisms by which it leads to
angiogenesis [1]. Namely, it has been reported that inflammation
precedes and accompanies pathological angiogenesis as
evidenced by increased vascutar permeability, monocyte!
macrophage and neutrophil recruitment at angiogenic sites [2].
During inflamrnatory processes, newty formed vessets supply
inflamed tissue with oxygen and nutrients as well as facilitate the
transport of inflamrnatoly celis. Recently, we have shown that
* Corresponding author. Montreal Heart Institute 5000 Belangcr Street
Montreal, QC, Canada, HIT 1C8. Tel.: +1 514 3763330x3583; tàx: + 514
3761355,
E-mail aclchess: (MG. Sirois).
VEGF-A165 increases vascular permeability through the syn
thesis of a potent inflamrnatoiy mediator, platelet-activating
factor (PAF) by endothelial ceils (EC) [3]. VEGF-mediated
endothelial PAF synthesis occurs via a rernodeling pathway in
which membrane phospholipids are converted by a phospholi
pase A2 (sPLA2-V) into lysa-PAF which is in tttm acetylated into
PAF by acetylCoA:Iyso-PAf acetyltransferase (lyso-PAF AT)
[4]. Ftirthermore, we have recently demonstrated that in bovine
aortic endothelial ceits (BAEC), VEGf-A1,5 activation of bath
p38 and p42144 rnitogen-activated protein kinases (MAPK) are
crucial ta VEGF-rnediated endothelial PAF synthesis whereas
phosphatidyl inositol-3-phosphate kinase (Pt3K) activation is
net required [5]. Moreover, newly synthesized PAF is essentiat
for VEGf-A165-mediated endothelial P-selectin transiocation
and neutrophit adhesion onto activated EC [3,6.7], essential
events in the induction ofacute inflamrnatory processes.
Recently, a new class of angiogenic factors, angiopoietins
(Angi and Ang2), was detined as ligands for the tyrosine kinase
receptor Tie2 [8,9] to which they bind with simitar specificity and
affinity [8,91. Angt bas been characterized as a Tie2 agonist,
ELSEWER
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synthesis ami ]2-integrin functional upregulation thereby pro
moting the acute recruitment of leukocytes and conferring a
proinflamrnatory capacity to angiopoietïns [13].
Based on our previous observations with regards to VEGf
A165 and on the potential capacity ofangiopoietins at regulatïng
vascular integrity, we sought to investigate whether Angi and/
or Ang2 modulate endothelial PAF synthesis and if so, to define
the intracellular signalling pathways.
2. Material and methods
2.1. CeIl culture
Bovine aortic endothelial cclls (BAEC) were isolated from freshly harvestcd
aortas. cukured in Dulbecco’s modified Eagle’s medium (DMEM: lnvitrogcn,
Pickedng ON) containing 5% fetal bovine sewm (FBS; Medicom Inc.,
Montreal, QC) and antibiotics (Sigma, St. Louis, MO). BAEC wcrc
chamcterized as previously descdbed and uscd bctween passages 3 and 7 [3.14].
2.2. 1stern bÏot analvsis of 7ïe2 and VEGFR-2 phosphoiylation
Confluent BAEC were semm-stawed in DMEM with antibiotics ovemight,
rinsed with Hank’s balanced sali solution (HBSS; Life Technologies, Burlington,
ON), then stimulated in s solution ofHBSSIHEPES (10 mM, pH 7.4), bovine
serum alburnin(BSA; I mg/mL; Sigma). and CaCI2(10 mM). Ceils were placcd
on tee for 30 min then stimulated with Dulbeeeo’s phosphate-buffered saline
(PBS), Ang I, or Ang2 (I nM; R&D Systems, Minneapolis, MN) at 37 C for up
b 2 h. In another set of experiments, BAEC were pretreated with selective
inhibitors of VEGFR-l and VEGfR-2 (VTK; 10 0M; 1C55’2.0 and 0.1 tM
respeetively) [15,16]. or VEGFR-2 (SUI498; 5 iM; 1C55=0.7 i.tM) [7.16,17]
(Calbiochem, La JolIs, CA), 15 min pdor to stimulation with AngI or Ang2
(I nM). In a third set ofexperimenis, we assessed the capaeity ofangiopoietins
(AngI and Ang2) to tmnsaetivate VEGFR-2 in fonction of time. Cells were
solubilized with lysis buffer. seraped, and pratein concentration determined hy
Bradford assay. CelI lysates were immunopnicipitated with rabbit polyclonal
anti-mouse Tie2 lgG or with anti-mouse VCGFR-2 1gO (Santa Cruz
Bintechnology. Santa Cruz. CA) and separated by SDS—PAGE. Proteins were
tmnsferred onto a polyvinylidene difluoride (PVCW) membrane and probed with
mouse monoclonal anti-phosphotyrosine 1gO (clone 4Glt), 1:1000 dilution;
Upstate Biotechnoloev Inc., Cake Placid, NY). Membranes were stripped using
Re-BIot Plus Strong stripping solution (Chemicon International. Temecula, CA)
and reprobed with rabbit polyclonal anti-mouse Tie2 IgG or VEGFR-2 1gO
(1:1000 dilution; Santa Cruz Biotechnology). Banda were visualized using
CurniGloiM (New England Biolabs. Pickering. ON). The density of the bands
tvas detetmined using Quantity One software (Bio-Rad, Mississauga. ON) [7j.
2.3. Western bio: analysis of p32. p42/44, and Ahi activation bv
angiopoietins
Confluent BAEC weœ semrn-starved ovemight. tinsed, and stimulated with
Angi or Ang2 (I nM) for various time dotations. In another series ofexperiments,
BAEC were pretreated with either a p36 MAPK inhibitor (SB203580. 10 tsM).
MAPK kinase (MAPKK) inhibitor (PD98059, 10 tM). or inhibitors ofihe PI3KI
Akt pathway (1X294002, 5 tM: Worflnannin, 500 nM) (Calbiochem) prior to
stimulation with AngI or Ang2 t I nM). As positive contml, BAEC were treated
with VEGF-A165 (I nM; PepmTech Inc.. Roeky Hill, Ni) for 7.5 min afler
pretreatruent with the afoternentioned pathway inhibitors. Cdl lysates were
separated by SDS—PAGE and proteins nanstèrred onto a PVDf membrane.
Activation of p38, p42/44 and Akt was determined by prubing membranes with
antibodies for their respective phosphrnylated fonris (1:1000 dilution; New
England Biolabs). Membranes were subsequently stripped and repmbed to
visualize corresponding total protein expression.
2.4. Measurement ofR4F synthestr
Confluent BAEC were rinscd, then stimulated in HBSS/HEPES containing
CaCI, (10 mM) and [3H]-acetate (25 itCi) (New England Nuclear, Boston. MA)
with angiopoietins (Ang I or Ang2; 0.lto 10 nM) or VEGF-A165 f1 nM) for 7.5 10
360 min. In another serics of experiments, BAEC verv pretreated with VTK
(10 tiM), SU1498 (5 0M), SB203580 (10 0M), PD98059 (10 .tM), CY294002
(5 )IM) or Wornnannin (500 nM) prior tu stimulation with Ang I, Ang2, or VEGF
A165. BAEC werc also pretrcated with either s selective ePCA2 and iPCA2 inhibitor
(AACOCF3; 10 15M; Calbiochem). s non-specific sPCA2 inhihitor (scalaradial.
10 0M; Calbiochem), ora selectivc sPCA2-V inhibitor (CY3 11727; 100 jiM; kindly
provided by Dr. Jerome Fleisch, CiIIy Research Caborntodcs, Indianapolis, IN) for
15 min prior to stimulation with Angl or Ang2 f I nM) tbr 240 min or VEGF-A155
for 15 min. The reactiun was haltcd by addition of acidifled methanol, polar lipids
isolated. cvaporated under N gas, and pudfled hy HPCC as desedbed pœvioualv
[3 5j. Fractions conesponding tu [3H]-PAF were quanfified with s )‘-eounter. The
authenticity of synthesized PAF waconflrmed by an idenfical elution panera tu
standard [3H]-PAF (Jew England NucIear [3.14].
2.5. VEGf ELISA
VEGF protein in BAEC supernatant and whole ccli extract was quantifled
using a commercial ECISA kit (PeproTech Inc.). Confluent ceils grown in 6-well
plates were serum-starved overnight in DMEM containing antibioties ptior tu
stimulation with AngI or Ang2 (I nMl in HBSS HEPES eontaining CaCI2
(10 mM) for various time periuds. Upon stimttlation, ccli supematant vas
collected. the cells scraped, and gently sonicated in PBS (pH 7.4) in ice. The
ELISA protoeol was canied out according tu the manufacturer’s instructions.
2.6. Conjbcat microscopv: insage acquisition, deconvolution and
image rendering
BAEC were grown tu confluence on glass coverslips coated with I .5%
gelatin, serurn-stawed uvemight. dnsed, and incubated with rabbit polyclonal
anti-human VEGF 1gO (1:100 dilution; Santa Crus Biotechnolugy) in the
prcsence of AngI or Ang2 (1 nM: 7.5 10 240 mm) in semm-free DMEM.
Following stimulation, the eells s’.’ere rinsed and flxed with a 1% paraformal
dehyde-PBS solution for 20 min. Nonspecific hinding ufprimaiy antihodies was
prevented by preincubating Iive BAEC with 4% serum from the speeies used to
taise the secondars’ antihodies. CeIls wcre nnsed and ineuhated with dunkey anti
rahbit Alexa 555 conjugated IgG (1:400 dilution; Molecular Probes, Eugene.
OR) for 90 min. Glass coverslips were mounted using 1.4-diazabicyclo-2-2-
2nctane (DABCO/glycerol (1:1) solution. BAEC were obsem’ed un a Zeiss
Axioven 10(1 M microscope equipped with s 63X/1 .4 Plan-Apoehroniat uil
objective lens (Zeiss, Oberkochen. Gerniany) adapted with an CSM 51 t) confucal
system and saved as CSM files. Donkey anti-rabbit conjugated tu Alexa 555 lgG
vas visualized using a 543 nm Helium—Neon laser. Vuxel sise s
143 X 143 X 160 nm (ÀÇ ) Z). Z stacks were deconvolved with the Huygens Pro
2.6.5a (Scietilific Volume imaging. SVI, Alcxanderlaan, The Netherlands) using
the Maxitiaum Cikelihood Estitisation (MCL) algorithm. Signal-to-noise ratios
were quantified for each Z stacks and added to the MCL algorithm. Point spread
fonction (PSf) vas derived from Z stacks of 15 fluorescent (540—560 nm) beads
of 170 nm in diameter (Invitrogen). PSF was acquired the sanie way as the images
of interest. Deconvolutions were applied until reaching 0.01% quality change
threshold fQCT) beaveen iterations. Deconvoived Zstacks were saved in Tiff file
format series. Transparent projections were produced using the projection tuol of
having the capacity to stabilize and prornote the maturation of
unstable vessels in the presence ofVEGF-A165 [10]. On the other
hand, Ang2 was initialÏy desctibed as a natural endogenous Tie2
antagonist, thereby destabilizing existing vessels prior to VEGF
A165-induced angiogenic sprouting [9]. However, recent findings
have shown that Ang2 may, under certain circumstances, induce
Tie2 phosphorylation and biologïcal activities such as EC
migration, and in vitro tubule capillary-like formation [11,12].
in addition, we recently demonstrated that both angiopoietins can
prornote endothelial P-selectin transiocation, directly activate
neutrophils through Tie2 signalling as well as modulate PAF
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A) IP: @Tïe2 140 kDa
WB: @p-Tyr
WB:@Tie2
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PBS + - - - -
AngI (1 nM) - + + + + + +
B) W: @T1e2 140 kDa
tVB @p.Tyr j
W& @Tie2 i.-afrL $fL -t
Time (mm) 7.5 7.5 15 30 60 90 120
P85 + . - - -
Ang2 (1 niI) - + + + + + +
fig. 1. Activation and expression ofTie2 in BAEC. Confluent BAEC were neated
with AngI (A), or Ang2 (B) for up to 2 h. Cell lysates were prepared and
irnmunoprecipitated (IP) with mbbit polyclonal anti-mouse Tie2 lgG from 500 pg
of lysate. following resolution by SDS PAGE and trnnsfcr, PVDF membranes
were probed with mouse monoclonal antiphosphotyrosine lgG and immunoreac
tive bands were visualized by chemilurninescence. Membranes were subsequently
strippcd using RcBlot Plus Strong stripping solution and Tic2 pratein expression
vas dctcmincd following incubation with mbbit polyclonal anti-mouse Tie2 IgG.
IP designates immunoprecipitation and WB represents Western blot.
the LSM 510 software. VEGF levels at the cdl surface membrane were assessed
by quantif3ring Oie summation of voxel intensity of the deconvolved Z stacks
volume using the Huygens Pro 2.6.5a software. The relative intensity (RI) of
VEGF at the cdl surface membrane vas set at 1 for the PBS-control treated cells.
2. 7. Statistical analvsis
Data are mean+SEM. Comparisons were made hy analysis of variance
followed by a Bonfenoni t-test. Data were considered significantly different if
values ofp<0.05 were observed.
3. Results
3.1. Activation of Tie2 receptor by angiopoietins
We first assessed the capacity of both angiopoietins (Ang t
and Ang2) to modulate Tie2 phosphorylation in function of
time. Treatrnent of confluent BAEC with AngI (1 nM) induced
a rapid and transient phosphotylation of Tie2, which was
maximal within 15 mm, and corresponding to a 21 -fold increase
over PBS-treated ceils (fig. tA). Treatment with Ang2 (1 nM)
also induced a rapid and transient activation of Tie2 leading to
an 8-fold increase in phosphorylation within 7.5 min (Fig. I B).
3.2. Activation of p38 MAPK, p42/44 MAPK, and Akt bv
angiopoietins
Previous studies reported that Angi is capable of activating
p38 and p42144 MAPKs [181 as weIl as the PI3KIAkt signal
transduction pathways [19]. Prior to our study, littie was known
with regards to potential intracellular events following the
activation ofTie2 by Ang2. Hereïn, we demonstrate that Ang2,
like Angi, can activate p42144 and p38 MAPK as well as PI3K
in a time-dependent manner (Fig. 2). In our study, stimulation of
BAEC with Angl (1 nM) activates p42!44 MAPK and Akt in a
time-dependent manner (Fig. 2A and E) with maximal effects at
7.5 min maintained through 30 min of stimulation. Treatment
with Angi induces a rapid and transient activation ofp38 MAPK
with a maximal phosphotylation at 7.5 min (Fig. 2C). Similarly.
Ang2 (1 nM) activates ail three pathways but with slight
variations in its kinetics. Firstly, maximal activation of p42744
MAPK occurs within 10 min of stimulation (Fig. 23) but as with
Angi, this activation is maintained 30 min post-stimulation.
Secondly, activation ofPI3KJAkt by Ang2 is delayed compared
to Angi and not sustained (20 min versus 7.5 mm; Fig. 2F).
Ang2 activation of p38 MAPK produces a pattem similar to
what was observed with Angi (fig. 2D). As a positive control,
BAEC were also stirnulated with VEGF-A165 (1 nM; 7.5 mm).
3.3. Regulation ofFAF synthesis kv Ang] and Ang2
We previously reported that VEGf-A165 induces a rapid and
transient (within 15 mm) endothelial PAF synthesis [3.14].
Therefore, we assessed the capacity of angiopoietins to mediate
endothelial PAF synthesis. The induction of PAF synthesis by the
angiopoietins was very rapid (significant increase within 7.5 mm).
maximal at 4 h and sustained for at least 6 h post-treatment
(Fig. 3A—B). Angiopoietin-mediated endothelial PAF synthesis is
characterized by a biphasic response profile. An initial rapid and
modemte synthesis is observed from 7.5 to 30 min followed by a
“burst” phase culminating at 4 h. The peak values of PAF
synthesis mediated by Angi and Ang2 correspond to a 1695%
and 851% increase, respectively, cornpared to PBS-treated celis.
Basal levels of PAF synthesis in PBS-treated ceils did flot change
significantly throughout the time course ofthe experiments (data
not shown). In addition, VEGF-A165 (I nM)was used as positive
control and induced maximal PAF synthesis within 15 min (78 8%
increase over PBS values) and was degmded within 30 mm, as
previously described [3,14]. We also assessed the potential of
Angi and Ang2 to mediate endothelial PAF synthesis in a
concentmtion-dependent manner. Cells were treated with Ang I or
Ang2 (0.1 to 1 nM) at an intermediate time period (2h) to ensure
that we were not reaching a saturation plateau of PAF synthesis.
PAF synthesis rnediated by Angi at 0.1 nM was almost as potent
as at I nM whereas Ang2 at 0.1 nM did not significantly increase
PAF synthesis but at I nM, Ang2 had an equivalent agonistic
activity, compared to Angl at mediating endothelial PAF
synthesis after 2 h (Fig. 3C). Interestingly, at a higher
concentration (10 nM), both AngI and Ang2 almost completely
lost (86% and 75°/, respectively) their capacity ofmediating PAF
synthesis in comparison to 1 nM (Fig. 3C).
3.4. Role ofendogenous VEGF in angiopoietin-mediateci PAF
synthesis
Since the stimulation ofBAEC with VEGF-A165 induces PAF
synthesis and that EC express VEGF [20--23], we hypothesized
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fig. 2. Angi and Ang2 activate p38 MAPK, p42144 MAPK, and PI3K pathways. Confluent BAEC were stimulated with Angi, or Ang2 (1 nM) for up to 30 min.
BAEC were also stimuiated with VEGF-A1 for 7.5 min as positive control. Ccli lysates equivaient to 100 pg total proteins were loaded in each lanc. Signailing
pathway activation was detcrmined by probing PVDF membranes with antibodies for the phosphoiyiated form of p42/44 MAPK, p38 MAPK, or Pt3KJAkt. Ang I and
Ang2 activate p42/44 MAPK (A and B, respectively), p38 MAPK (C and D, respcctively). and PI3KJAkt (E and f. respcctively). Membranes were thcn strippcd and
cdnTesponding protein expression dctermined.
that VEGF may contribute to angiopoietin-mediated endothelial
PAF synthesis. Therefore, we pretreated BAEC with inhibitors of
both VEGFR- 1 and VEGFR-2 (VTK; 10 j.tM) or VEGFR-2
(SU 1498; 5 l.LM) for 15 min pnor to stimulation with Angi or
Ang2 (1 nM) for4 h. Inhibition ofVEGfR-1 and VEGFR-2 with
VTK prompted a 51% and 43% decrease in PAF synthesis
mediated by Angl and Ang2, respectively (Fig. 4). When only
VEGFR-2 activity was inhihited, AngI and Ang2-mediated PAF
synthesis was diminished by 42% and 26%, respectively (Fig. 4).
As a positive control, the above inhihitors were added
individually prior to VEGF-A165 stimulation and completely
abrogated VEGF-A165-mediated PAF synthesis at 15 min (Fig. 4).
In addition, to assess that these inhibitors ofVEGF receptors were
flot interfering with Tie2 phosphoiylation rnediated by angio
poietins, we pretreated BAEC with VTK or SU 1498 15 min pnor
to stimulation with angiopoietins (I nM) for 7.5 min. Such
pretreatrnent with the aforementioned inhibitors did not alter
angiopoietin-mediated Tie2 phosphoiylation t data flot shown).
We then investigated whether VEGF was released from
BAEC to promote its autocnne activity on PAF synthesis. We
performed an ELISA assay and detected negligible amounts of
VEGF in the supernatant of BAEC treated with Ang 1 or Ang2
from 15 min to 6 h, whereas most endogenous VEGF was
quantifled from BAEC lysates (Fig. 5). Confocal microscopy
was then ernployed to visualize the distnbution ofVEGF within
BAEC. Labeling live ceils with prirnaty antibodies targeting
VEGF prior to stimulation allowed us to observe the relocaliza
tion of endogenous VEGF to the cell surfitce membrane. In
control PBS-treated ceils, the relative intensity (RI) of VEGF
protein detection on the ceil surface membrane was set to I
(Fig. 6A), and was slightly higher than the negative control in
which PBS-treated ceils were incubated with ïsotypic rabbit TgG
instead ofprimaiy VEGF IgG (RI = 0.9; Fig. 6B). Treatment with
AngI (1 nM) for 7.5 min resulted in a marked redistribution of
VEGF on the celI surface membrane (RJ= 10.2; Fig. 6C), which
remained noticeable up to 4 h post-stimulation (RII.97;
Fig. 6D). TreatmentofBAEC withAng2(1 nM)also induced an
actite but less intense relocalization ofendogenous VEGF within
7.5 min (RI=2.81; Fig. 6E), but was sustained up to 4 h
(RI= 3.56; Fig. 6F).
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Fig. 3. Angi and Ang2 are both capable of inducing endothelial PAF synthesis in a time and concentration-dependent manner. Confluent BAEC were stimulated with
Angi or Ang2 (I nM) for time periods ranging from 7.5 to 360 min in the presence of [H]-acetate. As positive control BAEC were treated with VEGF-A155 for
15 min. Angi (A) and Ang2 (B) mediate endothelial PAF synthesis with maximal values observed following 4 h of stimulation. Maximal angiopoietin-mediated
endothelial PAF synthesis is observed when Ang I and Ang2 are used at a concentration of I nM (C). Data are expressed as thousands (1 &) disintegrations per minute
(DPM) and represent the incorporation oftritiated acetate; [3HJ-acetate into lyso-PAF. Values are means±SEM ofat least 12 experiments. ***p<0.00l vs. PBS.
Since angiopoietins mediate VEGF relocalization to the ceil
surface membrane of endothelial ceils, and that VEGF-A165
mediates PAF synthesis through VEGFR-2 activation, we then
sought to assess whether angiopoietins can promote VEGFR-2
transactivation. We observed that a treatment with AngI or
Ang2 (1 nM) mediated a rapid and transient VEGFR-2 phos
phorylation, which was maximal within 15 and 30 min (6.3 and
9.2-fold increase), respectively (Fig. 7A and 3). Treatment with
VEGF-A165 (1 nM) for 7.5 min vas used as positive control
(Fig. 7C).
3.5. Contribution ofp38 MAPK, p42/44 MARK, ami PI3K to
angiopoietin-mediated PAF synthesis
We recently reported that endothelial VEGf-A165-mediated
PAF synthesis by BAEC involves p38 and p42144 MAPKs
activation whereas PI3K activation does not lead to PAF synthesis
[5]. Subsequently, in order to determine the intracellular pathways
by which the angiopoietins promote EC PAF synthesis, we
pretreated BAEC with selective inhibitors of the corresponding
signalling pathways. Pretreatment of BAEC with a MAPKK
inhibitor (PD98059; 10 isM), a p38 MAPK inhibitor (SB203580;
10 jsM), or two unrelated selective PI3K inhibitors (LY294002;
5 sM and Wortmannin; 500 nM) 15 min prior to treatrnent with
Ang 1 (1 nM) for 4 h, decreased EC PAF synthesis by 65%, 93%,
93%, and 100%, respectively (Fig. sA). Similarly, Ang2-
mediated EC PAF synthesis at 4 h was reduced by 73% to
100% following pretreatment with the aforementioned inhibitors
(Fig. 8A). As positive control, these inhibitors were used prior (o
VEGF-A165 stimulation and PAF synthesis was completely
blocked following pretreanTient with PD98059 and SB203580
whereas pretreatrnent with PI3K inhibitors did flot reduce PAF
synthesis (data not shown). We also performed Western blot
analyses to confirrn that the selective inhibitors at colTesponding
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4. Discussion
We have previously demonstrated the role of sPLA2-V in
VEGF-mediated EC PAF synthesis [4] and therefore sought to
determine which phospholipase A2 is implicated in angiopoie
tin-mediated EC PAF synthesis. We observed that inhibition of
cPLA2 and iPLA2 using AACOCF3 (10 1iM) failed to reduce
angiopoietin-mediated EC PAF synthesis (Fig. %B). However,
pretreatrnent with a broad-range sPLA2 inhibitor, scalaradial
(10 tM), inhibited Ang I and Ang2-mediated EC PAF synthesis
by 57% and 5 1%, respectively (Fig. %B). We also treated BAEC
with LY3 11727 (100 tM), an inhibitorofsPLA7-V 15 min prior
to stimulation with Angi or Ang2 (I nM; 4 h) and observed a
reduction of 43% and 55% in PAF synthesis, respectively
(Fig. 8B). In addition, we performed a positive control study in
which the corresponding inhibitors were added pnor to VEGF
A165 wherein we observed that EC PAF synthesis vas alrnost
totally abrogated (97% inhibition) following pretreatment with
In the present smdy, we observed that Angi and Ang2 are
both capable of mediating a rapid Tie2 phosphorylation, as weIl
as a rapid, progressive and sustained endothelial PAF synthesis.
This angiopoietin-mediated PAF synthesis, maximal at 240 min
is mediated in part by a relocalization ofendogenous VEGF to
the ceil membrane and through the activation ofthe p38 MAPK,
p42!44 MAPK. and PI3KJAkt intmcellular signalling pathways
acting on a secreted phospholipase A2 (sPLA2-V).
4.1. AngI and Ang2 botit act as Tie2 agonisîs
Our data showed that Ang I and Ang2 are both capable of
mediating a rapid and transient phosphorylation ofTie2 receptor,
which is in agreement with previous reports [8,11,12,18,24].
One of the major characteristics of our study is that Angi and
PBS Angi Ang2 PES AngI Ang2
15 min 60 min
as Angi Ang2 as Angi Ang2 PBS Angi Ang2
120 min 240 min 360 min
Fig. 5. Endothelial distribution of VEGF tipon stïinulation with angiopoietins. Confluent BAEC werc stimulated in scmrn-frce DMEM with Angl or Ang2 fi nM) for
up to 6 h. Supematants wcrc collectcd, conccntratcd and VEGF protein quantified by sandwich ELISA. Cd mcinbmncs wcrc gently scrapcd in cold PBS (pH7.4).
disnipted by sonication. and VEGF protein measurcd in the samc ELISA as the corresponding supematants. Values are mcans±SEM corresponding to threc
experiinents.
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Fig. 4. Pretreatment with VEGF receptor (VEGFR) inhibitors anenuates angiopoierin-rnediated endotheliai PA synthesis at 4 h. Confluent BAEC wcrc prctreated with
aselective VEGfR-2 inhibitor(SUi498; 5 iM)ora VEGFR-l/R-2 inhibitor(VTK; lOpM)foriS minpdorto stirnttlationwithAngl orAng2(l nM)for4h inthe
presence of[’Hl-acetate. Values are means±SEM ofat least three expedments. p<O.Ol and ***p<O.00l vs. PBS; fp<O.O5 and ttp<O.OI vs. agonist.
concentrations prevented the phosphoiylation of p42/44 MAPK,
p38 MAPK and PI3K (data flot shown).
3.6. The effect ofangiopoietins Ofl endothelial PAF s nthesis is
atte,iuated l’y sPLA2 inhibitors
both non-specific (scalaradial) and specific (LY3 11727) sPLA2-
V inhibitors whereas the inhibition of cPLA, (AACOCF,;
10 jtM) did not attenuate endothelial PAF synthesis (data flot
shown).
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Fig. 6. Treatment of BAEC with angiopoietins induces a relocalization of
endogenous VEGF to the ccli surface membrane. Subconfluent BAEC were
grown on gelatin-coated glass siides, rinsed with PBS, left untreated (A and B)
or treated with Angi or Ang2 (both I nM) for 7.5 min (C and E, respectively) or
4 h (D and F. respectively). Prior to angiopoietin stimulation, celis tt’ere
incubated with rahbit polyclonal anti-human VEGF antibody (A, C—f) or with
isotypic lgG (B) snd then fixed with 1% parafomialdehyde. The presence of
VEGf on the ccli surface membrane was observed by confocal microscopy.
Relative intensity (RI) for each image represents the summation of voxel
intensities compared to that of PBS vhich was normalized to 1. Bar represents
20 1m.
Ang2 at I nM were able to phosphoiylate Tie2 in a manner
corresponding to 21- and 8-fold increase compared to PBS
tteated celis, and at such concentration, both had their maximal
agonistic effect on PAF synthesis, increasing it by 1695% and
851%, respectively. Our resuits suggest that Ang2 might serve as
a partial Tie2 agonist on PAF synthesis, and are in agreement
with a recent study demonstrating that the potency of Ang2 to
support Tie2 activation is Iower than Ang] [25]. Interestïngly, at
a higher concentration (10 nM), Angi- and Ang2-mediated PAF
synthesis was almost completely Iost. This can be explained by
the fact that the binding ofa ligand to a receptor tyrosine kinase
(RTK) ïnduces receptor homo- or heterodimerization, which is
essential for the autophosphorylation of tvrosine residues and
the initiation ofdownstream signalling events [26]. However, an
overabundance of ligand impedes receptor dirnerization [27].
Considering that numerous studies reported the use of angio
poietins, in some cases, at concentrations exceeding 10 nM, our
study demonstrates the importance ofperforrning a dose-response
curve to establish the suitable concentration to achieve selective
biological activities thereby avoiding potentially false interpreta
tions with respect to the biological activities ofthe angiopoietins.
Recent reports indicate that Tie2 dimerization may be induced
to distinctly diffèrent extents by Ang 1 or Ang2 [28,29], thus it is
possible that Angi and Ang2, upon binding to Tie2, induce
conformational changes in Tie2 resulting in diflèrent activation
patteras, namely the phosphorylation of different tyrosine
residues or activation ofdifferent signalling pathways, explaining
the differential response between Angi and Ang2. Furthermore,
we demonstrate that the activation ofTie2 by Angi activates p38
and p42/44 MAPKs in a rapid and transient manner and PI3KJAkt
fora prolonged period oftime. Our data are in une with a previous
report demonstrating that upon binding to Tie2, Ang 1 activates
both p38 and p42/44 MAPKs [18] as well as Akt [30]. Most
studïes investigating signalling downstream of Tie2 rnainly
focused on PI3K’Akt [19,3 l-33] due to the ability ofAngi to
stabilize the vasculature. The ability of Angi to activate both
proapoptotic (p38 MAPK) and antiapopototic (p42/44 MAPK
and PI3K) pathways is not unique since endothelial ceil-specific
mitogens, such as VEGF. are also capable ofactivating multiple
pathways including p38 and p42/44 MAPKs, and PI3K [34].
Interestingly, we also observed the capacity of Ang2 to activate
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Fig. 7. Treatment of BAEC with Angi or Ang2 promotes VEGFR-2
phosphoiylation. Confluent BAEC werc stimulated with Ang I or Ang2
(I nM) for 7.5 min to 4 h. Ccli lysates (I mg) were prepared and
immunoprecipitated (IP) with rabbit polyclonai anti-mousc VEGFR-2 IgG.
Following resolution by SDS-•PAGE and transfcr. PVDF membranes wcre
probcd with mouse monoclonal antiphosphotyrosinc IgG and immunoreactive
hands were visualized by chemiluminescence. Membranes were subsequcntly
stripped and VEGfR-2 protcin expression was detcrmined following incubation
with rabbit polyclonal anti-mouse VEGfR-2 igG.
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Fig. 8. Angiopoietin-niediated endothelial PAF synthesis requires the activation
ofp38 MAPK. p42144 MAPK, and PI3KIAkt signalling pathways and sPLA2-V.
(A) Confluent BAEC were pretreated with either PD98059 (10 jiM). SB203580
(10 iiM), LY294002 (5 1iM), oi Wortmannin (500 nM) 15 min prior to 4 h of
stimulation with AngI or Ang2 (1 nM). (B) Contitient BAEC were pretreated
with selective PL.A2 phamiacological inhibitors AACOCf3 (10 tiM), scalaradial
(10 1tM), or LY3 11727(100 tiM) 15 min plior to 4h of stimulation with Angl or
Ang2 (I nM). Values are means±SEM of 3 experiments. p<O.0I and
***p<0.00l vs. PBS; tp<O.O5 vs. agonist.
p38 and p42144 MAPKs, which had yet to be docurnented, in
addition to PI3KIAkt which had previously been described
[24,251. Our observations demonstrate the complex dual nature of
Ang2 by its ability to similarly activate p38 and p42144 MAPK as
Ang t. However, Ang2 did flot activate Akt in the sustained
manner observed with Ang t. This difference may explain in part
the ability of Ang2 to destabilize vessels due to an inability to
sufliciently activate PI3K and in tum, Akt and focal adhesion
kinase (FAK), two crucial elements in the signalling pathway
leading to celi survival and migration [35].
4.2. AngI and Ang2 induce endothelial PAF synthesis
Our data demonstrate that the angiopoietins constitute a
second class of tyrosine kinase receptor ligands with proangio
genic activities. In the present study, we demonstrate that both
Angi and Ang2 induce endothelial PAF synthesis, however, the
profite of PAF synthesis mediated by the angiopoietins is
strikingly different to that seen with VEGF-A165. In contrast to
vhat we have previously reported with respect to VEGF-A165-
mediated PAF synthesis [3], both angiopoietins induce a rapid,
progressive, and sustained endothelial PAF synthesis (maximal
within 4 h) whereas VEGF-A165 induces a rapid and transient
synthesis of PAF [3]. In activated endothelial ceils, acute PAF
synthesis is mediated through the remodeling pathway and can
occur in a very early (2—5 mm), early (10—40 mm), or delayed
(4—8 h) [36] manner. The kinetics observed in the cuffent study
follow a biphasic response during which angiopoietins induce an
early response which is not as robust as that seen with VEGF
A165. This initial synthesis is followed by a “burst” phase where
maximal PAF synthesïs is hvice as high as the peak observed
with VEGF-A165. Based on the kinetics obsewed, angiopoietin
mediated endothelial PAF synthesis may be complementaiy to
VEGF-mediated PAF synthesis. Perhaps, under inflammatoiy
conditions, VEGF-mediated PAF synthesis provides an initial
rapid and transient synthesis followed by the prolonged
angiopoietin-mediated response sustaining neutrophil and EC
activation leading to endothelial P-selectin transiocation and
neutrophil adhesion onto EC.
The maximal PAF synthesis obsewed at 4 h is dependent upon
the activation of the p38 MAPK, p42144 MAPK, and PI3KIMct
signaïling pathways. Indced, pretreatment of BAEC with pharma
cological inhibitors for each of the aforementioned pathways
resulted in sirnilar inhibition pattems of PAF synthesis rnediated by
both Mgi and Ang2. We have recently suggested that the ability of
the MAPKK inhibitor to compietely block VEGF-A165-mediated
endothelial PAF synthesis resides in its ability to prevent PLA2
activation [5]. Based on our data, it appears that this inhibitor elicits
a similar response with respect to angiopoietin-mediated PAF
synthesis in BAEC since pretreatment with this inhibitor
substantially ruduced PAF synthesis. Since p38 MAPK bas been
shown to directly activate lyso-PAF AT [37], an enzyme essential
for PAF synthesis, it is flot surpnsing to observe that p38 MAPK
inhibition almost comptetely abrogated angiopoietin-mediated PAF
synthesis. The observation that the PI3KIAkt pathway regulates
angiopoietin-mediated PAF synthesis in a positive manner is in
stark contmst to what we have previously reported with respect to
VEGF-A165-mediated PAF synthesis [5]. Future studies will be
required to delineate how the activation of PI3KIAkt pathway
modulates downstream effectors involved in boffi VEGF- and
angiopoietin-mediated PAF synthesis.
The phospho]ipase A2 family has been irnplicated in a number
of cellutar responses and several isofonns of cytosolic (cPLA2),
calcium-independent (iPLA2) and secreted (sPLA2) have been
identified ([38] for review). As mentioned above, the remodeling
pathway ofEC PAF synthesis requires the conttibution ofa PLA2
to convert membrane phospholipids into lyso-PAF. Having
demonstrated that the angiopoietins activate three intracellular
signalling pathways known to participate in EC PAF synthesis, the
next step was to determine which PLA2 vas impticated in
angiopoietin-mediated PAF synthesis. Cytosolic PLA2 is
expressed in most ceti types and p42144 and p38 MAPKs have
been implicated in its activation [39—41]. The iPLA2s are the most
recently identified members ofthe PLA2 superfamily and share the
size, intracellular localization, and catalytic mechanisms with
cPLA2 [38]. It is apparent that angiopoietin-mediated PAF
synthesis is flot dependent on cPLA2 and iPLA2 as pretreatment
with a specific cPLA2 and iPLA2 inhibitor, AACOCF3 did flot
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9Fig. 9. Proposed mechanism by which angiopoictins mcdiatc endotheliai PAF synthesis. Stimulation of tyrosinc kinase Tic2 rcccptor by Ang I or Ang2 (1) activates
PI3K, p42144 MAPK, and p38 MAPK pathways (2). These intracetiular signailing pathways, through the action of sPLA2-V, indure endotheliai PAF synthcsis (3).
Concurrentiy, Tie2 activation, through a mechanism yet to be detined, promotes the relocalization ofendogenous VEGf to thc ccli membrane (4) whcre it can bind to
one of ils receptors, VEGFR-2 (5). Activation of VFGFR-2 ieads to p38 and p42144 MAPKs activation and endothehai PAF synthesis (6) which in aira potcntiatcs
angiopoietin-mediatcd PAF synthesis.
prevent but even slightly increased EC PAF synthesis by both
Ang 1 and Ang2 at 4 h. We have previously reported that sPLA2-V
is implicated in VEGF-A165-mediated EC PAF synthesis [4] and
thus opted to target this particular sPLA2 isoform. Using
phamiacological inhibitors, we demonstrated that pretreatment of
BAEC with a non-specific sPLA2 inhibitor, scalaradial, blocked
angiopoietin-mediated PAF synthesis by approximately 50%. In
addition, LY3I]727 at a concentration (100 tM) known to
specifically block sPLA2-IIA and -v activity sirnilarly inhibited
angiopoietin-rnediated PAF synthesis. Since sPLA2-IIA is flot
expressed in BAEC [4], this suggests the essential contribution of
sPLA,-V in angiopoietin-mediated PAF synthesis. Therefore, it is
interesting to note that although angiopoietins have a different PAF
synthesis profile than VEGF-A165, both require the same
phospholipase, thereby bestowing a critical role upon sPLA2-V
in EC PAF synthesis.
The peak in angiopoietin-rnediated PAF synthesis, could be
representative of a “delayed” PAF production as described
previously ([36] for review) and hence require newly synthe
sized proteins for ce!! activation. Since BAEC stimulation with
VEGF-A165 induces PAF synthesis and that EC express VEGF
[20—23], we sought to investigate whether VEGF was im
p!icated in angiopoietin-mediated PAF synthesis. First, we did
not detect an upregulation ofVEGF mRNA by RT-PCR analysis
when BAEC were stimulated with Angi or Ang2 (data flot
shown) nor did we sec significant fluctuations in the quantity of
endogenous VEGF by ELISA. We a!so observed that no or
marginal amounts ofVEGF were released into the supematant.
However, when BAEC were pretreated with VEGF receptor
inhibitors prior to stimulation with Ang 1 or Ang2, angiopoietin
rnediated EC PAF synthesis vas inhibited by approximately
50%. This partial reduction of PAF synthesis was tiot due to a
non-specific inhibition ofTie2 activation by VTK and SU 1498
since we observed by Western blot analysis (bat these inhibitors
ofVEGF receptors did flot alter Tie2 phosphorylation rnediated
by angiopoietins but prevented VEGF-A165-mediated VEGFR
1 and R-2 activation [7,16] and PAF synthesis. We then
postulated that endogenous VEGF was being shuffled from the
intracellular cornpartment to the endothelial cdl surface
membrane to interact with its cdl surface membrane receptors
and contribute to angiopoietin-induced PAF synthesis. This
hypothesis was confirmed by confoca! microscopy whereby we
observed the presence of a significant amount of endogenous
VEGF at the cefl surface within 7.5 min of stimulation with
Angl, and to a lesser extent with Ang2, which remained no
ticeable up to 4 h post-stimulatïon with both angiopoietins.
Furthermore, we observed that a treatment with Angi or Ang2
was capable of mediating VEGFR-2 phosphorylation. The
reduced capacity of Ang2 to promote PAF synthesis may be
related to its !ess intense activation of Tie2 and VEGF re
loca!ization on endothe!ial cdl surface membrane. Our data are
in line with previous studies reporting that a treatment of bovine
aortic endothelial ceils, namely with sphingosine l-phosphate
(S1P), can lead to VEGFR-2 phosphoiylation and activation of
downstream effectors [42]. To the best of our knowledge, our
smdy is the tfrst one tu demonstrate the capacity ofangiopoietins
to induce VEGFR-2 phosphorylation and biologica! activïties
such as PAF synthesis.
Based on our carrent observations as wel! as previous studies,
it appears that under specific conditions, both Angl and Ang2 are
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capable of mediating proinflammatoiy events. We have recently
reported that the angiopoietins are capable of promotÏng
endothelial P-selectin transiocation and the adhesion of neutro
phils onto activated hurnan umbilical vein endothelial cells
(HUVEC) as well as activating Tie2 receptors on neutrophils
leading to PAF synthesis promo ting a rapid upregulation ofthe 3,-
integrin complex (CD 11 /CD 1$) and contributing to an increase in
neutrophil adhesion onto activated EC thereby demonstrating that
the angiopoietins should be considered as acute proinflammatoiy
mediators [13]. However, in the aforementioned study. angio
poietins did flot induce PAF synthesis in HUVEC [13] whereas we
demonstrate their powerfiil capacity to mediate PAF synthesis in
BAEC, thereby suggesting tissue specificity. We have previously
observed that BAEC induce a more robust endothelial PAF
synthesis than HUVEC [4]. Recent studies reported ifiat Ang I
possesses anti-inflammatory properties. for instance, under in
vivo conditions, Angi bas been shown to prevent VEGf
rnediated vascular pemieability [10,43,44] and in vitro it reduces
the basal activation of vascular endothelial cadherin (VE
cadherin) and 3-catenin, concornitantly with a reduction of
VEGF-rnediated endothelial ceil pemieability [45.46]. Interest
ingly, the above studies utilized HUVEC and it is therefore
possible that the anti-inflammatory effects attributed to Ang I
under in vitro conditions stem from the inability ofangiopoietins
to promote PAF synthesis in this endothelial subtype.
In summaly, our study demonstrates for the first time that
AngI and Ang2 are both capable of inducing endothelial PAF
synthesis and this in a temporal resolution different than the
rapid and transient PAF synthesis induced by VEGF-A1(5.
Furthermore, this synthesis requires the activation of the p38
MAPK, p42144 MAPK, and PI3KJAkt intracellular signalling
pathways as well as the induction of sPLA2-V. In addition,
angiopoietin-mediated endothelial PAF synthesis is partly
regulated by a redistribution of endogenous VEGF to the ceil
surface membrane which may subsequentiy potentiate endothe
liai PAF synthesis (Fig. 9). In our smdy, Ang2 behaved as a
partial to full Tie2 agonist in fiinction ofits concentration, further
strengthening the current view of tissue and context specificity
with respect to Ang2 activity. Taken together, our results
demonstrate that the angiopoietins, like VEGF, constitute
another family of angiogenic growth factors capable of
promoting proinflammatoiy events.
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